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 1 
1 Introduction 
 
Infectious and parasitic diseases like HIV/AIDS, hepatitis, tuberculosis and malaria represent 
the second highest cause of death and are responsible for 20 % of the mortality worldwide[1]. 
In Africa, this proportion even increases to 65 %. The communicable diseases mentioned are 
followed by malignant neoplasms (13 % worldwide). In spite of the development of new and 
the improvement of existing drugs, these diseases together account for every third death 
worldwide, equal to cardiovascular diseases. In addition, the emergence of antibiotic-resistant 
and multi-drug resistant bacteria makes the situation worse and is nowadays a serious 
challenge to the clinical treatment of infections, particularly in hospitals. Many genera of 
gram-positive and gram-negative bacteria have developed resistance to commonly used drugs 
such as ß-lactams, quinolones, aminoglycosides and macrolides. Especially Streptococcus 
pneumoniae, enterococci-strains and Staphylococcus aureus are problematic bacteria. 
The problem of drug-resistance also appears in the treatment of cancer. Therefore, new targets 
in drug development are clearly needed. As different as these diseases are, there is an 
ubiquitous enzyme related to all of them: The methionine aminopeptidase (MetAP). This 
metal-dependent enzyme is involved in the N-terminal processing of proteins and essential for 
every organism, making it a target for the development of new antibiotic, antifungal or 
antiparasitic drugs. Besides, certain inhibitors of the MetAP can inhibit angiogenesis, an 
important step in cancer growth. This underlines the important role of this enzyme for the 
proper functioning of proteins and thus of whole cells. Insight into the mode of action of these 
inhibitors and characterization of the enzyme will not only be useful for the further 
development of anti-cancer drugs but will also lead to a better understanding of the 
physiological processes involved in the development of cancer and in cancer growth. 
Another aspect showing the importance of this enzyme is its use in the biotechnology 
industry: Often, large amounts of purified proteins are required for further testing (for 
example granulocyte-colony-stimulating factor, G-CSF[2]) or are to be produced as drugs in 
the pharmaceutical industry like insulin. Many of the recombinant proteins for therapeutic 
uses are based on the secretory products from mammalian cells. An intracellular heterologous 
production of these proteins in E. coli may result in a product with an unphysiological 
methionine at the N-terminus. This methionine should be removed in order to avoid potential 
immunogenicity. Chemical removal with cyanogen bromide under relatively strong acidic 
conditions essentially allows any residue to be adjacent to the methionine. Unfortunately, this 
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reaction is not terminal specific and therefore limited to proteins without an internal 
methionine. Another option is the use of exopeptidases that cleave amino acids sequentially 
from the N-terminal end of proteins. However, proteolysis and digestion of the rest of the 
protein are unwanted side effects in this case. Here, the use of MetAP is clearly useful. This 
can be done either by overexpression of MetAP with the protein of interest in the same cell 
(thus ensuring removal of methionine in situ) or treatment of the protein with purified MetAP 
after expression and isolation. The success of these methods was demonstrated with 
interleukin-1ß[3], interleukin-2 and ricin A both in vitro and in vivo[4]. Insufficient N-terminal 
processing due to the substrate specificity of the MetAP can be adjusted with certain 
mutations, used for example in the production of human haemoglobin[5]. Even MetAPs stable 
against heat and chemical denaturants are already known[6]. 
The diverse aspects clearly show the high potential of MetAPs and the relevance and 
importance of research done with these enzymes. This work will hopefully be useful for the 
further characterisation of the enzyme and especially for the development of inhibitors as 
potential drugs. 
 
 
 3 
2 The Target: Methionine Aminopeptidase (MetAP) 
 
Enzymatic activities that remove amino-terminal residues of methionine from certain proteins 
have been observed in both prokaryotes[7, 8] and eukaryotes[9-11]. It became evident that certain 
enzymes, the methionine aminopeptidases, play a much more important role than other 
unspecific exopeptidases and are responsible for the largest part of N-terminal methionine-
removal. Lower and higher eukaryotes as well as bacteria seem to share a similar N-terminal 
protein processing machinery, indicating universality of this system[12]. 
 
 
2.1 Classification of MetAPs 
 
MetAPs exist in two forms (type-I and type-II) that can be further distinguished (see Fig. 2-1). 
Whereas eubacteria express only type-I and archaeabacteria only type-II MetAPs, eukaryots 
posess both types. 
 
 
Fig. 2-1 Classification of MetAPs 
 
Type-I and type-II can be distinguished by an insert of about 60 amino acids, forming a 
helical subdomain whose function is still unknown. Thus, enzymes resembling the eubacterial 
form lacking this insert are designated type-I, while those with the insert (thus related to the 
Eukaryots 
I 
II 
Eubacteria a 30 kDa 
b 43 kDa 
b 53 kDa 
Archaebacteria a 33 kDa 
Catalytic domain 
Zn-Finger domain Insert, spec. for Type II 
N-terminal Polybasic/-acidic domain 
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first porcine MetAP described) are designated type-II. Moreover, MetAPs exist with and 
without an N-terminal extension, whose presence is the basis for additional differentiation: To 
further distinguish the eukaryotic MetAPs with the extension from those MetAPs without, 
those enzymes with the extension are labeled as type-Ib and type-IIb. Thus, eubacterial 
MetAPs (without the extension) have been designated type-Ia while archaebacterial MetAPs 
(also without the extension) are designated -IIa.  
 
 
2.1.1 N-terminal Extensions  
 
Some type-I and type-II MetAPs display large N-terminal extensions that contain either zinc-
finger motifs or poly-lysine and aspartic acid blocks[13-15]. The N-terminal extension of yeast 
MetAP-I (yMetAP) for example displays a sequence resembling zinc-finger domains. This 
indicates a possible protein-nucleic acid or protein-protein interaction and is believed to have 
a function in association with ribosomes[16]. In contrast, the human enzyme lacks the 
consensus zinc-finger sequence and instead contains the extended runs of basic and acidic 
residues. These N-terminal extensions are not required for in vitro enzymatic/catalytic activity 
but are important for the in vivo function. The N-terminal domains of the type-II enzyme 
seem to regulate the level of protein synthesis. MetAP-II(b) is a glycoprotein and was initially 
described in mammalian cells as p67[17], a cellular protein that associates with (and inhibits 
phosphorylation of) the eukaryotic translation initiation factor 2α (eIF2α). eIF2 is required for 
protein synthesis[18]: The formation of the initiation complex plays a significant part in the 
initiation of peptide chain synthesis. This process is blocked when eIF2 is phosphorylated, 
which happens in various stress-related situations and leads to a down regulation of the 
cellular protein synthesis. Phosphorylation of eIF2α blocks the initiation of translation and 
inhibition of this phosphorylation consequently stimulates the initiation[15]. The inhibition of 
this phosphorylation is a function of the N-terminal domain of MetAPs. The presence of 
terminal carbohydrate moieties is required for the “POEP-” (protection of eIF2α 
phosphorylation) activity of MetAP. The protecting property can be modulated by p67-
deglycosylase (p67-DG). Imbalance of p67 and p67-DG (a protein controlling the activity of 
p67 by removal of the p67- necessary glycosyl moiety) can lead to either cancerous growth or 
cell death[19] and the balance between MetAP and p67-DG will possibly determine the fate of 
the cells whether they will grow or induce apoptosis[19]. In summary, MetAP-II is a 
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bifunctional protein which catalyzes the cleavage of N-terminal methionine from nascent 
polypeptides and affects translational initiation through its ability to associate with eIF2α[20]. 
The N-terminus of MetAP-II is also able to interact with other proteins such as S100A4, a 
protein that regulates tumor metastasis and a variety of cellular processes. The binding of 
S100A4 does not affect in vitro MetAP activity but could modulate the N-terminal processing 
of nascent substrates by changing their localization[21]. 
The presence of the N-terminal domains in the eukaryotic isoforms implies that these 
enzymes have (perhaps additional and not yet known) functions that are not required in 
prokaryotes. Although many efforts have been made to understand the functional differences 
of the two types of MetAPs (see 2.3.5.2 Yeast MetAPs), the role of each type of MetAP is not 
yet entirely clear. In vivo substrate differences as well as interactions with other proteins have 
been described. Although the type-I MetAP seems to play a more important role in 
methionine metabolism, the two types of MetAPs can generally substitute each other. 
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2.1.2 Evolution of Different MetAPs 
 
The phylogenetic tree shows that the present-day type-I and type-II enzymes of eukaryotes are 
more closely related to the eubacterial and archaeal forms, respectively, than they are to each 
other. Due to the phylogenetical closeness of bacterial and eukaryotic MetAP-I (see Fig. 2-2), 
it seems likely that the eukaryotic MetAP-I has developed from eubacterial MetAP-I in the 
course of evolution according to the endosymbiont-theory. 
 
Eubacteria
Eukaryotic
MetAP-I
Archae-
bacteria
Eukaryotic
MetAP-II
MetAP-II Saccharomyces
Methanothermus
Sulfolobus
Synechocystis C
Mycoplasma
Chlamydia
Bacillus
Haemophilus
Synechocystis B
Synechocystis A
Escherichia
Salmonella
MetAP-I Saccharomyces
MetAP-I Human
MetAP-II Human
p67 Rat
 
Fig. 2-2 Evolutionary tree of MetAPs[22] 
 
 
2.2 Physiological Role of MetAPs 
 
2.2.1 Protein Synthesis in Eukaryotic and Prokaryotic Cells 
 
Although there are natural differences between eukaryotic and prokaryotic protein synthesis 
such as the size of ribosomes (for a review see Ref.[23]), the cellular machinery for protein 
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synthesis has been highly conserved and a common principle exists: Proteins are specified by 
mRNA after transcription of DNA and synthesized on ribosomes as depicted in Fig. 2-3. 
 
 
Fig. 2-3 Schematic protein synthesis (©1999, Addison Wesley Longman Inc.) 
 
Protein synthesis is normally initiated with the AUG codon that encodes for methionine (in 
the cytosol of eukaryotes) or formyl-methionine (in prokaryotes, mitochondria, and 
chloroplasts). Rare exceptions are, for example, the initiation with phenylalanine or 
tryptophane in prokaryotes[24, 25] or with glutamine both in prokaryotes and eukaryotes[26, 27]. 
The amino acids are transported to the ribosomes via activated tRNAs carrying the 
corresponding anticodons. After initiation of the complex, the polypeptide chain is elongated 
according to the coding sequence of the mRNA as shown in Fig. 2-4. 
 
 
Fig. 2-4 Protein synthesis on a ribosome (taken from http://tidepool.st.usm.edu/pix/protsynth.gif) 
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2.2.2 Methionine Metabolism and N-end Rule 
 
Methionine is the most “expensive” amino acid to synthesize[28] and plays a key role among 
the 20 amino acids which are incorporated into proteins because of its involvement in the 
initiation of translation. Thus, it serves as a signal measuring the general health of a cell and 
couples the translation to the metabolism and the chemical environment of a cell. This role 
appears to be ubiquitous[29]. Methionine metabolism is also an important aspect of cellular 
physiology and methionine is involved in oxidative stress, methylation, gene expression and 
has been linked to cell cycle progression. In E. coli, the metabolism of methionine is now 
well-known and all the important enzymes have been characterized: Methionyl-tRNA 
synthetase (EC 6.1.1.10) and Methionyl-tRNA formyltransferase (EC 3.5.1.27) are involved 
in the formation of N-formyl-Met-tRNA, peptide deformylase (EC 3.5.1.27) cleaves the 
formyl group from nascent formyl-methionine peptides and MetAP (EC 3.4.11.18) removes 
the N-terminal methionine (see Fig. 2-5). 
 
etc.
Met
mRNA
Met-tRNA-
Synthase
Trans-
formylase
Translation machinery
Deformylase
Methionine
Aminopeptidase
+
Met
NH2
Gly Trp
Met
NH CHO
f-Met-tRNAi
aa-tRNAe
tRNAi, tRNAe
Gly
Met
Trp
NHOHC
f-Met-pp
Gly
Met
Trp
H2N
Met-pp
Gly
Trp
NH2
pp
DNA
 
Fig. 2-5 Methionine cycle of eubacteria. pp, polypeptide; aa, amino acyl; tRNAi, initiator tRNA; tRNAe, 
tRNAs for peptide elongation 
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For a significant fraction of the intracellular proteins, the amino-terminal methionine is 
removed enzymatically after the initiation of translation (about 50-60 % in the case of E. 
coli[30]) by the MetAP. This process is mostly dependent on the adjacent residue. The 
(exposed) N-terminal moiety plays an important role in protein recognition by other enzymes 
and therefore MetAP activity is a determinating factor for further protein processing (such as 
acetylation and myristoylation), protein stability and intracellular protein localization. 
Cotranslational removal of the initiator methionine occurs when the nascent chain is still quite 
short (20-40 residues) and presumably in conjunction with Nα-acetylation[31] but after 
deformylation[32]. The absence of the N-terminal domains in the eubacterial and archaeal 
isoforms (type-Ia and -IIa) is consistent with the view that the removal of methionine in these 
organisms is largely a post-translational event. 
 
Statistical analysis of N-terminal methionine removal in both pro- and eukaryotic cytosolic 
proteins demonstrated that the penultimate residue determinates the fate of the methionine and 
that some amino acids inhibit and some others cause its removal[33]. The same removal-
specificity for the N-terminal methionine has also been predicted from mutant cytochrome 
sequences (altered iso-1-cytochromes c from yeast) by Sherman et al.[34]. In addition, it has 
been demonstrated that the half-lives of ßgal proteins in Saccharomyces cerevisiae are 
strikingly different, depending on the nature of the amino acid at the amino-terminus[35]. 
These findings led to the formulation of the N-end rule: 
 
Stabilizing and destabilizing residues can be distinguished at the N-terminus of a protein. 
Methionine is considered a stabilizing residue and thus the retention of the initiator 
methionine acts as a protectant that prevents premature or inappropriate protein degradation. 
When a newly formed protein is proteolytically processed in vivo and exposes one of the 
destabilizing residues Ile, Glu, His, Tyr, Gln, Asp, Asn, Phe, Leu, Trp, Lys or Arg, this 
protein is then subsequently targeted for multiple ubiquitination and selective degradation[36]. 
As a consequence, destabilizing amino acids are generally absent on the N-terminus of 
relatively long-lived, noncompartmentalized proteins.  
 
This degradative pathway, where amino-terminal recognition of proteolytic substrates is 
involved, is called the N-end rule pathway, distinguishing it from other proteolytic pathways 
and ubiquitin-dependent processes. Interestingly, the N-end rule inversely matches the 
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substrate specificity of MetAPs: N-terminal residues containing a destabilizing amino acid are 
non-MetAP substrates (see 2.3.1 Substrate Specificity). Thus, any protein that has its N-
terminal methionine removed by MetAP will retain a stabilizing N-terminal residue. 
 
 
2.2.3 Physiological Relevance of MetAP Activity 
 
Methionine is removed from the majority of proteins. This is essential for the further 
processing such as acetylation or myristoylation and thus MetAPs play a key role in the 
functional regulation of proteins. Myristoylation has been shown to be required for the proper 
functioning of several signaling proteins and in targeting towards membranes[37]. The removal 
of the starter methionine is in some cases also required for biological activity when N-
terminal residues have a role in catalysis as for example cysteine in yeast glutamine-fructose-
6-phosphate amidotransferase (GFA1)[38]. 
Taken together, methionine removal is important for proper subcellular localization of 
proteins, for degradation, protein turnover and for the targeting of proteins to cellular 
membranes[29, 39]. MetAPs have also been shown to be involved in gene regulation of genes 
connected with methionine synthesis and to be susceptible to the intracellular methionine 
concentration[40]. MetAPs and methionine metabolism are linked in several ways, including 
recycling of methionine, product inhibition, and gene regulation.  
The physiological importance of MetAP activity is underscored by the lethality of organisms 
where all MetAP genes have been deleted or all MetAP gene products are inhibited. This has 
been shown for E. coli, S. typhimurium and S. cerevisiae[41-43]. Whether this will also be the 
case in higher eukaryotes cannot be answered yet, but it is likely given the lethality of the 
yeast double null mutant. As there are only specific inhibitors for MetAP-II available up to 
now, specific inhibitors of the type-I isoenzyme, potent dual inhibitors or transgenic or knock-
out animals will be required to prove this assumption. 
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2.3 Properties of MetAPs 
 
2.3.1 Substrate Specificity 
 
As yeast null mutants lacking only one type of MetAP can survive[42, 44], the two MetAP types 
might have largely similar (perhaps redundant) functions. This is supported by the fact that all 
MetAPs have a similar substrate specificity. The MetAP activity is strictly methionine 
specific and it is dependent on the radius of gyration of the penultimate residue: The 
methionine residue is generally removed from proteins where the adjacent amino acid is small 
and uncharged (glycine, alanine, serine, threonine, cysteine, proline and valine). This has been 
shown in vitro using different substrates but also in vivo (see Fig. 2-6): 
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Fig. 2-6 Extent of methionine processing for E. coli determined in vivo for a protein with a N-terminal 
sequence (Met)-Xaa-Gln-Val-Ala- with 20 different amino acids for Xaa[45], Length of side chain: 
Maximal distance between the α-carbon and the most distal non-hydrogen atom of the side chain 
 
In most instances, an adjacent residue with a side chain size (radius of gyration) smaller than 
0.129 nm is preferred. For side chain sizes that are larger than 0.143 nm, MetAP is unable to 
remove the methionine. Thus, only proteins with a stabilizing amino acid (according to the N-
end rule) in the penultimate position are substrates of the MetAPs.  
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It has also been reported that the amino acid in the antepenultimate position has an influence 
on the MetAP activity. For example, proline is at least partially inhibitory[2, 45], and significant 
variations occur in MetAP activity among substrates that have identical residues at the first 
two positions[4]. In a similar fashion, processes like acetylation and myristoylation are also 
mostly determined by specific (exposed) amino acids but seem to be affected by other effects 
such as peptide length or downstream residues[46, 47]. 
 
E. coli MetAP utilizes only tripeptides or larger substrates and has an absolute specificity for 
a methionine residue at the amino terminus[4]. However, the third residue (as seen in X-ray 
structures with bound substrate-like inhibitors) is completely solvent accessible and makes no 
direct contact with the enzyme[48]. 
 
 
2.3.2 Metal Dependency 
 
MetAPs are metal-dependent enzymes. They have been claimed to be binuclear Co(II) 
dependent enzymes, but the identity and number of the in vivo metal ion is still under debate 
and is discussed in 4.2.3.5 (Metal Specificity). In short, Co(II), Zn(II), Mn(II), Ni(II) and 
Fe(II) are possibly relevant in vivo. It is not entirely clear whether MetAPs function as mono- 
or binuclear enzymes. However, it can be stated that Co(II) activates all MetAPs known so 
far, and that two metal ions are present in all existing MetAP X-ray structures. 
 
 
2.3.3 Structure of the EcMetAP 
 
The E. coli gene encoding this enzyme consists of 264 codons and encodes a monomeric 
enzyme with a molecular mass of 29,333 daltons[4]. The E. coli MetAP (EcMetAP) is a 
soluble, globular protein. 
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2.3.3.1 Tertiary Structure 
 
A limited number of folding motifs can be used to describe the three-dimensional architecture 
of globular proteins. One of these is the pita-bread fold of, for example, the E. coli MetAP, a 
protein scaffold that can support a diverse set of catalytic functions[14]. This structure displays 
internal pseudo-2-fold symmetry as can be seen in Fig. 2-7.  
 
 
Fig. 2-7 E. coli MetAP, above: tertiary structure of the EcMetAP, the central ß-sheet is depicted in yellow, 
the alpha helices in red and the loops in green, the cobalt ions are shown in magenta, 
surrounded by the five conserved active site residues; below: molecular surface of the EcMetAP 
(created with the program CHIMERA[49]), the cobalt ions are shown in magenta 
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Structurally, both halves of the polypeptide chain are arranged around a pair of cobalt ions. A 
central antiparallel ß-sheet is covered on one side by two pairs of α-helices and by a C-
terminal loop and on the other side forms the active site together with some irregular loops 
and two metal ions. 
 
Protein data base searches using both sequence- and structure-based profiles identified several 
other proteins with the pita-bread fold including creatinase, aminopeptidase P, proline 
dipeptidase and p67[13]. 
 
 
2.3.3.2 Metal Binding Site 
 
The EcMetAP active site is composed of a catalytically essential binuclear metal center 
generated by five strictly amino acids which are conserved in all MetAPs known so far: 
Asp97, Asp108, Glu204, Glu235 and His171. These ligands interact with the two metal ions 
in a monodentate (His171 and Glu204) or a bidentate manner (Asp97, Asp108 and Glu235) 
and lead to a trigonal bipyrimidal coordination for one cobalt ion (Co1) and an approximately 
octahedral coordination for the second one (Co2). In addition, several solvent molecules are 
present in the crystal structure of the apo-enzyme (2MAT). Two of them are directly 
coordinated to the metal centre: One of those bridges between the two cobalt ions, while a 
second one is terminally ligated to Co2. Individual mutation of the five metal-binding amino 
acids residues resulted in complete loss of enzymatic activity and ability to bind Co(II)[50]. 
The only other invariant amino acids (among all MetAPs known so far) in the active site are 
His79 and His178, located on opposite sides of the cavity and slightly above the metal 
center[14, 51] as can be seen in Fig. 2-8. The mutation of these two histidines results in a 
dramatic loss of activity. Seven cysteines are present but none of these form disulfide 
bridges.[51] 
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Fig. 2-8 Metal binding site of the EcMetAP, above: schematic drawing, below: picture based on the X-ray 
structure 2MAT 
 
In addition to the cobalt ions, a sodium ion can be seen in 90% of the published crystal 
structures. This Na+-ion is positioned near Val76 and about 15 Å away from the metal binding 
site and might mediate an interaction between the subdomains of the folded protein, thus 
stabilizing the metal center and/or positioning the solvent accessible loop that contains 
His79[52]. 
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2.3.3.3 Substrate Recognition Site 
 
Near the metal binding site, a hydrophobic cavity is lined by the side chains of a set of amino 
acids (see Table 2-1) that form the binding site for the amino-terminal methionine side chain, 
required for substrate recognition. 
 
Table 2-1 Comparison of the metal binding and substrate recognition sites of type-I and type-II MetAPs;  
a) for HsMetAP-II, b) according to sequence alignments with 8 different type-II MetAPs 
 
S1-subsite 
(recognizes Met) 
Metal binding Site S1’-subsite 
EcMetAP(-I) Cys59, Tyr62, 
Tyr65, Cys70, 
His79, Phe177, 
Trp221[51, 53] 
Asp97, Asp108, 
His171, Glu204, 
Glu235 
Tyr168, Cys169, 
Gly170, His185, 
Glu204, Pro205, 
Met206, Gln233[54] 
Type-II MetAPs Pro, Gly, Ile, His, 
Met, Tyra[55] 
Asp, Asp, His, 
Glu, Glua[56] 
Leu, Gly, Glu, Phe, 
Glub[54] 
 
Whereas the active site residues are strictly conserved, variations do occur among the putative 
substrate-binding residues. Type-I and type-II MetAPs use different sets of amino acid 
residues. This explains the (slight) differences in substrate binding and enzyme activities of 
the different types of MetAPs. 
 
Alignment studies revealed that Cys70 and Trp221 are conserved among type-I, but not  
type-II MetAPs[50]. In addition, extensive mutagenesis studies of the S1-site of EcMetAP[55] 
and of other residues[50] have been performed. The residues Tyr65 and Trp221 are essential 
for the proper functioning of the enzyme. Cys70 also seems to play a crucial role in substrate 
catalysis. Mutation of Cys70 opened up the binding pocket and changed substrate 
specificity[55, 57].  
 
A picture of the EcMetAP substrate recognition site with bound methionine is shown in  
Fig. 2-9. 
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Fig. 2-9 Structure of the EcMetAP with bound methionine (1C21). The metal binding site is depicted with 
sticks, the Co(II) ions are shown in magenta, the flanking histidines (His79 and His178) in light 
blue, methionine in yellow. The surface of the S1-subsite that recognizes methionine can be seen 
on the left side, the surface of the S1’-subsite can be seen opposite on the right. 
 
 
2.3.4 Reaction Mechanism 
 
Based on X-ray structures of EcMetAP with bound substrates and substrate-like inhibitors, on 
mutational studies and on comparison with enzymes with a similar active site, the following 
reaction mechanism has been proposed (Fig. 2-10): 
Binding of the substrate, which includes direct interactions with both metals, leads to an 
expansion of the coordination sphere of Co1 from five to six. This alternation in the electronic 
character of the binuclear center may activate the µ-hydroxide for nucleophilic attack and 
facilitate proton transfer to Glu204. The idea that the bridging water molecule is deprotonated 
is confirmed by computational and experimental results discussed in 4.3.3 (Protonation States 
of MetAP). Recent theoretical work on the reaction mechanisms of other enzymes indicate 
that the nucleophilic attack on the substrate might also originate from a “terminally” bound 
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and not a bridging hydroxide ion as its nucleophilicity is higher. The location of the carbonyl 
oxygen atom of the substrate upon binding also is under debate. 
The resulting tetrahedral intermediate is stabilized by chelation to Co1 and by hydrogen-
bonding interactions with His178 and His79. Proton transfer from Glu204 to the nitrogen 
atom of the scissile bond may facilitate breakdown of the intermediate to products. His79 may 
interact directly with the nitrogen of the scissile peptide bond, playing a critical role in 
substrate recognition and being a key residue[48]. A movement of that residue towards the 
metal center can be seen upon binding of a bestatin based inhibitor[53]. 
Due to the possibility that several MetAPs may use only one metal ion and the proximity of 
His79 to Co1, this residue could function as a proton donor to the leaving amino group as 
proposed for His141 of arginase[58]. The Co2-substrate interaction could be replaced by the 
acidic Co2 ligands and other residues in the vicinity. In these cases, the charged form of the 
N-terminus is most likely bound and the addition of the second metal ion may be inhibitory or 
utilized in the in vivo regulation of activity[58]. 
 
 
 
Fig. 2-10 Proposed reaction mechanism[48] 
2.3 Properties of MetAPs 19 
 
2.3.5 MetAPs of Different Species 
 
The E. coli MetAP (EcMetAP) was for the first time isolated and partly characterised by Ben-
Bassat[4], the Salmonella typhimurium MetAP (termed peptidase M) by Miller[3] and 
Wingfield[59]. The pepM gene of S. typhimurium has been cloned and the nucleotide sequence 
determined[60]. Additionally, the MetAPs of yeast[44, 61], of porcine liver[9] and human MetAPs 
have been overexpressed and characterized[62, 63]. The gene sequences of MetAPs have been 
determined in several clinically important pathogens such as Mycobacterium tuberculosis in 
tuberculosis, Enterococcus faecalis in urinary tract infection and endocarditis, Streptococcus 
pneumoniae in pneumonia, Haemophilus influenzae in respiratory tract infections and 
Helicobacter pylori in ulcers. MetAP genes have also been identified in Pyrococcus furiosus, 
Methanococcus jannaschi, Bacillus subtilis and in the cyanobacterium Synechocystis[62] 
among many other organisms. 
 
 
2.3.5.1 Pyrococcus furiosus MetAP (PfMetAP) 
 
PfMetAP has been cloned, overexpressed and characterized[64]. It seems to be evolutionary 
located at the eukarya-bacteria boundary[6], because on the one hand, there is a high degree of 
sequence homology in the stretches surrounding the five preserved cobalt-binding residues 
and it is lacking the N-terminal extension but on the other hand it has a long insert of about 60 
amino acid residues in the C-terminal domain as can be seen in type-II MetAPs. 
PfMetAP is thermostable and exhibits maximum activity at 90 °C. DSC (Differential 
scanning calorimetry) revealed that the heat stability is likely a result of electrostatic 
stabilization due to extra ion pairs compared to EcMetAP and a stable (globule-like) 
conformation[65]. The crystal structure supports these findings and contributes the heat 
stability to a unusually high number of internal hydrogen bonds and ion-pairs and the overall 
fold[66]. 
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2.3.5.2 Yeast MetAPs 
 
Due to the easy handling of yeast cultures and the possibility of genetic manipulations,  
S. cerevisiae has been used (apart from E. coli) for extensive studies of MetAPs. Both type-I 
and type-II MetAP can be found in S. cerevisiae. Apart from single amino acid mutations, 
null mutants lacking, for example, only one type of MetAP provide insight into the 
similarities and differences between the two types in vivo:  
Cloning of the yeast MetAP-I enzyme revealed a considerable degree of sequence identity 
(about 40 %)  between its C-terminal domain (~30 kDa) and the complete prokaryotic 
sequences[16]; however, the N-terminal domain (~12 kDa) is unique. Yeast MetAP-I (42 kDa) 
is 22 % homologous to yeast MetAP-II and about 40 % homologous to bacterial MetAPs. 
Yeast MetAP-II encodes a protein that shows 55 % homology with rat p67[42]. Both types are 
associated to ribosomes[47]. 
Unlike in the case of the prokaryotic gene, the deletion of the yeast MetAP-I gene is not 
lethal, although the mutant strain has a drastic change in its doubling time and decreased 
colony size[44]. The MetAP-II null strain, like the MetAP-I null strain, is also viable but with a 
slower growth rate compared to the wild type (but faster than the MetAP-I null strain, 
suggesting that MetAP-I plays a larger role than MetAP-II in promoting cell growth). The 
MetAP-I, MetAP-II double-null strains are nonviable[42]. 
The deletion of the N-terminal domain of yMetAP-I has no effect on its catalytic activity in 
vitro, but it does compromise the ability of the enzyme to complement the slow growth 
phenotype of a MetAP-I null yeast strain[16]. In addition, point mutations in the zinc finger 
region that almost completely abolish complementation ability result in dissociation of the 
enzyme from the ribosome[67]. Thus, the zinc finger region is important for ribosome 
association and for MetAP function in vivo. This result has been confirmed by coexpression 
experiments of truncated and wild type MetAP-II[68]. 
The two types of MetAPs seem to exhibit a different substrate cleavage pattern in vivo[47]. In 
addition, type-II MetAP seems to be more susceptible to product inhibition by methionine 
than type-I[40] and is therefore more sensitive to the intracellular methionine concentration. 
In conclusion, the removal of N-terminal methionine is an essential function in yeast, as in 
prokaryotes, but yeast requires two MetAPs to provide the essential function which can only 
be partially provided by MetAP-I or MetAP-II alone. 
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2.3.5.3 Human MetAPs (HsMetAP) 
 
As in the case of yMetAP, the N-terminus is not required for activity or stability of  
HsMetAP-II[69]. In spite of the similarities and the conserved active site residues, HsMetAP-II 
has different substrate specificity as it can also cleave substrates smaller than a dipeptide, 
such as Met-AMC and Met-pNA[69]. 
HsMetAP-II has become a target protein for drug development because this enzyme seems to 
be involved in the process of angiogenesis. Thus, specific inhibitors might be used as anti-
cancer drugs. A connection with tumor promotion can be suggested due to the upregulation of 
MetAP-II-levels by carcinogenic phorbolesters. MetAP-II expression correlates with cell 
growth and nondividing tissue culture cells lack immunodectectable levels of MetAP-II[20]. 
For further information about the physiological role of the human MetAP-II cfr. 4.3.2.2 
(Covalent Inhibitors, Mode of Action on the Molecular Basis). 
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3 Aims of this Work 
 
The Methionine Aminopeptidase plays a central role in the cellular protein metabolism of 
both eukaryotic and prokaryotic cells. The main aim of this work was the development and 
characterization of inhibitors of the E. coli methionine aminopeptidase as potential 
antibacterial, antifungal or antiparasitic drugs. As the human enzyme is involved in tumor 
progression and angiogenesis, a deeper understanding of this type of enzyme, the underlying 
mechanisms and the binding modes of inhibitors might also prove useful for the development 
of anticancer drugs. 
Expression and purification of the enzyme was the first essential step towards this aim. A 
stock of transformed BL21(DE3) cells was kindly provided by Prof. Brian Matthews 
(University of Oregon). After isolation of the plasmid and a new transformation of competent 
E. coli cells, the protein should be overexpressed and purified by affinity chromatography 
according to published procedures. 
For the screening of inhibitor, a cheap and easy to handle assay system was required. After an 
extensive literature research, a published assay procedure should be modified to an end-point 
method and optimized. 
After these initial steps, the enzyme should be characterized with respect to biochemical 
properties. This includes parameters such as pH-optimum and metal dependency but also the 
binding of an epoxide-containing inhibitor (fumagillin), a known covalent inhibitor of 
MetAPs. Besides, other small molecules with an epoxide group were to be synthesized and 
tested. 
For the discovery of new leading structures, computational screening methods and molecular 
modeling also performed in our working group should be combined with the screening of 
different classes of compounds. A series of derivatives should be synthesized to improve in 
vitro affinity and to gain insight into structure-activity relationships. Finally, the most 
promising compounds should be tested for their antibacterial potency and X-ray studies 
should be used to clarify the binding mode of the best compounds and of other inhibitors 
described in the literature. 
These results might prove useful for the further development of drugs. They hopefully will 
provide additional facts that can be used for the interpretation of certain phenomena that 
cannot be explained so far, for example the lack of correlation between the (high) in vitro and 
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(low) in vivo potency of known inhibitors. Furthermore, they are likely to have an impact on 
the proposed reaction mechanism of this enzyme and might lead to a better understanding of 
the demands of potential drugs. 
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4 Results and Discussion 
4.1 Expression and Purification of EcMetAP 
 
EcMetAP was overexpressed using the BL21(DE3) strain transformed with a modified 
pET(28b)-vector encoding for a His-tagged EcMetAP that was kindly provided by Prof. 
Matthews and Dr. Lowther[70]. As freshly transformed cells normally give much higher yields, 
the plasmid was isolated with commercially available kits and the E. coli strain re-
transformed. Plasmid isolation was checked with gel electrophoresis (see Fig. 4-1). The 
sequence encoding for EcMetAP is inserted in the cloning site between the NcoI and the 
XhoI-site and consists of about 1100 bp. The modified plasmid has a size of about 6.3 kb. 
Digestion with SmaI (4300) and NcoI (296) results in the two expected fragments of 2.3 kb 
and 4 kb. 
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Fig. 4-1 Left: Agarose gel after digestion of the isolated plasmid with SmaI and NcoI; right: pET-28b vector 
(Novagen) with restriction sites 
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The EcMetAP was then overexpressed and isolated according to literature procedures[70]. 
Affinity chromatography using a Ni(II)-loaded NTA-agarose-column was used for the 
purification of the overexpressed His-tagged enzyme. The tag was then cleaved off with 
biotinylated thrombin and the thrombin was removed with streptavidin agarose. After removal 
of the His-Tag by a second NTA-column, the MetAP was then further purified by size-
exclusion chromatography using a Superdex column (cf. Fig. 4-2).  
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Fig. 4-2 Schematic drawing of the expression and purification procedure for EcMetAP 
 
 
The purity of the enzyme was checked with SDS-PAGE (cf. Fig. 4-3), and the removal of the 
His-tag was further followed with ESI-MS-MS and MALDI-TOF-MS (cf. Fig. 4-4).  
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Fig. 4-3 SDS-PAGE of: induced E. coli cells (left), His-tagged EcMetAP after purification by a Ni-NTA-
column (middle) and EcMetAP after removal of the His-tag with thrombin and purification by a 
Superdex-column (right); 7 µl of a 0.5 mg/ml enzyme solution were applied. 
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Fig. 4-4 left: MALDI-TOF-MS measurements of EcMetAP before and after removal of the His-tag 
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The detected masses for the His-tagged and the “free” enzyme were as follows: 
 
 His-tagged 
after His-tag- 
removal 
∆ (MW His-Tag) 
MALDI-TOF-MS 30881 Da 29553 Da 1243 
ESI-MS-MS 30857 Da 29641 Da 1216 
calculated (MetAP-LVPR-|-
GSLEHHHHHH)a 
31,0 kDa 29,8 kDa 1,2 kDa 
a http://www.sciencegateway.org/tools/proteinmw.htm 
 
 
4.2 Assay Development and Characterization of EcMetAP  
4.2.1 Overview: MetAP Assays 
 
Several assays have been described in the literature for the testing of MetAP activity. Most of 
them are discontinuous assays where the reaction of the MetAP is separated from the 
detection of its activity. Frequently, a small peptide with an N-terminal starter methionine is 
used as substrate and cleavage of this methionine is performed in a buffer at neutral pH and 
37 °C. Usually, cobalt is used to activate the MetAP. There are some differences in how the 
reaction is stopped and the released methionine is detected: In general, EDTA is used to 
inactivate MetAP at the end-point but also denaturation of the enzyme by heat or TFA are 
common. Yeast MetAP for example is readily inactivated by “generic” metalloprotease 
inhibitors (such as EDTA or o-phenanthroline), sulfhydryl-modifying reagents (HgCl2 and 
pHMB) or by zinc ions[61].  
 
Most differences exist in the detection part. Two general principals can be distinguished: 
Either a chromatographic method is applied where the released methionine is separated from 
the shortened substrate[71, 72] (this method can be used in the presence of methionine or 
chromophores) or the released methionine is chemically modified resulting in a compound 
that allows photometric measurement. Of course, combinations of the two principles may be 
used (with precolumn derivatization procedures). For example, AQC (6-aminoquinolyl-N-
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hydroxysuccinimidyl carbamate) reacts with amino acids to form stable asymmetric urea 
derivatives which can be analyzed by reversed-phase HPLC[73, 74]. Other assays use either a 
chromogenic or a fluorogenic tag for derivatization and the resulting derivatives are also 
analyzed by HPLC or capillary electrophoresis.  
Although being very sensitive, these methods are often time-consuming and inconvenient, 
especially if a large number of tests should be performed, for example for the screening of 
inhibitors. Additionally, the colorimetric detection of single amino acids or the chemical 
derivatization of the peptides followed by chromatographic analysis require the removal of 
the methionine prior to the assay and are subject to interference by other chromophores[71]. 
 
An easy to handle continuous assay using thioesters as a substrate has been reported by Zhuo 
and coworkers[75]. A free thiol group is generated upon enzymatic removal of the methionine 
and quantitated with Ellman’s reagent (DTNB). However, this method seems inconvenient as 
DTNB also reacts with the thiol groups of MetAP-cysteines. It has been shown that DTNB 
inactivates MetAP due to the modification of a cysteine residue near the active site[71]. 
Additionally, initial tests performed in our group revealed that the thioester substrates are not 
very stable and generate problems with background noise depending on pH and (nucleophilic) 
solvent, thus decreasing sensitivity. 
 
Zhuo and coworkers also reported another continuous assay using Met-Pro-pNA coupled to a 
prolyl-aminopeptidase[75]. However, Met-Pro-pNA is not a good substrate for EcMetAP 
which prefers tripeptides or larger peptides and the prolyl aminopeptidase used is no longer 
commercially available. Besides, this enzyme is closely related to MetAP: It is also metal 
dependent and predicted to share the same pita-bread fold. All five conserved active site 
residues of the EcMetAP are also conserved in three different prolyl aminopeptidases[14]. 
Therefore, the probability of an interference (of for example inhibitors) with the detection 
enzyme is relatively high and metal-specific tests are difficult. 
Besides the detection of methionine with the ninhydrine reaction after TLC, a photometric 
method is very common that monitors the release of methionine using the highly toxic and 
carcinogenic o-dianisidine (3,3’-dimethoxybenzidine) together with an amino acid oxidase 
(AAO) and a peroxidase from horseradish (HRP)[4, 6, 50, 59]. Oxidation of the released 
methionine by AAO generates H2O2 that is used as a substrate by HRP to oxidize  
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o-dianisidine as a cosubstrate. The resulting product can be measured by absorption at 450 nm 
(cfr. Fig. 4-5). 
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Fig. 4-5 Reaction scheme for the photometric detection of o-dianisidine with horseradish peroxidase 
(HRP) 
 
Based on this procedure, an improved fluorogenic assay has been reported by Yang and 
coworkers[69]. This method uses the substance “Amplex Red” instead of o-dianisidine and the 
oxidation product can be measured fluorometrically. It is a cheap, easy to handle and sensitive 
assay, and it can be performed in 96 well plates. As there was a Wallac Victor multiplate 
reader available to us, it was decided to establish this fluorimetric assay. The complete 
reaction scheme is outlined in Fig. 4-6: 
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Fig. 4-6 Reaction mechanisms of the Amplex Red Assay for the quantification of MetAP-activity, AAO: L-
Amino acid oxidase, HRP: Horseradish peroxidase 
 
4.2 Assay Development and Characterization of EcMetAP 31 
 
However, the drawbacks of this assay should not be withheld. Besides being time-consuming 
as the detection reactions need 30-60 minutes to reach completion, any remaining MetAP 
activity (due to incomplete inactivation) or contaminating peptidase activity could generate 
significant background signal. In addition, substances with oxidizing or reducing properties 
must not be present in larger amounts because they may interfere with the chemistry of the 
detection part. However, testing of such substances at concentrations smaller than ~1 µM are 
possible. Taken together, the advantages surpass the disadvantages. 
 
 
4.2.2 Assay Development and Validation 
 
It was decided to change the continuous assay into an end point assay because of the 
following reasons: 
 
i) The amount of DMSO during the MetAP reaction should be as low as possible as 
the enzyme is very susceptible to organic solvents. As it is recommended to store 
the Amplex Red stock solution in DMSO, the addition after the MetAP reaction 
seemed advantageous. 
ii) The MetAP properties and activity should be influenced as little as possible by 
other enzymes; therefore the presence of AAO and HRP should be avoided during 
the substrate hydrolysis reaction. 
iii) There are difficulties in the measurement of starting velocities as is normally done 
in continuous assays when the assay is performed on a 96 well plate with a 
multiplate reader because of the nature of the instrument (time lag between the 
reading results of different wells) and because of liquid handling (simultaneous 
reaction start) which can easily be avoided in a discontinuous assay. 
 
Additionally, the volume was increased from 50 µl to 250 µl in order to reduce the error 
derived from handling small volumes. Concentrations in the following refer to the reaction 
part. Exceptions are the concentrations of EDTA, resorufine and Amplex Red that refer to the 
detection part. The volumes were 200 µl for the reaction part and an overall volume of 250 µl 
after the addition of the reagents of the detection part unless stated otherwise. 
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The assay development was started with the detection part. The following factors were 
important: 
 
i) Detection limit 
ii) Concentration of methionine to be detected 
iii) Concentration of MGMM during the MetAP reaction and consequently remnant 
MGMM present during the detection of the released methionine 
iv) Concentration of detection enzymes (L-Amino Acid Oxidase, Horseradish 
Peroxidase) 
v) Concentration of EDTA as reaction stopper 
vi) Concentration of Amplex Red 
 
 
4.2.2.1 Detection Limit 
 
Resorufine was used as standard for the evaluation of the detection limit (cf. Fig. 4-7). 
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Fig. 4-7 Detection range using resorufine as a reference (volume 250 µl) 
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A linear correlation between the concentration of resorufine and the fluorescence units 
measured is given in the range from zero up to 10 µM resorufine. The detection range was 
then checked with different concentrations of H2O2 in the presence of Amplex Red and finally 
with different concentrations of methionine in combination with the detection enzymes for the 
conversion of Amplex Red to resorufine. The fluorescence values obtained were slightly 
lower but comparable to those obtained with resorufine. 
 
 
4.2.2.2 Concentration of Detection Enzymes 
 
As there are two enzymes involved in the detection of methionine, it is important that the first 
reaction, the generation of H2O2, is the rate-limiting step. For this reason, the ratio of the 
detection enzymes was kept as published with a much higher concentration of HRP compared 
to AAO. Unfortunately, Amplex Red is converted to resorufine in the presence of the 
substrate MGMM even if no methionine is present (resp. released by the MetAP). In order to 
investigate if this oxidation of Amplex Red is unspecific or dependent on the detection 
enzymes, different concentrations of HRP/AAO were tested (cfr. Fig. 4-8). 
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Fig. 4-8 Dependency of the amount of detection enzymes and the increase of the blank in the presence of 
180 µM MGMM in the reaction part (100 µl, final concentration 72 µM), 40 µM Amplex Red and 9 
mM EDTA (final volume 250 µl) 
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This increase of the zero-value correlates with the concentration of detection enzymes present. 
Possibly, AAO is (to a small percentage) able to oxidize MGMM, which is confirmed by tests 
with different amounts of MGMM (see 4.2.2.3, Concentration of MGMM Present During the 
Detection).  
 
 
4.2.2.3 Concentration of MGMM Present During the Detection 
 
It should be tested if the increase of the blank is based on the oxidation of Amplex Red by 
H2O2 that is generated by the side reaction of AAO with the substrate. An alternative 
explanation would be a direct unspecific oxidation. This could happen either by the contact 
with oxygen or by a cross reaction with one of the detection enzymes. Thus, several 
concentrations of MGMM were incubated with the detection enzymes and Amplex Red 
(cf. Fig. 4-9). 
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Fig. 4-9 Dependency of the MGMM concentration (in the reaction part, 100 µl) and the increase of the zero 
value in the presence of 1.4 U/well HRP, 0.01 U/well AAO, 40 µM Amplex Red and 9 mM EDTA 
(final volume 250 µl) 
 
The increase of fluorescence correlates with the concentration of MGMM. In the case where 
no MGMM (and no methionine) is present, a slight increase can be observed that can possibly 
be attributed to the oxidation of Amplex Red on contact with air. 
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For calibration curves and other measurements, the difference of the measured fluorescence 
FP and the blank FZ was determined. The resulting curve(s) reached a plateau after 40-60 min 
that remained stable for about 30 min. In summary, it has been shown that 
 
i) the increase of the blank is dependent on the amount of detection enzymes used 
(Fig. 4-8) as well as on the MGMM concentration (Fig. 4-9) 
ii) the concentration of EDTA used does not influence the increase of the blank (data 
not shown) 
iii) the concentration of detection enzymes does have an impact on the detection time 
but does not influence the resulting fluorescence difference between FP and FZ 
(MAX (∆FP-∆FZ), data not shown). 
 
The absolute fluorescence values increase with the amount of detection enzymes. Thus, the 
detection limit is reached faster with higher concentrations of detection enzymes. The same 
applies for higher concentrations of MGMM, which decreases the sensitivity of the assay. 
Therefore, all of these concentrations should be as low as possible.  
On the other hand, a reduced amount of detection enzymes leads to a very long detection time 
and a reduced concentration of MGMM also brings up some problems: The amount of 
released methionine (from MetAP activity) depends within certain limits on the amount of 
substrate. Thus, less MGMM decreases the sensitivity of the assay as more MetAP is needed 
for the same amount of released methionine (or a longer reaction time is required).  
As there is a detection limit and for the assay results the difference between the measured 
fluorescence FP and the blank (zero value FZ) is determined, it is important to find a 
compromise between the concentration of MGMM and the detection enzymes. On the one 
hand, the MGMM concentration has to be high enough to allow the enzyme to work under 
saturated conditions during the whole reaction time, and the concentration of the detection 
enzymes also should be as high as possible in order to shorten the duration of the detection 
part. On the other hand, both the MGMM and the detection enzyme concentration should be 
as low as possible in order to avoid a strong increase of the blank. The reaction time should 
not be too long to minimize unspecific hydrolysis of MGMM although MGMM was shown to 
be stable even when incubated for 45 min at 37 °C (data not shown).  
200 µM MGMM, 1.05 U/well HRP, 0.0075 U/well AAO and 9 mM EDTA proved to be 
suitable conditions and were used for further tests. 
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4.2.2.4 Calibration Curves 
 
In Fig. 4-10, the calibration curve for 0-8.75 µM methionine in the presence of 200 µM 
MGMM is depicted.  
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Fig. 4-10 Calibration curve in the presence of 200 µM MGMM in the reaction part (200 µl, final 
concentration 160 µM), 1.05 U/well HRP, 0.0075 U/well AAO, 9 mM EDTA, 10 µM Amplex Red 
(final volume 250 µl) 
 
The results of other calibration experiments are summarized in Table 4-1. 
 
In general, 200 µM MGMM was used. The calibration curves with MGMM concentrations 
other than 200 µM were needed for the determination of the KM-value. The correlation 
coefficient R2 was always 0.99 or higher.  
 
It should be noted that – although always linear and in good correlation with the concentration 
of methionine – the absolute fluorescence values measured are dependent on factors such as 
age and state of used HRP, AAO and Amplex Red stock solution. Parameters of the 
Multiplate Reader such as intensity of the lamp also influence these values. 
 
4.2 Assay Development and Characterization of EcMetAP 37 
 
Table 4-1 Calibration curves for different MGMM concentrations present during detection 
Concentration of MGMM [µM] Calibration curve 
100 F = 65282*[µM Met] 
150 F = 64337*[µM Met] 
200 F = 63893*[µM Met] 
400 F = 61802*[µM Met] 
800 F = 60588*[µM Met] 
1200 F = 60188*[µM Met] 
2000 F = 55638*[µM Met] 
3000 F = 51562*[µM Met] 
 
 
4.2.2.5 Assay Optimization 
 
In the described continuous assay, 50 µM Amplex Red were used. It has been shown that up 
to 10 µM of released methionine can be detected and that 10 µM Amplex Red is sufficient 
and gives the same results as 20, 30 and 40 µM (data not shown), reducing the costs of the 
assay as well as the amount of DMSO present during detection. 
EcMetAP is highly interfering with plastic. For example, vortexing of the MetAP solution in 
Eppendorf vials diminishes the activity to 5 %. Even pipetting of MetAP solution into eight 
wells one well after the other reduces the activity to 20 %. In order to limit the inactivation of 
MetAP by minimizing the adsorption of the protein on plastic, several substances have been 
tested as additives such as detergents (for example Tween 20), glycerole or BSA. Although 
0.1 % BSA slightly reduces (and Tween 20 increases) the fluorescence values maintained, this 
does not affect linearity. Only BSA proved to be an effective additive reaching its maximum 
effect at concentrations from 0.05 to 0.1 %. Therefore, the MetAP dilutions used in the assay 
were made with 0.1 % BSA in buffer. 0.1 % BSA during the assay decreases the amount of 
required enzyme by a factor of 10 and was used for further assays. 
It should be noted that although substances with oxidizing or reducing properties interfere 
with the detection part, DTT is tolerated in small amounts (tested up to 3 µM) but reduces the 
linear detection range (data not shown). However, it is not possible to use GSH in the 
concentrations mentioned in the literature (5 mM) because it forms a precipitate with Co(II). 
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4.2.2.6 Assay Validation 
 
In order to optimize the reaction time and to adjust the concentrations of enzyme and substrate 
used, the turnover rate of the MetAP for different conditions should be investigated. 
 
It has been shown that 
i) the turnover of MGMM after a given reaction time is proportional to the amount of 
MetAP used (Fig. 4-11) 
ii) the turnover of MGMM with a constant amount of MetAP is proportional to the 
reaction time up to about 20 min (Fig. 4-12). 
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Fig. 4-11 Correlation between the concentration of EcMetAP and substrate turnover (15 min reaction 
time), 200 µM MGMM, 1.05 U/well HRP, 0.0075 U/well AAO, 9 mM EDTA, 10 µM Amplex Red (final 
volume 250 µl) 
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Fig. 4-12 Correlation between the reaction time and substrate turnover (10 nM MetAP), 200 µM MGMM, 
1.05 U/well HRP, 0.0075 U/well AAO, 9 mM EDTA, 10 µM Amplex Red (final volume 250 µl) 
 
The reaction time was set to 15 min with 10 nM MetAP and 200 µM MGMM used during the 
reaction part. 
After these successful experiments, the assay was used for the subsequent characterization of 
the EcMetAP and for further tests. 
 
 
4.2.3 Characterization of the EcMetAP 
4.2.3.1 Determination of the KM-value 
 
The KM-value (substrate concentration with the semi-maximal conversion-rate) was 
determined by incubation of the enzyme with eight different substrate concentrations. The 
conversion rate(s) and the parameters mentioned in Table 4-2 were calculated from the 
calibration curves (Table 4-1) and analyzed using the Lee and Wilson modified Lineweaver-
Burk-equation[76]. 
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Table 4-2 Substrate- and product-concentrations after 15 min reaction and resulting conversion rates 
Initial Fluoresc. Conversion Released Final Medium 1/s* Reaction- 1/v*
MGMM value factor Met substrate- substrate- rate v*
conc. meas. (Fluoresc. for conc. conc. s*
µM 1 µM Met) µM µM µM µM-1  µmol/(l*15 min) l*15 min/µM
100 41305 65282 0.633 99.367 99.684 0.010 0.633 1.580
150 58469 64337 0.909 149.091 149.546 0.007 0.909 1.100
200 63690 63893 0.997 199.003 199.502 0.005 0.997 1.003
400 101329 61802 1.640 398.360 399.180 0.003 1.640 0.610
800 157792 60588 2.604 797.396 798.698 0.001 2.604 0.384
1200 201657 60188 3.350 1196.650 1198.325 0.001 3.350 0.298
2000 211828 55638 3.807 1996.193 1998.096 0.001 3.807 0.263
3000 227404 51562 4.410 2995.590 2997.795 0.000 4.410 0.227
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Fig. 4-13 Graphical portrayal of 1/s* against 1/v* after Lee-Wilson for the determination of the KM-value 
 
The KM-value was determined in three independent measurements as the reciprocal of the 
negative x-axis-intercept of the graphical portrayal of 1/s* against 1/v* (see Fig. 4-13). After 
solving the equation  
nmxy +=  ⇔  
m
n
x −=  
 
the KM was determined to be 804 µM (± 105 µM). 
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Normally, the substrate concentration within an assay should be in the range of the KM-value 
and up to 20% of the substrate should be cleaved within an assay. It was clear from Fig. 4-7 
that only up to 10 µM Met could be detected. Therefore, 200 µM MGMM were judged to be 
sufficient for the enzyme to work under saturated conditions (with a turnover of max. 10 µM 
or 5 %) and this substrate concentration was used for the further testing. 
 
 
 
4.2.3.2 Stability of the EcMetAP Kept on Ice 
 
Unlike HsMetAP-II that can be stored at 4 °C for several months without a significant loss of 
activity[69], EcMetAP is very susceptible to oxidation. In the literature, it is described that in 
the presence of 15 mM Met at 4 °C it takes 14 days for EcMetAP to lose 90 % of its activity 
and that in the absence of Met, the rate of activity loss increases 10-fold. Addition of fresh 
Met does not restore activity[71].  
The MetAP is immediately inactivated by bubbling molecular oxygen through the solution 
and inactive MetAP is not reactivated by fresh Co(II). This can be explained considering the 
redox potential of Co(II)/Co(III). This potential is 1.18 V, much higher than the potential of 
Fe(II)/Fe(III) with 0.77 V that is readily oxidized on contact with air. Thus, simple oxidation 
of the metal is not the likely route of inactivation. A likely target of oxidation is one or more 
of the seven cysteine residues in the molecule as cysteine modification with iodoacetamide 
leads to inactivation[59]. The sulfur atoms in Cys59 and Cys70 are close enough to form a 
disulfide bond which would partially close the opening to the active site or induce 
conformational change. This is supported by the fact that TCEP, a reagent specifically 
reducing disulfide bonds, can reactivate oxidized MetAP; and untreated MetAP was more 
active than MetAP treated with DTNB, a substance specifically reacting with cysteine RSH 
groups[71].  
 
For these reasons, the activity of EcMetAP-aliquots kept on ice was determined after different 
storage times:  
The amount of released Met drops by about 80 % when the solution is kept on ice for about 8 
hrs (Table 4-3). This is mainly due to the aging of the (diluted) MetAP solution.  
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The findings above support the facts described in the literature as methionine or another 
antioxidant was absent in the stock solution of EcMetAP and during the assay. In addition, 
BSA was also absent, therefore much higher MetAP-concentrations were needed and 
adsorption to plastic surfaces might also partly explain the drop in activity. 
Table 4-3 Dependency between the age of MetAP solutions kept on 
ice and MetAP activity for 400 nM MetAP, without BSA 
Storage Time [hrs]  Activity [%] 
0 100 
4 84.2 
8 27.1 
 
 
4.2.3.3 Influence of DMSO and EtOH 
 
As many of the inhibitors described in the literature are only sparingly soluble in water, stock 
solutions of DMSO or EtOH are often necessary for the testing of compounds. Therefore, the 
impact of different concentrations of DMSO and EtOH on the activity of EcMetAP was 
examined (Fig. 4-14). 
 
It has been shown that the turnover rate of MGMM is strongly decreased by the presence of 
DMSO or EtOH (Fig. 4-14). Even small amounts (1 %) result in a drop of activity of about  
30 % for EtOH and even 60 % for DMSO. As a consequence, more EcMetAP would be 
needed for testing. Thus, the amount of these solvents (derived from inhibitor solutions) 
should be minimized in order to retain the high sensitivity of the assay. For further tests, a 
maximum concentration of 0.1 % DMSO or EtOH was used. 
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Fig. 4-14 Influence of EtOH and DMSO on MetAP activity (10 nM MetAP, 200 µM CoCl2, 200 µM MGMM, 1.05 
U/well HRP, 0.0075 U/well AAO, 9 mM EDTA, 10 µM Amplex Red, final volume 250 µl) 
 
 
4.2.3.4 pH-Profile of MetAP Activity 
 
The activity of EcMetAP over a broad pH-range was examined (cfr. Fig. 4-15) and the region 
with the highest activity was again measured in detail (cfr. Fig. 4-16). 
The pH-optimum was determined to be 7.5. This is in accordance with the value from 
literature. Several tests demonstrate that MetAP has a pH optimum near neutrality: 7.5 was 
reported for EcMetAP[75, 77] and 7.0 for ScMetAP[44, 61]. 
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Fig. 4-15 Dependency between MetAP activity and pH-value, range 5 - 8.5 (10 nM MetAP, 200 µM CoCl2, 
200 µM MGMM, 1.05 U/well HRP, 0.0075 U/well AAO, 9 mM EDTA, 10 µM Amplex Red, final 
volume 250 µl) 
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Fig. 4-16 Dependency between MetAP activity and pH-value, range 6.5 – 8 (10 nM MetAP, 200 µM CoCl2, 
200 µM MGMM, 1.05 U/well HRP, 0.0075 U/well AAO, 9 mM EDTA, 10 µM Amplex Red, final 
volume 250 µl) 
 
4.2 Assay Development and Characterization of EcMetAP 45 
 
4.2.3.5 Metal Specificity 
 
4.2.3.5.1 Overview 
 
The identity of the metal ion bound in vivo has not been firmly established. All types of 
MetAPs are known to be stimulated by Co(II) and inactivated by EDTA, therefore it has been 
assumed that MetAPs are Co(II)-dependent enzymes. Activity has also been observed with 
other metal ions, depending on the type and origin of MetAP, assay conditions and substrate 
used. These results are summarized in Table 4-4. 
 
Table 4-4 Metal dependency of different MetAPs 
MetAP of activated by inactive with Other observations Ref. 
Synechocystis Co(II), Mn(II), Zn(II), Mg(II)  
Synechocystis expresses three different MetAPs-I 
differing in substrate specificity, divalent metal ion 
requirement, pH and temperature optima 
[62]
 
S. typhimurium Co(II)  The metal is loosely associated and lost during purification 
[59]
 
S. aureus Co(II), Mn(II), Zn(II)  
Ni(II) activates the enzyme at low concentrations and 
strongly inhibits the Co(II)-activated enzyme at 
higher concentration; an activation by Fe(II) was not 
reproducible 
[78]
 
E. coli Co(II)  The metal is loosely associated and lost during purification 
[59]
 
E. coli Co(II) 
Mn(II), 
Cu(II), Zn(II), 
Mg(II) 
The enzyme is inactive in the presence of EDTA and 
its activity is Na+/K+-dependent 
[4]
 
E. coli 
anaerobically: 
Co(II), Fe(II), 
Mn(II), Zn(II), 
Co(II)+GSH, 
Fe(II)+GSH, 
Zn(II)+GSH 
 
Fe(II) is proposed as the relevant metal ion, this is 
underlined by ICP analysis. Whole cell analysis 
showed that the Fe(II)-, Mn(II)- and Zn(II)-levels 
increase upon MetAP-expression with the largest 
increase for Fe(II). Excess metal ions are inhibitory. 
The addition of Co(II) and Fe(II) resulted in the 
highest activity even in the presence of glutathione. 
Zn(II) and GSH resulted in a slightly active enzyme, 
Mn(II) and GSH were not tested. 
[79]
 
E. coli anaerobically: Co(II), Fe(II)  
Only one metal ion seems to be relevant for activity 
and is tightly bound, this is underlined by ICP 
analysis, EPR spectra and 1H-NMR spectra. The  
second ion is loosely associated and there is a weak 
binding site for a third metal ion. KD = 200 nM for the 
first and 2.5 mM for the second binding site. 
[80]
 
E. coli aerobically: Fe(II)   
[78]
 
E. coli Co(II), Zn(II)  
Activity with Zn(II) is observed when MetAP is prior 
treated with EDTA, MetAP is inactivated by higher 
Zn(II)-concentrations. 
[52]
 
E. coli Mn(II)  Maximum activity was observed with one equivalent 
of metal, KD = 3-6 µM for the first binding site 
[81]
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MetAP of activated by inactive with Other observations Ref. 
E. coli  Co(II), Mn(II), Zn(II), Ni(II)  
The activation by Ni(II) and Zn(II) is substrate 
dependent: Ni(II) activates the enzyme only with Met-
AMC, Zn(II) not with Met-AMC but with Met-S-Gly-
Phe 
[82]
 
P. furiosus Co(II)   [66]
 
P. furiosus Fe(II), Co(II) Zn(II) 
Maximum activity was observed with one equivalent 
of metal, KD = 20-50 nM for the first, 350 µM for the 
second binding site 
[83]
 
P. furiosus Co(II), Mg(II) Zn(II), Mn(II)  [6]
 
P. furiosus Mn(II)  Maximum activity was observed with one equivalent 
of metal, KD = 1 µM for the first binding site 
[81]
 
S. cerevisiae I 
Co(II), Zn(II), 
Mn(II), Ni(II),  
Zn(II)+GSH, 
Mn(II)+GSH 
Ca(II), Cu(II), 
Fe(II), Mg(II), 
Co(II)+GSH, 
Ni(II)+GSH 
Zn(II) is  proposed as the relevant metal ion [84]
 
S. cerevisiae I Co(II), Zn(II), Mn(II) 
Ni(II), Mg(II), 
Ca(II), Cd(II), 
Cu(II) 
Met-S-Gly-Phe was used as a substrate [85]
 
S. cerevisiae II Co(II) 
Mg(II), 
Mn(II), 
Cu(II), Fe(II), 
Zn(II) 
MetAP is inactivated by EDTA, o-phenanthroline and 
by Zn(II) 
[61]
 
S. cerevisiae II Co(II)   [44]
 
Human MetAP I 
Co(II), Mn(II), 
Zn(II)+GSH, 
Co(II)+GSH, 
Fe(II)+GSH 
  
[86]
 
Human MetAP I Co(II), Zn(II)   [87]
 
Human MetAP II 
Mn(II), Co(II), 
Mn(II)+GSH, 
Co(II)+GSH 
 
The importance of Mn(II) is underlined by in vivo 
inhibition tests with metal selective inhibitors, 
Zn(II)+GSH and Ca(II)+GSH resulted in a slightly 
active enzyme 
[86]
 
Human MetAP II Co(II) Zn(II) Zn(II) and excess Co(II) are inhibitory, Zn(II) was 
excluded as relevant 
[69]
 
 
Apart from Co(II), also Zn(II), Mn(II), Ni(II) and Fe(II) have been claimed to be the relevant 
metal ion.  
The idea of Fe(II) being the in vivo metal ion is supported by the analysis of the metal content 
changes of whole E. coli cells by inductively coupled plasma emission analysis. Nevertheless, 
Fe(II) activates EcMetAP only under anaerobic conditions.  
Activation by Zn(II) is generally observed under special assay conditions such as the presence 
of 5 mM GSH. However, anaerobic analysis of EcMetAP suggested that Zn(II) is not the 
relevant ion[52, 80, 88].  
Only few results concerning metal-specificity have been obtained under in vivo conditions. In 
1987, the influence of different metal ions that had been added to the growth medium on the 
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Met-cleavage of TNF in E. coli has been analyzed. A linear correlation was observed with 
Mn(II) (see Fig. 4-17) and there is clear indication that N-terminal excision is strongly 
stimulated by the addition of external manganese to the growth medium[89]. Additionally, the 
pH value has an influence: Met cleavage is promoted at a pH above neutral[89]. The second in 
vivo result also favours Mn(II) as the in vivo relevant metal ion[86], albeit for HsMetAP-II. 
Here, metal-selective inhibitors with Mn(II)-specificity correlate with growth inhibition 
whereas an inhibitor without Mn(II)-specificity does not inhibit growth (although the 
compound accumulates in the cytosol). In addition, several Mn(II)-specific inhibitors tested 
and crystallized with human MetAP-II are active in vivo[90]. Recently, Wilce et al. reported 
the crystal structure of proline aminopeptidase from E. coli, which contains two manganese 
ions per subunit and shows similarity to the E. coli MetAP in sequence and structure[91].  
 
 
Fig. 4-17 Dependency of Mn(II) addition and N-terminal methionine of TNF, according to [89] 
 
 
However, the activation of MetAPs by different metal ions is dependent on the assay 
conditions and factors such as type and origin of the MetAP or substrate used and varies with 
aerobic or anaerobic conditions. For the screening of inhibitors, Co(II) is generally used as it 
reliably activates all MetAPs. Thus, the question of the relevant metal ion still is contentious. 
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4.2.3.5.2 Concentration of Co(II) 
 
First, the concentration of Co(II) was varied over a broad range (1-10000 equivalents, cfr. 
Fig. 4-18) and the area with the highest activity was studied in detail (cfr. Fig. 4-19). 
 
The highest activity was observed with 50-300 µM CoCl2. This amount is in the lower range 
of metal concentrations used by other groups. Concentrations of 100 µM[75] up to even  
1.5 mM Co(II)[92] are used. The drop of activity at higher metal concentration has been 
observed before, for example in Co(II)-loaded yMetAP and in the zinc dependent enzyme 
carboxypeptidase[93]. In the case of MetAP, excess cobalt may be binding to the bridging 
hydroxide ligand which is crucial for catalytic activity. 
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Fig. 4-18 Dependency of MetAP activity from Co(II) concentration; range 0.1-1000 µM (10 nM MetAP, 200 
µM MGMM, 1.05 U/well HRP, 0.0075 U/well AAO, 9 mM EDTA, 10 µM Amplex Red, final volume 
250 µl) 
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Fig. 4-19 Dependency of MetAP activity from Co(II) concentration; range 10-500 µM (10 nM MetAP, 200 µM 
MGMM, 1.05 U/well HRP, 0.0075 U/well AAO, 9 mM EDTA, 10 µM Amplex Red, final volume 250 
µl) 
 
 
4.2.3.5.3 Metal Specificity 
 
The following divalent metal ions were tested for their ability to activate the isolated apo-
enzyme: Zn(II), Mn(II), Mg(II), Ni(II), Ca(II), Cu(II), Fe(II) and Fe(III). Co(II) was used as a 
reference. 
 
Apart from Co(II), only Mn(II) was able to activate the apo-enzyme, albeit higher 
concentrations were needed and the maximum turnover rate was only about 30 % when 
compared to the maximum activation of the Co(II)-loaded form. Contrary to Co(II), no 
optimal concentration could be determined for Mn(II) up to a concentration of 1 mM and the 
activity of the Mn(II)-loaded MetAP seems to reach a plateau. 
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Fig. 4-20 Metal specificity of EcMetAP (10 nM MetAP, 200 µM MGMM, 1.05 U/well HRP, 0.0075 U/well AAO, 
9 mM EDTA, 10 µM Amplex Red, final volume 250 µl) 
 
When competing the above mentioned metal ions individually against 200 µM Co(II), all ions 
acted as inhibitors and decreased MetAP activity. Cu(II) and Zn(II) are most effective 
inhibitors of the Co(II)-activated EcMetAP and have an IC50-value between 1 and 10 µM, 
Mn(II), Fe(II) and Mg(II) have an IC50-value of 100 µM whereas Mg(II), Ca(II) and Fe(III) 
had no (dose dependent) effect on MetAP activity. The results are summarized in Table 4-5. 
 
Table 4-5 Metal competition tests with 200 µM CoCl2 and various concentrations of different metal ions. 
Shown is the residual activity [%] compared to 200 µM CoCl2 without any other metal  
ion added (100 %) 
[µM]/Me Zn(II) Cu(II) Ni(II) Fe(II) Mn(II) Mg(II) Fe(III) Ca(II) 
0.01 97.3 100 100 100 100 100 100 100 
0.1 94.8 100 100 100 100 100 100 100 
1 90.1 96.4 100 100 100 91.6 100 100 
10 22.9 3.7 100 91.0 100 96.4 100 100 
100 0 0 39.5 45.1 63.5 95.5 100 100 
200 0 0 14 9.1 51.2 98.1 100 100 
400 0 0 2.9 4.5 41.2 88.3 100 100 
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The inactivation by other divalent metal ions may not be due to an interference with the active 
site but can also stem from an influence on the protein fold or an interaction with other metal-
binding residues such as cysteines or histidines. Therefore, these results do not shed light on 
the question of the relevant metal ion. However, these findings at least seem to rule out Ca(II), 
Mg(II) and Fe(III) as relevant cations as they seem to be unable to compete with Co(II) and 
do not disturb the activity of a Co(II)-loaded enzyme. 
In summary, the results from the metal specificity-tests together with the findings described in 
the literature clearly favour Co(II) and Mn(II) as candidates for the in vivo metal ion of the 
EcMetAP. 
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4.3 Covalent Inhibitors 
 
4.3.1 Angiogenesis 
 
In 1974, Folkman[94] suggested that many cells capable of forming tumors appear in the body 
at a certain frequency but the vast majority never develop into detectable tumors. The growth 
of these silent “microtumors” is limited due to the lack of an adequate blood supply needed to 
provide the nutrients and oxygen to rapidly dividing cells. These tumors never increase in size 
as the cells continue to divide but simply replace the cells lost due to lack of nutrients. 
However, at an unknown critical stage in tumor progression, a small percentage of these size-
restricted “microtumors” gain the ability to induce new blood vessel formation 
(neovascularization) in the surrounding tissue. An increase in newly formed, highly 
permeable blood vessels serves to provide oxygen and essential nutrients as well as to 
increase the potential for tumor cells to be released into circulation. Recent experimental 
evidence confirms a major role for angiogenesis in the metastasis by providing conduits 
through which invasive tumor cells can disseminate.  
Because angiogenesis contributes significantly to both the growth of tumors and their 
metastasis (tumor progression) and has also been established as an important step for the 
pathogenesis of a number of human diseases including diabetic retinopathy and rheumatoid 
arthritis, inhibitors of this process have significant clinical potential. In comparison with 
conventional chemotherapy, it is hoped that anti-angiogenic therapy will have a number of 
clinical advantages, including low toxicity, lack of drug resistance, and easy access of the 
drugs to the targeted endothelial cells. 
 
 
4.3.2 Fumagillin and Analogs 
 
4.3.2.1 Overview 
 
The fungal metabolite fumagillin and some derivatives (i.e. Ovalicin and TNP-470, cfr. Fig. 
4-21) suppress the formation of new blood vessels and tumor growth. 
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Fig. 4-21 Fumagillin and analogs 
 
Fumagillin was originally identified as an antibacteriophagic[95] and amebicidal agent[96, 97] 
but fell into oblivion afterwards. Its rediscovery reminds of the story of penicillin: In 1990, a 
group working with cell cultures noticed a fungal contamination that selectively inhibited 
endothelial cell proliferation[98]. The fungus was classified as Aspergillus fumigatus fresenius 
and cultivated. Then, the active compound was isolated and identified as fumagillin. 
Subsequently, many attempts have been made to improve the activity of fumagillin. TNP-470 
is a semisynthetic analogue and entered human clinical trials for the treatment of AIDS-
related Kaposi’s sarcoma, metastatic breast cancer, androgen-independent prostate cancer, 
brain cancer, pediatric solid tumors, lymphomas, acute leukemias, advanced squamous cell 
cancer of the cervix, and metastatic renal carcinoma[99-102]. Another TNP-470 based MetAP-II 
inhibitor has been reported useful for the treatment of rheumatoid arthritis[103]. These 
compounds are also potent against P. falciparum and other parasites and might be useful for 
the treatment of malaria or leishmaniasis[104]. 
However, there are also known side effects of these drugs: Prolonged administration of 
fumagillin or TNP-470 leads to severe weight loss. TNP-470 has a short serum half-life (2-6 
min in human) and dose-limiting side effects such as a (reversible) characteristic 
neuropsychiatric symptom complex (anaesthesia, disturbance of equilibrium and 
agitation)[105]. Chemical derivatives are still being synthesized in order to improve the poor 
pharmacokinetic behaviour and dose-limiting toxicity of TNP-470 that can at least in part be 
attributed to the presence of two epoxides and a chloroacetyl group[106]. Replacement of the 
fatty-acid residue in Fumagillin by a trans-cinnamic acid ester with a tri-methyoxy phenyl 
moiety gave a 1000 times more potent substance (CKD-731) than TNP-470[107]. 
In spite of the side effects, these inhibitors have been reported to be useful in combination 
with traditional chemotherapeutic agents and may be utilized to potentiate conventional 
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chemotherapy[108, 109]. Drug resistance in tumor cells or endothelial cells does not appear to 
occur during angiogenesis inhibition. In addition, these drugs might be tolerated for chronic 
use. 
Epoxides are normally considered to be highly reactive chemical species. In the absence of 
general acid or Lewis acid catalysis however, reactions with physiological nucleophiles that 
open the epoxide ring can be expected to be extremely slow. Furthermore, additional 
structural elements of the inhibitor including chirality have a strong effect on reactivity. 
Examples of inhibitors that exploit electrophilic functionality besides fumagillin are, for 
example, the clinically used drug fosfomycin and inhibitors for HIV protease or cysteine 
proteases[88]. These and other (natural) compounds are able to alkylate or acylate their protein 
targets with incredible specificity in spite of their chemical potential for reactivity. 
 
 
4.3.2.2 Mode of Action on the Molecular Basis 
 
The underlying molecular mechanism of the effects observed by fumagillin and its derivatives 
was unknown until a fumagillin-binding protein, the human MetAP-II was identified 
independently by two groups[110, 111]. 
First, fumagillin was thought to inhibit only the human MetAP-II. It has been demonstrated 
that wild type yeast treated with fumagillin continues to grow; yeast only lacking MetAP-II is 
also resistant to its addition and growth of a MetAP-I deletion strain is strikingly inhibited[110]. 
Thus, the action of this epoxide is selective and highly specific for MetAP-II in vivo. Later it 
has been shown that both yMetAP-I and EcMetAP(-I) can also be inhibited by using higher 
concentrations and longer incubation times[70]. Fumagillin also binds to the Mn(II)-loaded 
EcMetAP[112]. A computational approach supports the hypothesis that the parasitic MetAPs 
are also the targets of fumagillin[113].  
Fumagillin was found to form an irreversible adduct with one of the conserved histidine 
residues in the active site, His79 of EcMetAP and the corresponding His231 of HsMetAP-II. 
With E. coli, this has been shown by Lowther and coworkers[70], for the human enzyme this 
was demonstrated by Griffith and coworkers[92]. The crystal structure of HsMetAP-II with 
bound fumagillin is available[56] (cfr. Fig. 4-22). 
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Fig. 4-22 above: schematic drawing of the fumagillin binding, numbering is forEcMetAP; below: picture of 
HsMetAP-II with bound fumagillin, generated from 1BOA[56]. The nitrogen from His231 binds to 
the carbon of the spirocyclic epoxide and the oxygen liberated from the epoxide is coordinated 
to a cobalt ion and hydrogen bonded to a water molecule. 
 
Some precedent can be found in which an active-site histidine is specifically alkylated by 
inhibitors such as the inhibition of chymotrypsin by tos-L-phenylchloromethylketone[114]. 
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Only the epoxide at C3 of fumagillin confers to binding and anti-angiogenic activity[111]. 
Changes in the substituent at the C6 position influence potency and bioavailability and also 
may cause different side effects[98, 111]. 
The question arises why fumagillin inhibition is specific for MetAP-II over MetAP-I because 
the two enzymes have very similar active sites. Several explanations seem possible: 
Considering MetAP-I, the binding histidine (His-79) might be too far away from the epoxide 
group and moving either fumagillin towards the histidine or vice versa would lead to sterical 
clashes[56]. In addition, an increased side chain flexibility of the histidine that is covalently 
modified by fumagillin can be observed in the HsMetAP-I enzyme in computational 
studies[115]. Recent results show that a single amino acid residue is responsible for the 
specificity exhibited by the class of anti-angiogenic agents for MetAP-II over MetAP-I and 
for ovalicin-resistance[116]. Alanine in the position 362 of the HsMetAP-II is substituted by a 
threonine in the type-I enzyme. Mutation of this residue to alanine conferred ovalicin-
sensitivity to MetAP-I, but it is not clear how these mutations affect the movement of amino 
acids in the binding pocket in response to the binding of the inhibitor. 
 
 
4.3.2.3 Mode of Action on the Physiological Basis and Role of MetAP-II 
 
Fumagillin or TNP-470 arrest endothelial cells in the late G1 phase of the cell cycle at low 
nanomolar concentrations[117]. The correlation between the antiproliferative activity of 
fumagillin with the ability to inhibit MetAP-II activity in vitro[111, 118] and in vivo[119] suggests 
that MetAP-II is the physiologically relevant target.  
Many groups have tried to clarify the relation between MetAP-inhibition and endothelial cell 
cycle arrest. Although MetAP-II expression correlates with cell growth and MetAP-II is found 
at higher concentrations in tumors[120, 121], it has been ruled out that differential expression of 
MetAPs in different types of cells[122, 123] is the reason for selective inhibition of endothelial 
cell proliferation. Upregulation of MetAP-II by exposure to fumagillin can be observed both 
in endothelial and in non-endothelial cells. 
As fumagillin-based inhibitors only interfere with the catalytic moiety of the enzyme, a 
different substrate spectrum has been postulated to be the reason for the physiological effects. 
MetAP-I and MetAP-II can widely compensate for each other, but MetAP-II specific cellular 
substrates with MetAP-II being 1000-fold more efficient than MetAP-I have been identified, 
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for example glyceraldehyde-3-phosphate dehydrogenase (GAPDH), cyclophilin A[119] and  
14-3-3γ. 14-3-3 proteins are ubiquitous cytosolic adaptor proteins involved in cell cycle 
control, apoptosis and transcriptional control. Retention of the amino-terminal methionine 
even only in a small subset uf cellular proteins might further lead to dysfunction of proteins, 
to changes in protein stability or to mislocalization of proteins within cells due to prevention 
of N-terminal myristoylation[124]. 
An impact on kinases and the activation of the so-called “p53-pathway” could also be the 
answer for cell cycle arrest upon MetAP-II inhibition. Activation of p53, a protein acting as a 
transcriptional activator of genes, leads to the inhibition of Cyclin dependent kinases (CDKs). 
CDKs drive cell cycle progression and are in turn regulated at cell cycle checkpoints by CDK 
inhibitors such as p21CIP/WAF or p16INK4a. CDK inhibition consequently leads to cell cycle 
arrest at the G1 to S transition[125, 126]. This is called the “p53-pathway”. TNP-470 induces 
expression of p21CIP/WAF only in endothelial cells but not in embryonic or adult fibroblasts and 
thus potently inhibits the activation of CDKs. Moreover, primary endothelial cells isolated 
from p53-/- and p21CIP/WAF-/- mice are resistant to the cytostatic activity of TNP-470[123]. This 
p21WAF1/CIP1 accumulation and concentration dependent induction of apoptosis has also been 
observed with other MetAP-II inhibitors[127]. 
However, a variety of other observations has been mentioned in the literature such as the 
inhibition of thymidine uptake that would suggest specific inhibition of DNA  
synthesis[128, 129]. Fumagillin can also induce apoptosis owing to early mitochondrial damage 
in malignant cells[129]. The anti-angiogenic effect of fumagillin has also been attributed to the 
inhibition of Ets-1 transcription factor expression[130] and down-regulation of the anti-
apoptotic gene bcl-2 and of telomerase activity[131] whereas bcl-2 overexpression counteracted 
the effect of MetAP-II inhibition[129]. 
The crucial role of MetAP-II in cell cycle progression is strengthened by a report that 
proliferation of human endothelial cells can be blocked by human MetAP-antisense 
oligonucleotides[129, 132]. Another group, however, found that depletion of MetAP-II by siRNA 
did not inhibit endothelial cell growth and MetAP-II-depleted endothelial cells remained 
responsive to inhibition by fumagillin[133]. Furthermore, a bengamide analogue can selectively 
inhibit MetAP-II without inhibiting endothelial cell proliferation. These results indicate that 
MetAP-II is not required for endothelial cell proliferation and are strengthened by tests with 
Cytochalasin E, an epoxide-containing metabolite of Aspergillus clavatus resembling TNP-
470. Cytochalasin E is a potent and selective inhibitor of endothelial cell growth in vitro and 
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inhibits angiogenesis and tumor growth in vivo, but does not inactivate MetAP-II even at high 
concentrations[134]. 
In summary, the link between MetAP-inhibition and cell cycle arrest still remains unknown. 
One possibility for an explanation might be the existence of another MetAP-family in 
humans: MetAP-III[135]. MetAP-III and MetAP-I/MetAP-II might exhibit different expression 
and tissue distribution profiles, suggesting additional or different roles for MetAP-III in 
cellular metabolism and in an organism as a whole. Unfortunately, this enzyme has not been 
characterized and its physiological role is not yet clear. Further studies are clearly needed. 
 
 
4.3.3 Protonation States of MetAPs 
 
4.3.3.1 Computational Studies 
 
The aim of this study was to clarify the native protonation state of the enzyme, which is 
needed for the development of novel inhibitors. When using molecular modeling techniques 
for the screening of compound-databases, not only the tertiary structure of the target protein 
but also the distribution of charges is crucial for the result of the docking process. Especially 
the metal-binding site and the cavity for substrate binding are important as these areas 
represent the expected binding site of potent novel inhibitors. Protons cannot be “seen” in 
electron density maps with normal X-ray experiments. Thus, it is not clear whether an oxygen 
atom represents a water molecule or a hydroxide ion. As a first step toward an understanding 
of the catalytic and inhibitor-binding mechanisms of MetAPs, we have performed a 
computational study of different protomeric states of the methionine aminopeptidase active 
site using a combined quantum-mechanical/molecular mechanical simulation approach[136] in 
our group.  
 
Due to the uncertainty of the Co spin system and the multiplicity of the bi-cobalt system, Zn 
was used for the simulations. Before, it was checked that there were no major geometric or 
dynamic differences to a bi-zinc system, confirming another previously performed theroretical 
analysis[137].  
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In the 1.9-Å resolution X-ray structure of EcMetAP (pdb code 2MAT), one water molecule 
(or hydroxide ion) is bridging the two cobalt ions and another water molecule is bound to the 
cobalt ion that is not coordinated to the histidine. Three different protomeric states were 
examined (cfr. Fig. 4-23), one with two bound water molecules (A), one with a bridging 
hydroxide ion and a water molecule (B), and one with two hydroxide ions(C). As the bridging 
water molecule is more activated by the metal ions than the terminally bound water molecule, 
a protomeric state with a bridging water molecule and a bound hydroxide ion seems unlikely. 
 
 
 
Fig. 4-23 Three different protomeric states of EcMetAP for which CPMD simulations were performed 
 
 
The results of this study indicated that two protonation states are possible, namely A and B. 
They are intrinsically stable and quite similar to the 2MAT X-ray structure. The main changes 
are as follows:  
 
i) The bridging water leaves the position between the two metals in the bi-water 
simulation (A) and remains bound to one of the cobalt ions, resulting in a stable 
system. 
ii) In the water-hydroxide simulation (B), the bridging hydroxide remains in place and 
one of the metal-coordinating carboxylic acid groups twists to a position that is 
perpendicular to the X-ray structure. Nevertheless, this residue remains a binding 
partner for one of the metal ions and the system remains stable. 
iii) Large deviations from the crystal structure were observed in the bi-hydroxide system 
(C). This system proved to be unstable. 
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These results are confirmed by X-ray structure analysis as in a structure determined at a more 
acidic pH no bridging water molecule is present between the two metals (pdb code 1BN5) 
contrary to the structure determined at a pH larger than 7 (2MAT).  
 
 
4.3.3.2 pH-Dependency of Fumagillin Binding 
 
The binding of fumagillin is expected to be favoured at more acidic pH as it requires 
protonation of the epoxide oxygen, whereas a more basic pH would be required for catalysis. 
To experimentally verify the theoretical results, the substrate hydrolysis and inhibitor binding 
reaction at different pH values were studied (cfr. Fig. 4-24). Covalent modification 
experiments can also help to clarify the active site residues if not known, their protonation 
state and to give an insight into the apparent pKa values of reactive groups[138]. 
 
Whereas the pH-optimum of the substrate hydrolysis is at pH 7.4-7.5 (see Fig. 4-15), the 
binding of fumagillin becomes increasingly favoured at lower pH. This becomes even more 
apparent when looking at the %-inhibition values (cfr. Fig. 4-25). A shift of one pH-unit to a 
more acidic pH increases the inhibition of the enzyme by a factor of about 2-3. 
 
Apart from the different binding capacity of fumagillin at different pH-values, another 
interesting observation was made: Preincubation of the MetAP at a more acidic pH (for 15 
min prior to the reaction at pH 7.4) increased the activity of the enzyme compared to the 
preincubation at pH 7.4. It can only be speculated that (maybe) in the pH range from pH 6-7 
the enzyme is better protected from oxidation whereas an even more acidic pH (< 6) or more 
basic pH (>8) inactivates the enzyme by an irreversible denaturation. Another possible 
explanation for this phenomenon might be a reduced interference with plastic at a more acidic 
pH. 
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Fig. 4-24 Dependency of the fumagillin-binding on EcMetAP and the preincubation pH-value 
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Fig. 4-25 Dependency of the inactivation of EcMetAP upon fumagillin-binding and the preincubation pH-
value 
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4.3.3.3 Conclusions 
 
The results indicate that two protonation states are possible without disrupting the active site 
geometry: At a more basic pH, one water molecule is deprotonated and bridging the two 
metal ions. This protonation state (B, cfr. Fig. 4-23) is expected to be relevant for the catalytic 
process of substrate hydrolysis. The other protomeric state (A) with two water molecules 
present in the active site at more acidic pH, each one coordinating a different metal ion, is 
relevant for the covalent binding of fumagillin to MetAP. This process requires protonation of 
the epoxide oxygen. Proton donation from an active site group, in particular from one of the 
active site water molecules, is more likely in the protonation state with two water molecules 
(i.e. at more acidic pH).  
 
However, the increased binding capability of fumagillin at a more acidic pH-value might 
surprise at first as it may be argued that an active site residue is more likely protonated than 
the metal-coordinating water/hydroxide ion that induces the binding of fumagillin. Only the 
histidines His79 and His178 site are likely to be protonated but as  
i) the literature values for the histidine side chain pKa are about 6.2 and the histidines 
therefore are less basic than the hydroxide ion with an apparent pKa value of about 
7 and  
ii) a protonated and therefore positively charged His79 is less prone to act as a 
nucleophile on fumagillin 
it can be assumed that both His79 and His178 remain neutral. 
 
These findings have implications for the development of covalent inhibitors of the MetAP and 
add a new perspective to the pharmacological properties of the anti-angiogenic drug 
fumagillin. The fact that the extracellular pH in tumors is more acidic than in normal tissues 
and assuming that the endothelial cells of vessels in tumors are under the influence of the 
acidic extracellular tumor pH, the pH profile of the fumagillin-MetAP binding reaction might 
lead to selectivity (or targeting) of the fumagillin effect to tumor vessels.  
Irreversible inhibitors different from fumagillin should preferably be compounds that are 
activated by a nucleophilic attack (coming from the hydroxide ion) or by deprotonation. Such 
inhibitors would be much more active at physiological pH than fumagillin.  
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Furthermore, the results presented above allow the following conclusions:  
 
i) In the X-ray structure of E. coli MetAP (2MAT), the bridging water molecule is 
most probably deprotonated. However, an active site with two (fully protonated) 
water molecules coordinated to the metal ions is also stable, albeit with a different 
coordination geometry. 
ii) The active site of binuclear EcMetAP is therefore characterized by the presence of 
a water molecule with a pKa-value of ~ 7. This value is lower than the apparent 
pKa-value of 8.1 obtained by kinetic and spectroscopic methods[77]. This value is 
also at the lower border of the pKa values reported for waters coordinating to zinc 
ions in organic complexes[139]. 
iii) The substrate hydrolysis reaction starts with the attack of the metal-bound 
hydroxide ion to the carbonyl carbon of the scissile peptide bond. This mechanism 
differs slightly from the one that is given in the recent literature[58] where the 
deprotonation of the metal-bridging water occurs after the substrate has been 
bound in the active site. 
 
Recent theoretical work on the reaction mechanism of imipenem binding to the di-nuclear 
zinc-ß-lactamase[140] and the substrate hydrolysis mechanism of the di-nuclear bovine lens 
leucine aminopeptidase[141] indicate that the nucleophilic attack on the substrate originates 
from a “terminally” bound and not a bridging hydroxide ion. The nucleophilicity of a 
hydroxide ion that is complexed to one metal ion is higher than that of a bridging 
hydroxide. Considering these results, we suggest a mechanism in which a bridging 
hydroxide (as in the crystal structure) is found in the resting state of the enzyme and the 
binding of the substrate causes a rearrangement of the complexation pattern. 
Subsequently, the amide carbonyl carbon is attacked by the terminally bound hydroxide 
ion, which has an increased nucleophilicity as compared to the bridging hydroxide ion in 
the resting state. 
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4.3.4 Testing 
 
4.3.4.1 Fumagillin Analogs 
 
A series of fumagillin analogs was kindly provided by Prof. Giannis (University of Leipzig) 
and was tested for inhibitory activity. The results are summarized in Table 4-6. 
Although some compounds resemble fumagillin and TNP-470 very much and would be 
expected to have some potency against EcMetAP, none of the compounds showed any 
remarkable inhibitory activity. This is probably due to the fact that these compounds were 
made available as stock solutions in DMSO (10 and 100 mM). In analogy to our own 
observations with fumagillin, these substances may be susceptible to oxidation or hydrolysis 
of the epoxide moieties and thus to inactivation. The IC50-value of fumagillin decreases to 50-
80 µM upon storage compared to 9 µM of freshly isolated substance. This is the case if it is 
dissolved in DMSO and stored at -20° but even if it is stored as a solid at room temperature. 
However, the increase in inhibition-potency at a lower preincubation-pH seen with fumagillin 
can also be observed with these substances but was not sufficient for the determination of 
IC50-values. 
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Table 4-6 Inhibition tests of fumagillin analogs; preincubated 15 min at pH 7.5 (resp. pH 6.5) 
Cpd. Formula 
IC50 
[µM] % inhibition (at a certain concentration) 
Fumagillin 
O
H
O
O
O
OH
OOMe
 
9.2 a --- 
MAZ152 OMe
O
O
O
OMe
MeO
MeO
O
 
> 10 0 % inhibition at 10 µM 
MAZ173 
O
OMe
O
O
N
H
O
Cl
O
 
> 300 
23 % inhibition at 100 µM 
28 % inhibition at 200 µM 
31 % inhibition at 300 µM 
18 % inhibition at 50 µM (preincubated at pH 6.5) 
MAZ281 
H O
O
OMe
O
O
N
H
O
Cl
 
> 10 1 % inhibition at 10 µM 
MAZ283 
O
O
N
H
O
OMe
O
Cl
 
> 300 
18 % inhibition at 100 µM 
26 % inhibition at 200 µM 
33 % inhibition at 300 µM 
23 % inhibition at 50 µM (preincubated at pH 6.5) 
MAZ289 
H
Cl
O
OMe
O
O
N
H
O
 
> 300 
17 % inhibition at 100 µM 
19 % inhibition at 200 µM 
29 % inhibition at 300 µM 
15 % inhibition at 50 µM (preincubated at pH 6.5) 
MAZ234 
O
OMe
O
O
 
> 300 
2 % inhibition at 100 µM 
9 % inhibition at 200 µM 
7 % inhibition at 300 µM 
14 % inhibition at 50 µM (preincubated at pH 6.5) 
MAZ290 
O
O
N
H
O
O
OMe
OH
Cl
 
> 300 
15 % inhibition at 100 µM 
23 % inhibition at 200 µM 
31 % inhibition at 300 µM 
19 % inhibition at 50 µM (preincubated at pH 6.5) 
MAZ293 
OO
O
O
OMe
O
N
H
O
Cl
 
> 300 
10 % inhibition at 100 µM 
18 % inhibition at 200 µM 
24 % inhibition at 300 µM 
13 % inhibition at 50 µM (preincubated at pH 6.5) 
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Cpd. Formula 
IC50 
[µM] % inhibition (at a certain concentration) 
MAZ294 
O
OMe
OH
O
O
N
H
O
Cl
 
> 10 2 % inhibition at 10 µM 
MAZ295 
O
O
O
OMe
O
N
H
O
Cl
 
> 10 11 % inhibition at 10 µM 
H344.1 
O
O
OMe
O
N
H
O
Cl
OMe
O
 
> 300 
2 % inhibition at 100 µM 
7 % inhibition at 200 µM 
6 % inhibition at 300 µM 
 
H352.1 
O
O
OMe
O
N
H
O
Cl
OH
O
 
> 10 8 % inhibition at 10 µM 
H353.1 
O
O
OMe
O
N
H
O
Cl
OOH
 
> 10 9 % inhibition at 10 µM 
NSP113 
N
H
O
OMe
O
N
H
O
Cl
O O
 
> 300 
16 % inhibition at 100 µM 
22 % inhibition at 200 µM 
28 % inhibition at 300 µM 
 
a) preincubated 30 min at pH 7.5 
 
 
 
4.3.4.2 Peptide-based Reactive Inhibitors 
 
The following compounds were kindly provided by Prof. Schirmeister (Würzburg University, 
Germany). Many of them are peptide-based and contain a reactive moiety, such as an 
aziridine-ring or and epoxide-group (cfr. Table 4-7). 
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Table 4-7 Peptide-based reactive inhibitors, preincubated 30 min at pH 7.5 
Cpd.  
IC50 
[µM] % inhibition (at a certain concentration) 
SCH1 
O
S
O
O
O
O
O
O
 
< 100 69 % inhibition at 100 µM 95 % inhibition at 300 µM 
SCH2 
O
S
O
O
OO
OO
 
< 100 68 % inhibition at 100 µM 
80 % inhibition at 300 µM 
SCH3 
O
O
O
O
O
 
> 300 7 % inhibition at 300 µM 
SCH4 
N
H
O
O O
N
H
O
O
 
> 300 16 % inhibition at 300 µM 
SCH5 
N
H
O
O O
N
H
N
H
O
O
O
 
< 100 81 % inhibition at 100 µM 90 % inhibition at 300 µM 
SCH6 N
O
O
O
O
 
> 300 27 % inhibition at 300 µM 
SCH7 
N
H
O
O
O
O
 
> 300 35 % inhibition at 300 µM 
SCH8 
N
H
O
O
O
O
 
> 300 22 % inhibition at 300 µM 
SCH9 
O
O
O
O
O
 
100-
300 
24 % inhibition at 100 µM 
66 % inhibition at 300 µM 
SCH10 
O
O
O
O
O
 
< 100 52 % inhibition at 100 µM 82 % inhibition at 300 µM 
SCH11 
N
H
O
O
O
O
 
> 300 24 % inhibition at 300 µM 
SCH12 
N
H
O
O
O
O
 
> 300 21 % inhibition at 300 µM 
SCH13 
N
H
O
O O
N
N
O
O
 
> 300 27 % inhibition at 300 µM 
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Cpd.  
IC50 
[µM] % inhibition (at a certain concentration) 
SCH14 
N
O O
O O
O
O
 
< 100 28 % inhibition at 100 µM 58 % inhibition at 300 µM 
SCH15 
N
O O
O O
O
O
 
< 100 69 % inhibition at 100 µM 
80 % inhibition at 300 µM 
SCH16 O
O
O
 
100- 
300 52 % inhibition at 300 µM 
SCH17 
N
H
O
O
O
O
Li
+
 
> 300 4 % inhibition at 300 µM 
SCH18 
N
H
O
O
O
O
Li
+
 
> 300 10 % inhibition at 300 µM 
SCH19 
N
H
O
O
O
O
 
> 300 16 % inhibition at 300 µM 
SCH20 
O
O
N
H
O
N
H
O O
 
> 300 39 % inhibition at 300 µM 
SCH21 OH
O
N
H
O
N
H
N
O OO
 
> 300 43 % inhibition at 300 µM 
SCH22 
O
N
H
O
N
H
N
O OO
O
 
> 300 27 % inhibition at 300 µM 
SCH23 
O
N
H
O
N
H
N
O OO
O
 
100-
300 
46 % inhibition at 100 µM 
84 % inhibition at 300 µM 
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In contrast to the inactive fumagillin analogs, some potent inhibitors could be identified 
among the peptide-based compounds, such as SCH1, SCH2 and SCH5. Whether these 
substances are competitive or non-competitive inhibitors of the EcMetAP remains to be 
established. When comparing SCH4 and SCH5, the finding that replacing glycine at the 
penultimate residue of the active compound SCH5 by isoleucine in SCH4 diminishes activity 
reminds of the substrate specificity of EcMetAP which prefers small residues adjacent to 
methionine. Another fact that becomes clear is that the stereochemistry is an important factor. 
This can be seen when comparing a corresponding pair of compounds such as SCH22 and 
SCH23 or SCH9 and SCH10. 
 
 
4.3.4.3 Substituted Epoxides and Other Covalent Inhibitors 
 
Based on the inhibition of EcMetAP by fumagillin, a series of small epoxides was 
synthesized. The idea was that groups with different electronical effects could have an impact 
on the reactivity of the epoxide-moiety and thus influence the activity. The results are 
summarized in Table 4-8. 
 
Most of the epoxides were readily available by starting either from the corresponding styrenes 
or aldehydes (Fig. 4-26).  
 
O
H
O
CH2Cl2 CH3CN
RR R
mCPBA TMSJ, KOH
 
Fig. 4-26 General procedures for the synthesis of epoxides 
 
In addition, several styrenes and aldehydes were tested, among these the starting materials for 
the synthesis of the epoxides (cfr. 8 Appendix, Table 8-1 and Table 8-2). 
 
The effect of an enhanced potency at a more acidic pH could also be observed for these small 
molecules, comparable to the fumagillin analogs. Thus, an inhibitor exerts the same inhibitory 
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effect when preincubated at a more acidic pH with a reduced preincubation time compared to 
the original assay conditions. 
 
Table 4-8 Testing of small phenyloxiranes preincubated for 30 min at pH 7.5 unless stated otherwise 
(see footnote) 
Compound 
O
R
 
IC50 
[µM] % inhibition (at a certain concentration) 
Fumagillin see above 9.2  
R/S-Phenyloxirane R = H > 300 
20 % inhibition at 100 µM (preinc. at pH 6.5)a 
19 % inhibition at 100 µM 
30 % inhibition at 300 µM 
R-Phenyloxirane R = H > 300 
4 % at 100 µMa 
6 % inhibition at 100 µM (preinc. at pH 6.5)a 
9 % inhibition at 100 µM 
17 % inhibition at 300 µM 
S-Phenyloxirane R = H > 300 
18 % at 100 µMa 
23 % inhibition at 100 µM (preinc. at pH 6.5)a 
31 % inhibition at 100 µM 
38 % inhibition at 300 µM 
RS 1 2-(2-Chloro-phenyl)-oxirane 2-Cl > 300 
9 % inhibition at 100 µM (preinc. at pH 6.5)a 
6 % inhibition at 100 µM 
14 % inhibition at 300 µM 
RS 2 2-(3-Chloro-phenyl)-oxirane 3-Cl > 300 
15 % inhibition at 100 µM (preinc. at pH 6.5)a 
23 % inhibition at 100 µM 
40 % inhibition at 300 µM 
RS 3 2-(4-Chloro-phenyl)-oxirane 4-Cl 
100-
300 
25 % inhibition at 100 µM (preinc. at pH 6.5)a 
42 % inhibition at 100 µM 
56 % inhibition at 300 µM 
RS 4 2-o-Tolyl-
oxirane 2-Me > 300 17 % inhibition at 300 µM 
RS 5 2-m-Tolyl-
oxirane 3-Me > 300 45 % inhibition at 300 µM 
RS 6 2-p-Tolyl-
oxirane 4-Me > 300 
30 % inhibition at 100 µM 
59 % inhibition at 300 µM 
RS 7 2-(2-Methoxy-phenyl)-oxirane 2-OMe > 300 46 % inhibition at 300 µM 
RS 8 2-(3-Methoxy-phenyl)-oxirane 3-OMe > 300 40 % inhibition at 300 µM 
RS 9 2-(4-Methoxy-phenyl)-oxirane 4-OMe > 300 42 % inhibition at 300 µM 
RS 10 2-(2-Nitro-phenyl)-oxirane 2-NO2 > 300 9 % inhibition at 300 µM 
RS 11 2-(3-Nitro-phenyl)-oxirane 3- NO2 > 300 27 % inhibition at 300 µM 
RS 12 2-(4-Nitro-phenyl)-oxirane 4- NO2 > 300 0 % inhibition at 300 µM 
a) 15 min preincubation 
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Table 4-9 Testing of small epoxides preincubated 30 min at pH 7.5 
Compound  
IC50 
[µM] % inhibition (at a certain concentration) 
Fosfomycin 
O
P
OH
OH
O
 
> 500 0 % inhibition at 500 µM 
7-Oxa-bicyclo[4.1.0]heptane O
 
> 300 7 % inhibition at 300 µM 
RS 13 
3-Phenyl-
oxirane-2-
carboxylic acid-
methyl ester O O
O
 
> 300 25 % inhibition at 300 µM 
TH7 NH
N
O
O
 
> 300 12 % inhibition at 300 µM 
RS 14 3-Phenyloxiran-2-carbonitrile 
O
N
 
100-
300 
39 % inhibition at 100 µM 
53 % inhibition at 300 µM 
RS 15 
1-Oxa-
spiro[2.5]octane
-2-carbonitrile 
O
N
 
> 300 13 % inhibition at 100 µM 
RS 16 
4-((E)-1-
Methyl-
propenyl)-1-
oxa-
spiro[2.5]octane O
 
> 100 
7 % inhibition at 100 µMa 
6 % inhibition at 300 µM 
a) 15 min preincubation 
 
None of the small epoxides was able to significantly inhibit EcMetAP, possibly because of the 
lack of the required stereochemical properties and because of the small size of these 
compounds. Both these factors are very important for affinity. In addition, no pattern relating 
to activity with either the position of a substituent or its inductive and mesomeric effect could 
be observed. Although there are differences in activity (even simple molecules such as R- and 
S-phenyloxirane differ by a factor of two), this can have many reasons as the binding site of 
these compounds is not known and relatively high concentrations are needed to observe any 
effects. 
 
The same applies for the styrenes and aldehydes tested. Interestingly, the aldehydes were 
generally better inhibitors than the epoxides. The best compound tested was 2-hydroxy-
benzaldehyde with an IC50-value of about 6 µM, thus better than fumagillin under otherwise 
identical conditions. If the aldehydes also act as covalent inhibitors is not clear. They could 
react with one of the seven cysteine residues of EcMetAP in an aldol-like reaction. In the case 
of 2-hydroxy-benzaldehyde, interaction with the metal ions and thus a competitive mode of 
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action also seems possible. However, inactivation of the enzyme by any of these compounds 
seems to be unspecific.  
 
In summary, no promising lead structure for new, covalent inhibitor could be identified and 
we focused on competitive inhibitors. 
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4.4 Competitive Inhibitors 
 
4.4.1 Overview 
 
The interest in MetAP-inhibitors is mainly focused on fumagillin and over covalent inhibitors 
of MetAP-II due to its role in angiogenesis. There are only a few inhibitors reported for type-I 
MetAPs, although it is a unique and essential enzyme in bacteria. Since the metal ions are part 
of the catalytic site, the design of metal chelators has been a popular approach for developing 
MetAP inhibitors both for type-I and type-II. Competitive MetAP-inhibitors can be divided 
into different classes. 
 
One class contains compounds that mimic peptide substrates and coordinate to the metal ions. 
These inhibitors use for example an α-hydroxy-β-aminoacyl (bestatin) group[142] or an internal 
hydroxamic acid as a structural group to chelate the metal ions[143]. The bengamides (a marine 
natural product isolated from sponges) and synthetic analogs thereof[124] share a similar 
binding mode.  
 
A second class contains a triazole or a pyrazole group as the metal complexing or 
coordinating ligand. 1,2,4-triazoles represent a novel class of potent non-peptidic inhibitors 
for the MetAPs[78, 86, 144]. Structural moieties such as carboxylic acids or thiazole-2-
oxalamides[145] or thiazole-2-ylamides[146] are present in some other potent inhibitors.  
 
A third class of competitive inhibitors consisting of α-keto heterocycles and aminoketones 
bind as transition-state analogs.  
 
Recently, a series of furan-carboxylic acids has been reported as competitive inhibitors of 
Mn(II)-loaded EcMetAP and the crystal structure of the enzyme-inhibitor-complex has been 
determined (pdb code 1XNZ). An overview of the reported inhibitors together with their 
metal selectivity, their in vitro and in vivo activity is given in Table 4-10. 
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Table 4-10 Competitive inhibitors of MetAPs, the summary describes the type of MetAP/species a class of 
inhibitors is active against, the metal ions it was tested with, its in vivo activity and whether a 
crystal structure with bound inhibitor exists or not 
Ref. Class of compounds described Summary: 
[146]
 N
O
N
H
S
N
X
R
X=NH, O
 
EcMetAP / ScMetAP: 
Co(II) 
in vivo inactive 
no crystal structure available 
[86]
 
S N
N
NH
 
HsMetAP-II: 
Zn(II), Ni(II), Co(II), Fe(II) 
in vivo inactive 
no crystal structure available 
[86]
 
N
H
S
O
OH
NH2
 
HsMetAP-II: 
Mn(II), Zn(II), Ni(II), Co(II), Fe(II) 
in vivo active 
no crystal structure available 
[147]
 
NN
Q
R
Q=aryl or heteroaryl group
 
HsMetAP-II: 
Co(II) (other metals not tested) 
in vivo active 
no crystal structure available 
[148]
 N
H
NN
R3 N
R1
R2
 
HsMetAP-II: 
Co(II) (other metals not tested) 
in vivo active 
no crystal structure available 
[82]
 N
O
N
H
S
N
X
R
X=NH, O
          
N
H
S
NN
 
EcMetAP: 
Co(II), Ni(II), inactive with Mn(II) 
and Zn(II) 
no crystal structure available 
[82]
 
NH2
O
OH
R
              
NH2
S
O
S
R
N
H
O OH
COOH
 
EcMetAP: 
Co(II), Ni(II), Mn(II), Zn(II) 
no crystal structure available 
[143]
 N N
H
N
O OH
O
NH2
S
 
EcMetAP (Factor 25/50 worse 
against HsMetAP-I/II): 
Co(II) 
no crystal structure available 
[124]
 
NH
O
O
O
N
H
O
O
OH
OH
OH
Bengamid based, binds
by three hydroxyl groups
 
HsMetAP-I/II: 
Co(II) (other metals not tested) 
in vivo active 
crystal structure availablea 
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Ref. Class of compounds described Summary: 
[78]
 
N
H
NN
NH2 S N
NN
S N
H
NN
S
NH2
S
 
N1 and N2 coordinate to the active site 
SaMetAP: 
Co(II), Zn (II) (other metals not 
tested, right: in vitro inactive) 
in vivo inactive 
crystal structure availablea 
[118]
 
NH2
R O
OH
NHR2
                
NH2
O
OH
S
N
H
N
H
O
Cl
 
HsMetAP-II (weak against type-I): 
Mn(II) (other metals not tested) 
in vivo active 
crystal structure availablea 
[90]
 
N
H
N
H
S
O
OH
NH2
O
Cl
 
HsMetAP-II (weak against type-I): 
Mn(II) (other metals not tested) 
in vivo active 
crystal structure available (1R58) 
[149]
 
N
H
S
O
S
N
     
N
H
S
O
N
     
SN
H
NH2
O
 
SaMetAP: 
Co(II) 
crystal structures available (1QXW, 
1QXY, 1QXZ) 
[85]
 
N
H
NN
NH2 S
NC
              
N
O
N
H
S
N
X
R
X=NH, O
 
ScMetAP: 
Co(II) (other metals not tested) 
in vivo inactive 
no crystal structure available  
[87]
 N
O
N
H
S
N
X
R
X=NH, O
 
EcMetAP (weak against  
HsMetAP-I) 
Co(II) (other metals not tested) 
no crystal structure available 
[145]
 N
H
N
HS
N
O
O
   
N
H
N
HS
N
O
O
   
N
H
N
HS
N
O
O
N
 
EcMetAP: 
Co(II)-selective 
no crystal structure available 
[145]
 O
OH
O
Cl
O
OH
O
Cl
O
OH
O
CF3
 
EcMetAP: 
Mn(II)-selective 
crystal structure available (1XNZ) 
[144]
 
NH
N
N
N
F
S O
O
S
 
HsMetAP-II: 
Co(II)-selective, Factor 40 worse 
with Mn(II), cell-permeable 
in vivo inactive 
no crystal structure available 
a) not deposited in the PDB 
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4.4.1.1 Mode of Action on the Molecular Basis 
 
Up to now, X-ray structures are available for the characterization of the inhibitory mechanism 
of the bestatin based inhibitors, of the transition-state analogs, of the carboxylic acid 
derivatives and of the triazoles: All of these compounds interact with the active site metal ions 
and are able to replace the bridging water molecule. For the bestatin-like inhibitors, generally 
three vicinal chelating groups are present for the complexation of the metal ions. The binding 
mode of the bestatin-based inhibitors is depicted in Fig. 4-27.  
 
NH2 NH
OH
O
O
OH  
 
Fig. 4-27 left: Bestatin; right: Binding mode of a bestatin based inhibitor, picture generated from  
pdb code 3MAT 
 
In the case of the triazole-based inhibitors, each of the triazole nitrogen atoms in positions 1 
and 2 interacts with one of the two cobalt ions in the di-nuclear cobalt-binding site such that 
their N-N-bond is nearly parallel to the Co-Co-axis of the metal binding site[78]. The 
carboxylic acid derivatives that inhibit the Mn(II)-loaded EcMetAP (1XNZ) use the 
carboxylic acid moiety to replace the bridging water molecule and to coordinate to the metal 
ions.  
Despite the common mode of action of these substances, selectivities can be observed 
depending on the kind and origin of MetAPs and on the metal ions used. 
 
 
4.4.1.2 Mode of Action on the Physiological Basis: Biological Activity 
 
Although the triazoles are a potent class of inhibitors described for the MetAP-I, they do not 
show antibacterial activity when tested against various organisms. The lack of correlation 
between in vitro potency and in vivo activity has also been observed for other in vitro highly 
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active compounds (normally tested against Co(II)- loaded MetAPs) such as the pyridine-2-
carboxylic acid-thiazole-2-ylamides. Other in vitro potent inhibitors against HsMetAP-II 
found by screening with a Co(II)-loaded enzyme failed to inhibit endothelial cell proliferation 
in a cellular assay[144]. There are various possible explanations for these phenomena, including 
permeability, efflux, in vivo affinity or kind and number of the relevant in vivo metal ion. It 
might also be possible that certain inhibitors need the presence of two divalent metal ions to 
be able to bind to the metal binding site. Whether metal-selective inhibitors against the 
Mn(II)-loaded form of EcMetAP are active in vivo is not yet clear. 
 
 
4.4.2 Derivatives of a Published Inhibitor 
 
Compound RS 17 was reported as a potent EcMetAP inhibitor[146]. The compound was 
synthesized (cfr. Fig. 4-28) and tested as a reference. It has an IC50-value in the lower 
nanomolar range. 
 
N
O
N
H
S
NN
O
OH
NH2
S
N DCC
+
 
Fig. 4-28 Synthesis of RS 17  
 
Several derivatives of this substance were synthesized in order to 
 
i) improve the activity and 
ii) gain insight into structure activity relationships 
 
Structural modifications (RS 18 - RS 25) of the lead compound RS 17, however, had no 
beneficial effect. Replacement of the thiazole ring by an isoxazole ring or changing the 
carboxamide into a sulfonamide decreased the potency whereas the sulfonamide group had a 
stronger effect. Furthermore, the picolinic-acid moiety was kept as a structural key element 
and several cyanoalkyl-esters and –amides were synthesized and tested. These structural 
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elements were added (RS 21 - RS 24) to change the competitive inhibitor to a covalent 
inhibitor as explained for RS 26 and RS 27 below in Fig. 4-29. However, the idea to add 
reactive groups to the picolinic acid moiety did not increase the activity. The results are 
summarized in Table 4-11. 
 
 
Table 4-11 Testing of pyridine-2-carboxylic-acid derivatives 
Compound  IC50 [µM] % inhibition (at a certain concentration) 
RS 17 
Pyridine-2-
carboxylic 
acid thiazol-
2-ylamide 
N
O
N
H
S
N
 
0.063 ± 
0.011  
RS 18 
Pyridine-2-
carboxylic 
acid (5-
methyl-
isoxazol-3-
yl)-amide 
N
O
N
H
N O
 
2.84  
RS 19 
Pyridine-2-
sulfonic acid 
thiazol-2-
ylamide 
N S
O
N
H
S
N
O
 
98.5  
RS 20 
Pyridine-2-
sulfonic acid 
(5-methyl-
isoxazol-3-
yl)-amide 
N S
O
N
H
N O
O
 
120.1  
RS 21 
Pyridine-2-
carboxylic 
acid 
cyanomethyl-
amide 
N
O
N
H
N
 
109.5  
RS 22 
Pyridine-2-
carboxylic 
acid 
cyanomethyl-
ester 
N
O
O
N
 
79.9  
RS 23 
Pyridine-2-
carboxylic 
acid 2-cyano-
ethyl ester 
N
O
O N
 
>> 100 
0 % inhibition at 50 µM 
17 % inhibition at 100 µM 
RS 24 
Pyridine-2-
carboxylic 
acid 3-cyano-
propyl ester 
N
O
O
N
 
> 100 
12 % inhibition at 1 µM 
45 % inhibition at 100 µM 
RS 25 
4-Nitro-N-
thiazol-2-yl-
benzamide 
N
O
O
O
N
H
N
S
 
> 100 21 % inhibition at 100 µM 
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4.4.3 Screening 
 
As structural modifications of the potent substance RS 17 yielded no promising results, a new 
leading structure should be identified. Based on docking runs and virtual screening results, 
several substances were tested for activity against the EcMetAP.  
 
Among these were drugs, drug-like compounds, compounds from our own in house-library 
but also intermediates from synthetic procedures of the synthesis of the epoxides (cfr. 
4.3.4.3). In addition, several other compounds were synthesized and tested. The most 
interesting compounds are listed below (cfr. Table 4-12) and a complete summary of the 
residual results is given in chapter 8 (Appendix). 
 
RS 26 and RS 27 were synthesized to use methionine as a recognition element for the 
substrate binding site and the cyanoethylester moiety as a binding group for nucleophiles. The 
deprotonation of the cyanoethylester causes cleavage of the ester bond and subsequent 
formation of acrylonitrile, which can then bind (as a “Michaelis-like” electrophile) to one of 
the cysteine residues near the MetAP active site. The sequence of reactions is depicted in  
Fig. 4-29 and would be based on a “basic activation” and not on an acidic activation as with 
fumagillin. 
 
R
O
O
R
H
N
R
O
O
R
N
R
N
HO
O
R
- H
Nu
-
 
Fig. 4-29 Basic activation and subsequent possible binding mode of a cyanoethylester 
 
The same idea was applied for the synthesis of the compounds RS 21 - RS 24. However, none 
of the compounds with a cyanoalkyl moiety showed any significant inhibition. 
 
 
4 Results and Discussion 80 
 
Table 4-12 Screening of inhibitors against Co(II)-loaded EcMetAP 
Compound Formula IC50 [µM] 
% inhibition (at a certain 
concentration) 
Pyridine-2-carboxylic acid N
OH
O
 
20.3  
Nicotinic acid N
OH
O
 
> 300 0 % inhibition at 300 µM 
Ethacridine lactate 
N
NH2
O
NH2
 
96.2  
Chlorpromazine-HCl 
S
N
N
Cl
ClH.
 
32.9  
Anthrone 
O
 
~10 
19 % inhibition at 1 µM 
49 % inhibition at 10 µM 
95 % inhibition at 25 µM 
Phenothiazine 
S
N
H
 
1-10 
13 % inhibition at 1 µM 
65 % inhibition at 10 µM 
80 % inhibition at 25 µM 
RS 26 Methionyl-
cyanoethylester 
NH2
O
O
S
N
ClH.
 
>> 100 0 % inhibition at 100 µM 
RS 27 Boc-Methionyl-
cyanoethylester 
O
N
H
O
O
O
S
N
 
>> 50 0 % inhibition at 50 µM 
Thiabendazole 
N
H
N N
S
 
0.472  
Quinolin-8-ol N
OH
 
0.772  
Phenanthroline N
N
 
0.489  
 
As expected from the virtual screening, planar substances that fit nicely in the active site 
showed moderate to good IC50-values. Of all the compounds tested, the metal-complexing 
substances such as thiabendazole, phenanthroline and quinolin-8-ol showed the best activity.  
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4.4.4 Quinoline-Derivatives 
 
As quinolin-8-ol had an IC50-value in the lower micromolar range, the substance itself and 
some corresponding derivatives like quinolin-2-ol or quinolin-8-amine are commercially 
available (at a low price) and can easily be modified, a small series of quinoline-derivatives 
was prepared and tested. The results are summarized in Table 4-13. 
 
Table 4-13 Testing of quinoline-derivatives 
Compound  IC50 [µM] % inhibition (at a certain concentration) 
Quinolin-8-ol N
OH
 
0.772 ± 
0.017  
Quinolin-2-ol 
N OH
 
>> 1 5,2 % inhibition at 1 µM 
Quinolin-8-ylamine N
NH2
 
> 10 37,4 % inhibition at 10 µM 
RS 28 
Benzoic acid 
quinolin-8-yl 
ester 
N
O
O
 
> 10 23,2 % inhibition at 10 µM 
RS 29 
N-Quinolin-
8-yl-
benzamide 
N
N
H
O
 
> 10 0 % inhibition at 10 µM 
RS 30 
N-Quinolin-
8-yl-
benzenesulfo
namide 
N
N
H
S
O
O
 
> 10 46,8 % inhibition at 10 µM 
RS 31 
Benzenesulfo
nic acid 
quinolin-8-yl 
ester 
N
O S
O
O
 
>> 1 5,7 % inhibition at 1 µM 
RS 32 
Toluene-4-
sulfonic acid 
quinolin-8-yl 
ester 
N
O S
O
O
 
>> 1 1,0 % inhibition at 1 µM 
RS 33 
Pyridine-2-
sulfonic acid 
quinolin-8-yl 
ester 
N
O S
O
O
N
 
> 10 
1,8 % inhibition at 1 µM 
37,4 % inhibition at 10 µM 
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Disruption of the metal binding moiety led to an almost complete loss of activity in all cases. 
Esterification with either a carboxylic acid or a sulfonic acid led to the non-active compounds 
RS 28 and RS 31-RS 32. The idea to strengthen the metal-chelating properties by the use of a 
2-pyridine ring (RS 33) had no beneficial effect.  
 
As the starting materials for the preparation of other (substituted) quinoline-derivatives are 
quite expensive and structurally distinct derivatives are not easy to synthesized, we focused 
on the preparation and testing of the more easily accessible benzimidazoles. Besides, 
thiabendazole and many other benzimidazole anthelminthics are well-known drugs in clinical 
practice, and therefore thiabendazole congeners can be expected to have acceptable 
pharmacokinetic properties and less side effects than the unspecific metal chelator  
quinolin-8-ol. 
 
 
4.4.5 Benzimidazoles 
 
4.4.5.1 Overview 
 
Benzimidazole derivatives such as thiabendazole, mebendazole or carbendazim are used as 
broad-spectrum anthelmitic and/or antifungal drugs. Helminths infect 25% of the world’s 
population[150]. Certain benzimidazoles such as albendazole, a thiabendazole analogue, have 
been reported to be effective in treating AIDS-associated microsporidian infection, and other 
benzimidazoles showed in vitro potency against AIDS-associated fungal infections[151]. There 
is biochemical, genetic and cytological evidence that benzimidazoles prevent microtubule 
formation by binding to ß-tubulin.[152-154]. Additional effects, e.g. inhibition of fumarate 
reductase[155, 156], inhibition of superoxide dismutase[157], an influence on the energy balance 
of parasitic worms[158] or on the glucose/glycogen levels[159] have been observed. Interference 
with the terminal electron transport system[160] and with the vitamin B12 metabolism (due to 
competition with 5,6-dimethylbenzimidazole in the formation of the coenzyme)[161] have also 
been proposed. However, these mechanisms do not seem to be valid generally and the 
relevance of these additional effects is difficult to assess, since they have usually been 
observed either at comparably high and probably unphysiological concentrations of the 
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benzimidazole drugs or only in specific organisms. Resistance to benzimidazoles is based on 
a mutation in ß-tubulin genes[154] and often linked to a single amino acid change. 
 
 
4.4.5.2 Thiabendazole 
 
Thiabendazole was the first anthelmintic drug of the benzimidazole group and discovered in 
1964[150]. Thiabendazole was originally described as an anthelmintic[162] and later on as 
fungicidal[163]. As other benzimidazoles, for example mebendazole and carbendazim, were 
reported to interfere with microtubule formation, a similar mode of action has been assumed 
for the antifungal activity of thiabendazole because: 
 
i) thiabendazole has a similar spectrum of activity against fungi compared to 
carbendazim  
ii) acquired resistance to carbendazim implies resistance to thiabendazole and vice 
versa 
 
This assumption has been proven in 1978 by Davidse[152]. Thiabendazole completely inhibits 
mitosis in hyphae of Aspergillus nidulans based on interference with microtubule assembly by 
tubulin interaction with a Ki-value of 35 µM[152]. Thiabendazole causes cell elongation in  
E. coli and in cyanobacteria, possibly by acting in a similar manner on FtsZ, a structural 
analogue of tubulin and a bacterial cell division protein[164].  
Despite side effects like frequent anorexia and nausea, occasionally dizziness and 
vomiting[165], thiabendazole is still in use for the treatment of strongyloidiasis[166, 167], a 
parasitic infection widely distributed in tropical and subtropical areas. Serious clinical 
problems with complications and refractory strongyloidiasis are observed especially in 
immunocompromised patients[150] such as those infected with human T cell leukaemia virus 
Type 1 (HTLV-1), HIV or corticosteroid-treated patients. Thiabendazole is nowadays mostly 
used for postharvest fruit treatment and in veterinary medicine, especially for the treatment of 
dermatoses[168]. 
 
 
4 Results and Discussion 84 
 
4.4.5.3 Determination of the Ki-value of Thiabendazole 
 
The KM’-value was determined as described in 4.2.3.1 by incubation of EcMetAP with eight 
different substrate concentrations and 500 nM Thiabendazole. The KM’-value was determined 
in three independent measurements as the reciprocal of the negative X-axis-intercept of the 
graphical portrayal of 1/s* against 1/v* to be 1904 ± 195 µM. The KM’-value allows the 
calculation of the Ki-value (a). The Ki-value can alternatively be determined from the IC50-
value and the substrate concentration (b): 
 
a) Ki = [I]/((KM’/KM)-1) 
b) Ki = IC50/(1+([S]/KM)) 
 
The results are summarized in Table 4-14. Thus, the Ki-value derived from the IC50-value 
(according to the Cheng and Prusoff equation for competitive inhibitors[169]) is 0.378 µM and 
is in excellent agreement the Ki-value determined according to the Lee and Wilson modified 
Lineweaver-Burk equation[170] of 0.366 µM. 
 
Table 4-14 Constants for EcMetAP 
KM [µM] KM' [µM] Ki [µM] (Method a) Ki [µM] (Method b) 
907 ± 176 1904 ± 195 0.366 0.378 
 
Compared to the Ki-values of 34 µM resp. 68 µM for the binding of thiabendazole to fungal 
tubulin from two Penicillium expansum strains (competed against [14C]carbendazim)[152], the 
Ki-value of 0.4 µM for the E. coli MetAP shows the high potential of this compound and 
might offer a new explanation for the mechanism of action not of the benzimidazoles 
generally but at least of thiabendazole. Therefore, thiabendazole might serve as a new lead 
compound for the development of anti-cancer but also anti-bacterial and anti-fungal 
substances that act by inhibiting the methionine aminopeptidase. 
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4.4.5.4 Procedures for the Synthesis of Thiabendazole Analogs 
 
A variety of benzimidazoles is readily available by several procedures. Generally, a 
(substituted) diamine is heated with an appropriate carboxylic acid in the presence of 
polyphosphoric acid or with an amidine in the presence of sodium acetate to yield the desired 
benzimidazole (Fig. 4-30).  
Method B is more preferable due to its shorter reaction time (10 min compared to 2-4 hrs). In 
addition, it seems to work for all kinds of amidines whereas there can be problems with 
method B depending on the used carboxylic acids. Method B normally requires prior steps for 
the preparation of the amidine salt. However, the amidine salts are generally readily available 
from the corresponding nitriles. 
 
NH2
NH2
NH
NH2
N
H
N
R'
R'-COOH
180 °C
RR
PPA
150 °C
NaOAc
. HCl
+
+ R'
 
Fig. 4-30 Procedures for the synthesis of substituted benzimidazoles; PPA = Polyphosphoric acid 
 
As thiazole-4-carboxylic acid is rather expensive, a synthetic procedure was established that 
was also suitable for large scale production. Therefore, thioformamide is generated from 
formamide and P4S10 and reacted in situ with 3-bromopyruvic acid that is readily available 
from pyruvic acid (cfr. Fig. 4-31). 
 
O
OH O
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O
CH3
OH O Br2
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O
NH2
H
S
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+
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Fig. 4-31 Procedure for the synthesis of thiazole-4-carboxylic acid 
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The resulting product precipitates as a hydrobromide and can be filtered off. The salt can then 
be dissolved in water/NaOH and the carboxylic acid precipitates at pH 2-3. 
Thus, a series of substituted benzimidazoles and thiabendazole analogs was synthesized and 
tested. 
 
 
4.4.5.5 Testing of Thiabendazole Analogs 
 
In order to gain insight into structure-activity relationships, several strategies should be 
embarked on: 
 
1. changes of the heterocycle 
2. alkylation of the benzimidazole moiety 
3. substitutions in the 5-/6-position(s) 
4. changes in the benzimidazole skeletal structure 
 
As different heteroaryl carboxylic acids as well as o-phenylenediamine are commercially 
available, a considerable number of thiabendazole analogs can easily be synthesized in a short 
time. Thus, the thiazole ring of thiabendazole was substituted by other heterocycles. 
Commercially available thiabendazole analogs like mebendazole or albendazole normally 
have a carbamic ester substitution in this position and were also tested. 
As the the nitrogen in position one of the benzimidazole moiety can be deprotonated, it is 
accessible to electrophilic substitutions. Alkylation of this nitrogen with alkylhalogenides 
should be used to introduce substituents that might reach a binding pocket near the metal 
binding site. This idea was derived from our docking results with manual positioning of 
thiabendazole into the active site. 
Several 5-/6- substituted diamines can either be purchased or are readily available. Thus, the 
benzimidazole moiety was substituted in the positions 5 and/or 6.  
Finally, the benzimidazole-moiety was changed by introducing one or more nitrogens, thus 
changing the benzimidazole for example to a purine.  
The results are summarized below (cfr. Table 4-15 to Table 4-18). 
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Table 4-15 IC50-values of 2-substituted benzimidazoles with Co(II)-loaded EcMetAP 
N
H
N
R
 
Cpd.: Nr (Name) 
R 
IC50 [µM] 
(% inhibition at 10 µM) 
Thiabendazole 
N
S
 
0.472 ± 0.060 
Carbendazim 
N
H
O
O
 
> 10 (17.6 ± 2.9) 
RS 34 
N
 
> 10 (4.2 ± 2.7) 
RS 35 
S
 
> 10 (5.4 ± 5.0) 
RS 36 
Fuberidazole O
 
> 10 (10.4 ± 3.7) 
RS 37 
OH
 
> 10 (30.4 ± 6.3) 
RS 38 
N
H
NH2
S
 
8.956 ± 1.319 
RS 39 N
H N
S
 
0.540 ± 0.028 
RS 40 
N
 
0.574 ± 0.082 
RS 41 N
OH
 
1.343 ± 0.274 
RS 42 
N
OH
 
0.777 ± 0.033 
RS 43 
N
N
 
4.591 ± 0.389 
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Table 4-16 IC50-values of N-alkylated benzimidazoles with Co(II)-loaded EcMetAP 
N
N
R1
R2
 
Cpd. 
R1 R2 
IC50 [µM] 
(% inhibition at 10 µM) 
RS 44 
N
S
 
CH3
 
0.497 ± 0.007 
RS 45 
N
S
 
C
H2
 
0.461 ± 0.013 
RS 46 
N
 
C
H2
 
0.992 ± 0.130 
 
 
Table 4-17 IC50-values of 5- and/or 6-substituted benzimidazoles with Co(II)-loaded EcMetAP 
N
H
N
R1
R2
R3
 
Cpd. 
R1 R2 R3 
IC50 [µM] 
(% inhibition at 10 µM) 
RS 47 
N
S
 
CH3
 
H 7.157 ± 0.065 
RS 48 
N
 
CH3
 
H 2.086 ± 0.286 
RS 49 
N
S
 
CH3
 
CH3
 
> 10 (47.8 ± 3.5) 
RS 50 
N
 
CH3
 
CH3
 
2.433 ± 0.284 
RS 51 
N
S
 
CH3
CH3
CH3
 
H 3.906 ± 0.582 
RS 52 
N
 
CH3
CH3
CH3
 
H 2,598 ± 0.376 
RS 53 
N
S
 
NO2
 
H 1.218 ± 0.128 
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N
H
N
R1
R2
R3
 
Cpd. 
R1 R2 R3 
IC50 [µM] 
(% inhibition at 10 µM) 
RS 54 
N
 
NO2
 
H 0.162 ± 0.019 
RS 55 
N
S
 
NH2
 
H 3.390 ± 0.242 
RS 56 
N
 
NH2
 
H 0.967 ± 0.024 
RS 57 
N
S
 
F
 
H 4.307 ± 0.635 
RS 58 
N
 
F
 
H 1.511 ± 0.192 
RS 59 
N
S
 
Cl
 
H 5.153 ± 1.023 
RS 60 
N
 
Cl
 
H 1.695 ± 0.147 
RS 61 
N
S
 
O
 
H 2.397 ± 0.470 
RS 62 
N
 
O
 
H 0.403 ± 0.045 
RS 63 
N
 
CN
 
H 0.431 ± 0.018 
Mebendazole 
N
H
O
O
CH3
 
O
 
H > 10 (29.0 ± 6.3) 
A lbendazole 
N
H
O
O
CH3
 
S
 
H > 10 (15.5 ± 7.2) 
Fenbendazole 
N
H
O
O
CH3
 
S
 
H > 10 (6.1 ± 4.5) 
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Table 4-18 IC50-values of different 2-substituted heterocycles derived from benzimidazole with Co(II)-
loaded EcMetAP 
X
W
N
H
N
R1Y
z
 
Cpd. 
R1 W X Y Z 
IC50 [µM] 
(% inhibition at 10 µM) 
RS 64 
N
S
 
N H H H 0.078 ± 0.007 
RS 65 
N
 
N H H H 0.105 ±0.001 
RS 66 
N
S
 
H N H H 1.724 ± 0.158 
RS 67 
N
 
H N H H 0.550 ± 0.081 
RS 68 
N
 
N H N H 0.376 ± 0.023 
RS 69 
N
 
N H H N 0.240 ± 0.041 
 
 
4.4.5.6 Structure-Activity Relationships 
 
At first, the thiazole-ring of thiabendazole should be substituted by different aromatic 
heterocycles. Only the substitution by a 1,3-thiazole-2-yl-amine moiety (RS 39) or by 2-
pyridine (RS 40) gave active compounds. Other substituents such as 3-pyridine, 2-thiophene, 
2-furane or 2-phenol resulted in almost complete loss of activity as was the case for the 
commercially available thiabendazole derivatives mebendazole, albendazole, carbendazim 
and fenbendazole with the carbamic ester residue in the 2-position of the benzimidazole 
system. This indicates that the binding of thiabendazole and the active congeners is based on 
interaction with metal ion(s) as it is known that both thiabendazole and the compound with a 
(2-)pyridine ring replacing the thiazole ring (RS 40) are metal-chelating agents: For both these 
compounds metal complexes with different divalent metal ions have been characterized; for 
thiabendazole even Co(II)-complexes have been synthesized and analysed. Efforts to improve 
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the activity of RS 40 by adding a hydroxy-group in 3- or 6-position of the pyridine were 
unsuccessful and slightly decreased the potency in both cases.  
 
Using compound RS 40 as secondary lead compound, the benzimidazole-nitrogen was 
methylated or benzylated. The alkylation of this nitrogen from thiabendazole had no effect but 
the benzylated compound RS 40 (RS 46) was slightly less active than the parent compound. 
These results support the idea that N-3 of the benzimidazole is involved in metal binding and 
that changing the N-1 substituent has no effect on the binding motif. However, the original 
aim to reach a substrate binding pocket and to improve the potency by introducing a large 
substituent at N-1 was not achieved. Next, the effects of small substituents in the 5- and the 6-
position of the benzimidazole moiety have been explored. Changes in these positions (with 
some exceptions) led to a decline in potency. Most derivatives were less active than the parent 
compound by a factor from two to five, regardless of which substituent was chosen (halogen, 
amino, methyl or dimethyl). Derivatives of the lead compound RS 40 tolerated substitutions 
in the 5- and the 6- position better than the corresponding derivatives of thiabendazole. The 
compounds RS 61 and RS 62 suggest that even larger substituents might be accepted. This 
observation would rule out any sterical reasons for the loss of potency observed but implies 
the assumption of an identical binding mode. The nitrile-derivative and the 5-nitro derivative 
of RS 40 were more active than the parent compound. In contrast, the corresponding 5-nitro-
thiabendazole was less active than thiabendazole.  
 
The hint that a polar substituent in position 5 can improve the potency in some cases led to 
changes in the benzimidazole scaffold: Introducing a nitrogen in position 5 of the 
benzimidazole had no effect on the pyridine-derivative but decreased the activity of the 
thiabendazole-derivative. When shifting the position of the nitrogen from 5 to 4, the affinity 
increased independently of the nature of the heterocycle in position 2: Both modified lead 
compounds (RS 64 and RS 65) had an IC50 in the nanomolar range (80-100 nM). Other 
variations of the pyridine derivative yielded no further improvement: Introducing another 
nitrogen in position 7 and thus changing the benzimidazole into a pyrazine decreased the 
potency to an IC50-value of 240 nM and changing it into a purine resulted in a further decline 
of the IC50-value to 376 nM.  
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In summary, substitutions of the thiazole-ring were only tolerated if the metal-binding motive 
was not disrupted. Further substitutions had either no effect (for example N-alkylation) or led 
to a decrease in potency (with some exceptions). However, the pyridine-derivative is less 
sensitive to changes in the 5- and 6-position. Changing the benzimidazole-scaffold to  
1H-imidazo[4,5-b]pyridine resulted in two compounds with improved potency with an IC50-
value close to compound RS 17. 
 
Thus, three compounds were available for further tests that showed a high in vitro-activity –
the compound RS 17 described in the literature and the two modified parent compounds  
RS 64 and RS 65. All of them have IC50-values between 50-100 nM against Co(II)-loaded 
MetAP). However, none of all the compounds mentioned was able to inhibit the EcMetAP 
when tested with Mn(II) up to 10 µM. Nonetheless, these compounds together with the parent 
compounds were chosen for further testing on their antibacterial activity. 
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4.5 Crystal Structures 
 
The most promising compounds were tested for their antibacterial activity. However, activity 
could only be observed at rather high concentrations (cfr. 4.6 Determination of MIC-values) 
and there was no correlation between in vitro and in vivo potency. This lack of correlation has 
been observed by other groups before. These findings, together with an unsatisfying docking 
pose, the disappointing results of compounds such as RS 45 or RS 46 that were synthesized 
because of ideas based on the manual positioning of thiabendazole into the metal binding site 
during molecular modeling, and the goal to continue this work with a rational inhibitor design 
brought us to clarify the binding mode of thiabendazole by resolving the crystal structure. 
 
 
4.5.1 Published X-ray Structures 
 
The first crystal structure of the E. coli MetAP was published in 1992 with a resolution of  
2.4 Å. The resolution of this structure could later be improved to 1.9 Å and permitted 
visualization of the coordination geometry and solvent structure of the active-site bi-nuclear 
metal center[52] (see Fig. 2-8). Up to now, 32 structures of MetAPs are deposited in the PDB. 
A summary is given in Table 4-19. 
 
Table 4-19 Crystal structures of MetAPs deposited in the PDB (www.pdb.org) 
Year Code Res. [Å] Species Me(II) Complex 
1992 1MAT 2.40 E. coli Co(II) without bound inhibitor 
1997 1XGM 2.80 P. furiosus Co(II) without bound inhibitor 
1997 1XGN 2.90 P. furiosus Co(II) without bound inhibitor 
1997 1XGO 3.50 P. furiosus --- without bound inhibitor 
1997 1XGS 1.75 P. furiosus Co(II) without bound inhibitor 
1998 1BN5 1.80 Human-II Co(II) without bound inhibitor 
1998 1BOA 1.80 Human-II Co(II) in complex with fumagillin 
1999 1B59 1.80 Human-II Co(II) in complex with ovalicin 
1999 1B6A 1.60 Human-II Co(II) in complex with TNP-470 
1999 1C21 1.80 E. coli Co(II) in complex with methionine 
1999 1C22 1.75 E. coli Co(II) in complex with trifluoromethionine 
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Year Code Res. [Å] Species Me(II) Complex 
1999 1C23 2.00 E. coli Co(II) in complex with methionine phosphonate 
1999 1C24 1.70 E. coli Co(II) in complex with methionine phosphinate 
1999 1C27 1.95 E. coli Co(II) in complex with norleucine phosphonate 
1999 1QQ9 1.53 S. griseus Zn(II) in complex with methionine 
1999 2MAT 1.90 E. coli Co(II) without bound inhibitor 
1999 3MAT 2.00 E. coli Co(II) transition-state complex with 
aminohydroxyheptanoic acid 
1999 4MAT 2.00 E. coli --- His79Ala mutant 
2002 1KQ0 2.00 Human-II Zn(II) in complex with D-methionine 
2002 1KQ9 1.90 Human-II Zn(II) in complex with L-methionine 
2002 1O0X 1.90 T. maritima --- without bound inhibitor 
2003 1QXW 1.67 S. aureus Co(II) in complex with an aminoketone inhibitor 54135 
2003 1QXY 1.04 S. aureus Co(II) in complex with a ketoheterocycle inhibitor 618 
2003 1QXZ 1.68 S. aureus Co(II) in complex with a ketoheterocycle Inhibitor 119 
2003 1QZY 1.60 Human-II Co(II) in complex with a bengamide inhibitor Laf153 
2003 1R58 1.90 Human-II Mn(II) in complex with A357300 
2003 1R5G 2.00 Human-II Mn(II) in complex with A311263 
2003 1R5H 2.40 Human-II Mn(II) in complex with A320282 
2004 1TKJ 1.15 S. griseus Zn(II) in complex with D-methionine 
2004 1WKM 2.30 P. furiosus Mn(II) in complex with methionine 
2004 1XNZ 1.52 E. coli Mn(II) in complex with 5-(2-chlorophenyl)furan-2- 
carboxylic acid 
2004 1Y1N 1.51 M. 
tuberculosis --- without bound inhibitor 
 
 
4.5.2 Inhibitor Binding Modes 
 
A few structures with bound competitive inhibitors are known, for example EcMetAP with 
bound transition state analogs, bestatin based inhibitors or triazole based inhibitors (pdb codes 
1C21, 1C22, 1C23, 1C27, 3MAT, cfr. Table 4-10 and Table 4-19). All these inhibitors 
somehow coordinate to the metal ion(s) in the active site. Recently, the crystal structure of a 
Mn(II)-form of the E. coli MetAP complexed with a Mn(II) specific inhibitor has been 
described[145], pdb code 1XNZ. The active site aligns very well with those of the di-Co(II)-
form, indicating no major changes in geometry upon the replacement of Co(II) by Mn(II)[145]: 
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Fig. 4-32 Alignment of Mn(II)- and Co(II)-loaded EcMetAP (1XNZ and 2MAT). Co(II) ions are shown in 
magenta and the corresponding MetAP in silver/blue, Mn(II)-ions are shown in red and the 
corresponding MetAP in green/blue 
 
The inhibitor coordinates to the active site metal ion. Additionally, high-resolution crystal 
structures of S. aureus MetAP-I in complex with various keto heterocycles and aminoketones 
were determined that also coordinate to the active site and form an uncleavable tetrahedral 
intermediate upon binding[149]. In two of these cases, the formation of the tetrahedral 
intermediate results in a favourable metal binding environment that allows trapping of a 
cobalt ion that in turn helps in the stabilization[149]. However, the stabilization by a third metal 
ion under in vivo conditions was questioned because 10 mM CoCl2 were present during 
crystallization[149]. Thus, neither the binding mode nor the use of a different metal ion can 
explain the discrepancy between in vitro and in vivo activity of some compounds. 
Therefore, it was tried to clarify the binding mode of thiabendazole by X-ray structure 
determination.  
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4.5.3 Crystal Structure Determination 
 
Crystallization screens and crystallization trials based on literature procedures were 
performed in cooperation with Prof. Klebe, Marburg University (Germany). For 
transportation, the protein was shock-frozen on dry-ice/ethanol at about 20 mg/ml. About 400 
different conditions were tested but these initial screenings yielded no results. Thus, the 
concentration of the enzyme solution was varied (13 mg/ml, 23 mg/ml and 33 mg/ml) and 
screenings were performed with and without the addition of octanoylsucrose as an additive. 
Then, different protein charges were used for crystallization screens, the salt composition of 
the buffer of the protein stock solution was changed and the same tests as mentioned were 
performed again. In addition, these tests were also performed with the His-tagged protein 
obtained during the purification of the protein and with Co(II)-loaded- and apo-MetAP. As 
there were still no crystals, a new batch of protein was prepared and several crystallization 
trials were performed in Saarbrücken before freezing the protein. Thus, many small crystals of 
apo-EcMetAP were obtained (cfr. Fig. 4-33) after 24 hrs using conditions described in the 
literature[52]. The size of a single crystal was about 0.25 x 0.25 mm. 
 
It can be stated that only freshly prepared protein is suitable for crystallization. Therefore, the 
protein was concentrated and kept at 4 °C for the following procedures. However, it was 
possible to obtain crystals after freezing a small sample of the solution at very high 
concentration (about 60 mg/ml) and storage for 2 days at -80 °C. If crystallization is possible 
after a longer storage period remains to be established. Crystals were also obtained with 
freshly prepared EcMetAP isolated from a frozen cell pellet. When kept at 4 °C, the 
concentrated protein solution can be used for about 10 days for crystallization trials, although 
the quality of the crystals declines. The addition of TCEP, a compound that reduces disulfide 
bonds and can reactivate oxidized EcMetAP might be used to prolong this time period. 
 
It should also be noted that even with the use of freshly and not frozen protein, no crystals 
were obtained with any of the screening conditions of the applied screening sets (cfr. 7.3.2). 
In addition, Co(II) could not be substituted by Mn(II) under the successful conditions.  
The slightly different conditions mentioned by Roderick and coworkers [51, 171] are also 
suitable for crystallisation. However, more protein is needed here.  
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Fig. 4-33 Crystals of EcMetAP without an inhibitor 
 
Cocrystallization of the EcMetAP with thiabendazole yielded fewer but slightly larger crystals 
(cfr. Fig. 4-34). 
 
                
Fig. 4-34 Crystals of EcMetAP cocrystallized with thiabendazole 
 
The same procedure was applied for three different inhibitors: Thiabendazole (I), RS 40 (II) 
and RS 17 (III). A suitable crystal was measured for each inhibitor and the determination of 
the structure revealed surprising results:  
      1 mm 
   0,3 mm 
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In all cases, the inhibitor does not coordinate towards the metal ions of the active site as could 
be expected but binds with an auxiliary third metal ion to His79. This metal complex is 
connected to the water molecule bridging the two Co(II) ions in the metal binding site. A 
schematic drawing can be seen in Fig. 4-35 and images generated from the crystal structures 
in Fig. 4-36. 
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Fig. 4-35 Schematical drawing for the binding mode of thiabendazole (Tbz) to EcMetAP 
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N
N
H
N
S
 
I 
N
N
H
N
 
II 
N
O
N
H
S
N
 
III 
I 
 
II 
 
III 
 
Cpnd. HOH Bave Bsdv Bmin Bmax 
I 270 35.66 9.66 14.90 63.24 
II 239 37.75 13.10 13.74 87.18 
III 292 35.36 11.25 11.66 71.59 
 
Cpnd. Lig Bave Bsdv Bmin Bmax 
I 14 29.37 4.17 20.34 40.16 
II 15 54.21 11.23 40.17 72.43 
III 14 37.38 7.65 24.10 47.08 
 
Cpnd. Protein Bave Bsdv Bmin Bmax 
I 
2064    
  1063 main c. 
  1001 side c. 
24.86 
22.18 
27.72 
10.75 
7.34 
12.86 
11.64 
11.64 
12.48 
101.18 
72.88 
101.18 
II 
2033    
  1063 main c. 
  1001 side c. 
23.38 
20.55 
26.40 
11.08 
6.26 
13.92 
8.13 
8.13 
8.3 
111.21 
67.42 
111.21 
III 
2033    
  1063 main c. 
  1001 side c. 
21.97 
18.89 
25.24 
10.95 
6.82 
13.31 
7.09 
7.09 
7.80 
96.96 
66.90 
96.96 
 
Bave 
Cpnd. 2 Co(II) 
act. site 
1 bound 
Co(II) 
1 add. 
Co(II) 
1 add. 
Na(I) 
I 17.36 25.09 54.86 22.46 
II 17.61 35.22 not refined 18.11 
III 13.67 30.50 41.37 22.18 
 
Fig. 4-36 Electron density of thiabendazole (above), of 2-pyridine-2-yl-1H-benzimidazole (middle) and of 
pyridine-2-carboxylic acid thiazole-2-ylamid (below) near the active site. The 2Fo - Fc electron 
density is contoured at 1σ in blue and shown within a radius of 1.5 Å around the inhibitor, the 
auxiliary cobalt ion and the complexing water molecules. 
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Table 4-20 Data Collection and Refinement Statistics for the MetAP-inhibitor complexes. a Values in 
brackets are statistics for the highest resolution shell; b Rsym =[ΣhΣi|Ii(h) - <I(h)>|/ΣhΣi Ii(h)] x 
100, where <I(h)> is the mean of the I(h) observation of reflection h. c Rcryst = Σhkl|Fo - 
Fc|/Σhkl|Fo|. d Rfree is calculated in the same manner as Rcryst but from 5 % of the data that 
were not used for refinement. e From Procheck[172]. f The residue Asn77 is in a disallowed 
region. This residue is characteristic of all MetAPs and is the second residue contained 
within a distorted type II’ ß-turn (residues 76-79), observed in all structures thus far studied. 
The distortion is most likely induced by a putative sodium ion coordinated to the carboxyl 
oxygens of Asn77, Cys234 and Glu79[173]. 
ligand: I II III 
space group P21 P21 P21 
unit cell parameters (Å, deg for β) a = 38.9 , b = 66.1,  
c = 48.5, β =111.2 
a = 38.9 , b = 64.7,  
c = 48.8, β =111.5 
a = 38.7 , b = 65.0,  
c = 48.6, β =111.5 
data statistics    
 resolution range (Å) 30-1.6 20-1.7 30-1.6 
 highest resolution shell (Å) 1.63-1.6 1.73-1.7 1.63-1.6 
 no. of observations 101657 47499 68688 
 no. of unique reflections 29881 23646 27964 
 completeness (%) 98.2 [75.8]a 95.0 [91.9] 94.5 [72.6] 
 mean I/σ 14.8 [2.9] 10.7 [2.3] 17.3 [3.6] 
 Rsym (%)b 8.6 [41.8] 7.0 [37.4] 4.4 [21.3] 
Refinement statistics and RMS deviations:    
 refined residues 262 262 262 
 refined inhibitor atoms 14 15 14 
 refined Co/Na atoms 4/1 3/1 4/1 
 refined water molecules 270 239 292 
 Rcryst (Fo > 4σ Fo; Fo)c 16.0, 16.8  16.5, 17.7 16.3, 16.8 
 Rfree (Fo > 4σ Fo; Fo)d 22.2, 23.3 25.4, 26.7 22.1, 22.9 
 bond lengths (Å) 0.009 0.006 0.009 
 bond angles (deg) 2.3 2.0 2.3 
Average B values    
 protein atoms (Å2) 24.9 23.4 22.0 
   main chain (Å2) 22.2 20.6 18.9 
   side chain (Å2) 27.7 26.4 25.2 
 Co1, Co2 (active site, Å2) 17.4 17.6 13.7 
 Co3 (inhibitor, Å2) 25.1 35.2 30.5 
 inhibitor atoms (Å2) 29.4 54.2 37.4 
 waters (Å2) 35.7 37.8 35.4 
 B values Na+ / Co4 (Å2)  22.5 / 54.9 18.1/--- 22.2 / 41.4 
Ramachandran plote    
 most favoured (%) 91.7   91.2 91.2 
 additionally allowed (%) 7.9 8.4 8.4 
 generously allowed (%) 0.0 0.0 0.0 
 disallowed (%)f 0.4 0.4 0.4 
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This way, these inhibitors block the entrance of the active site without interfering with the 
active site itself as can be seen in Fig. 4-37 for thiabendazole: 
 
 
Fig. 4-37 E. coli MetAP with bound thiabendazole (red), the cobalt ions are shown in magenta 
 
The structure with thiabendazole as a ligand was deposited in the PDB (pdb-code 1YVM). 
The two other structures were not deposited because different binding modes cannot be ruled 
out. For III, the density was only partly visible and for II, the B-values are very high. 
Nevertheless, clear density for the third Co(II)-ion could be observed in all cases. It was 
checked that this Co(II) ion is not present under otherwise identical conditions. 
 
This binding mode offers an explanation for the in vivo-inactivity: These inhibitors are in 
need of Co(II) ions to exhibit their inhibitory ability as they bind as metal complexes. 
Possibly, the in vivo Co(II)-concentration is too low to allow the formation of this complex 
and Co(II) can probably not be substituted by another metal ion. Katz et al. were the first to 
describe serine protease inhibitors that are zinc-mediated and thus use metal ions for their 
binding capability[174], similar to the binding of thiabendazole. Other substances are likely to 
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share the same binding mode, as many of the EcMetAP inhibitors described possess structural 
elements with metal complexing properties such as hydroxamic acids or heterocycles flanked 
by an amine group. In vitro screening results of metal dependent enzymes should therefore be 
considered with caution and should be accompanied by either a screening with different metal 
ions (when the cofactor can be substituted) or by in vivo screening assays. 
 
The binding mode of thiabendazole might also give the explanation why excess cobalt is 
inhibitory for EcMetAP. Comparing the ratios of Co(II) and EcMetAP during the assay 
procedure and during crystallization, it becomes clear that the ratio is much higher during in 
vitro tests (200 µM metal ions:10 nM enzyme compared to 1 mM metal ions:0.4 mM protein). 
Therefore, it may well be possible that at very high Co(II)-concentrations within an assay, a 
Co(II)-ion binds even without the presence of an inhibitor to His79 (or perhaps His178) and 
not to the bridging hydroxide ligand which was suggested by other authors[93] (cfr. 4.2.3.5.2, 
Concentration of Co(II)). This would block the entrance to the active site in the same way as 
an inhibitor-cobalt-complex.  
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4.6 Determination of MIC-values 
 
Some of the thiabendazole-derivatives, for example RS 48, RS 60 and RS 54 have been 
described to be active against E. coli and other bacteria, with MIC-values of 10-100 
µg/ml[175]. Thus, the even (in vitro) more active derivatives were expected to be promising 
candidates for antibacterial drugs. Consequently, the three compounds with the lowest IC50-
values (Compounds RS 17, RS 64 and RS 65) together with the parent compounds 
thiabendazole and RS 40 were tested for their antibacterial activity, using the E. coli strain 
BL21(DE3) as the test organism and ciprofloxacine as a reference. The results are shown in 
Fig. 4-38. 
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Fig. 4-38 MIC-value determination of different benzimidazoles with E. coli, 48 hrs incubation 
 
None of the thiabendazole derivatives significantly inhibited the growth at concentrations up 
to 100 µg/ml in spite of the good in vitro activity against EcMetAP. The substance with the 
lowest IC50-value, RS 17, also showed the best in vivo activity. However, RS 64 and RS 65 
with similar IC50-values in vitro were not as active as RS 17. Among the thiabendazole 
derivatives, RS 40 was the most active compound. As only high concentrations of these 
substances led to observable effects (125 and 250 µg/ml) and other aspects such as 
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pharmacokinetic properties and a possible metabolism have to be taken into account, it is 
difficult to obtain a proper correlation between the in vitro IC50-values and the MIC-values. 
 
Given the fact that Co(II) is needed for the binding of thiabendazole and its derivatives, the 
following hypothesis should be tested: Thiabendazole and its congeners should have (in 
theory) a higher in vivo-potency when applied as a Co(II)-complex. The pharmacokinetic 
properties of these complexes are not known, just like the stability constants of the 
complexes. These factors could counteract the expected improvement. Nevertheless, an 
increase in intracellular Co(II)-levels is very probable if Co(II) is added externally. Even 
without proper permeation of the Co(II)-complexes through the cell membrane these 
substances should be more effective in vivo. This can be supposed assuming “normal” cell 
permeation of the substances and subsequent formation of a Co(II)-complex within the cells. 
This process and the corresponding binding capacity to the target protein should correlate 
with (increasing) Co(II)-levels.  
In addition, antimicrobial activity of several thiabendazole-metal complexes has been 
observed[176] and the preparation of complexes of thiabendazole with transition metals has 
been described in the literature[177]. 
 
After initial tests with different amounts of Co(II)-ions added to the growth medium, RS 17 
(as the compound with the best MIC-value) and thiabendazole (as the lead compound for the 
synthesized library) were chosen as test compounds and the following results were obtained. 
 
 
4.6.1 Comparison of MIC-values with and without Co(II) 
 
First, three different Co(II)-concentrations were tested: 0.0122 mM, 0.122 mM and 1.22 mM 
CoCl2. Whereas the addition of 0.0122 mM CoCl2 had almost no effect on either bacterial 
growth or the MIC-values of the compounds, the addition of 1.22 mM CoCl2 was lethal for 
the E. coli strain BL21(DE3) and inhibitors could not be tested. The addition of 0.122 mM 
CoCl2 proved advantageous and was used for the further testing as it offered the possibility to 
observe effects combined with only a minor decline in bacterial growth without inhibitors. 
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For compound RS 17, the following curves were determined (cfr. Fig. 4-39). A clear left-shift 
of the curve could be observed, confirming the expected influence of Co(II)-addition.  
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Fig. 4-39 MIC-value determination with compound RS 17 and 0.122 mM CoCl2 added to the growth 
medium, 16 hrs incubation, values with inhibitors were determined in duplicate, blank values in 
quadruplicate 
 
For thiabendazole, this effect was also visible but only became apparent at high 
concentrations and a longer incubation time. The results for both RS 17 and thiabendazole are 
shown in Table 4-21. 
 
In summary, the addition of Co(II) improved the MIC-values of both compounds tested. The 
effect was more pronounced with compound RS 17 compared to thiabendazole. This could be 
based on the higher stability of its Co(II)-complex and the correlating lower IC50-value 
compared to the thiabendazole-Co(II)-complex but could also be the result of differing 
pharmacokinetic properties. Defining the MIC-value as the concentration that inhibits 
bacterial growth by more than 90 %, the potency of RS 17 was improved by a factor of about 
6-8 and a complete inhibition of bacterial growth could be reached by 125 µg/ml - 250 µg/ml 
thiabendazole. This result could not be achieved when no Co(II) was present. 
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Table 4-21 Inhibition of bacterial growth of compound RS 17 and thiabendazole with and without the 
addition of 0.122 mM CoCl2. Inhibition rates smaller than 15 % are titled “---“. Incubation times 
were 16 hrs for Compound RS 17  and 45 hrs for thiabendazole; values with inhibitors were 
determined in duplicate, blank values in quadruplicate 
Compound RS 17 Thiabendazole 
Concentration 
[µg/ml] 
% inhibition 
without 
Co(II) 
% inhibition 
with Co(II) 
Concentration 
[µg/ml] 
% inhibition 
without 
Co(II) 
% inhibition 
with Co(II) 
250.0000 99.8 ± 0.3 98.1 ± 0.8 250.0000 57.8 ± 3.3 99.2 ± 2.1 
125.0000 96.1 ± 0.5 92.7 ± 2.0 125.0000 44.1 ± 8.1 76.8 ± 0.3 
62.5000 70.9 ± 2.3 88.3 ± 0.5 62.5000 23.3 ± 1.6 44.1 ± 7.0 
31.2500 38.7 ± 2.2 94.7 ± 1.7 31.2500 --- --- 
15.6250 24.7 ± 1.4 89.2 ± 1.6 15.6250 --- --- 
7.8125 19.9 ± 2.8 79.8 ± 2.0 7.8125 --- --- 
3.9063 15.4 ± 4.2 66.9 ± 1.5 3.9063 --- --- 
1.9531 15.2 ± 3.6 36.3 ± 1.0 1.9531 --- --- 
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5 Summary and Conclusion 
 
After the successful expression and purification of the E. coli methionine aminopeptidase, a 
cheap and easy to handle assay system was developed for the screening of inhibitors and for 
the characterisation of the enzyme. Experiments with fumagillin, a covalent inhibitor that 
inhibits angiogenesis, confirmed computational studies trying to calculate the protonation 
state of the active site of the EcMetAP. This enzyme is metal dependent, although the identity 
of the metal ion is not yet entirely clear. Co(II) activates all MetAPs known so far but also 
Mn(II) seems a promising candidate. The active site consists of five conserved residues 
surrounding two metal ions that are “connected” by a bridging water molecule. The 
protonation state of this water molecule, however, is not entirely clear. Both the 
computational studies and the experiments investigating the pH-dependency of the binding of 
fumagillin indicated that two protonation states are possible: One (at a lower pH) is relevant 
for the binding of fumagillin, an epoxide that is more easily bound when it is protonated prior 
to the nucleophilic attack of a histidine near the active site. A more basic pH is relevant for 
the cleavage of substrates. The pKa-value of the bridging water molecule can be estimated to 
be about 7. Based upon these results, a modified reaction mechanism could be proposed. 
Additionally, these differences in enzymatic behaviour might be exploited for the further 
design and development of anticancer agents. 
 
After this initial characterisation of the enzyme, a screening of inhibitors was performed. 
Small epoxides were synthesized and tested in addition to fumagillin analogs, 
peptidomimetics, known drugs and substances from our in-house library. In summary, several 
hundred substances were tested. With the aid of molecular modeling and virtual screening it 
was possible to find an in vitro active substance: Thiabendazole, a known antifungal and 
antiparasitic drug has an IC50-value of about 500 nM. Subsequently, a series of thiabendazole-
analogs was synthesized and tested. It became clear that only substances with a functional 
metal-binding motif are able to inhibit Co(II)-loaded EcMetAP. However, it was difficult to 
gain further insight into structure-activity relationships even with the assistance of molecular 
modeling methods. In addition, all of the substances proved inactive against the Mn(II)-
loaded EcMetAP. They were also unable to inhibit the growth of E. coli in concentrations up 
to 100 µg/ml in spite of supposedly acceptable pharmacokinetic properties and a high in vitro-
potency with Co(II) present. These findings, together with a questionable docking-pose, the 
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desire to continue this work with a rational drug design and the need to use high 
concentrations of in vitro highly active substances to observe an effect on bacterial growth 
brought us to resolve crystal structures of the EcMetAP with bound inhibitor. A new and 
surprising binding mode was the result: Thiabendazole exerts no direct interactions with the 
active site metal ions as could be expected by X-ray structures of other competitive inhibitors, 
docking results and of the molecular properties of thiabendazole. In contrast to other 
competitive inhibitors, thiabendazole binds via a third “auxiliary” metal ion (thus as a metal-
complex) to a conserved histidine near the active site and blocks the entrance to the catalytic 
site. Further X-ray structures of a thiabendazole analogue and of a competitive inhibitor 
described in the literature (of a different class) revealed an identical mode of action, indicating 
a possible generalisation of this binding mode for at least to classes of compounds: Properties 
and in vivo-results of other structurally distinct classes of competitive inhibitors give cause for 
the assumption that this binding mode might be even more widespread.  
 
The unexpected binding mode explains the inactivity of many compounds when tested for 
antibacterial or anti-angiogenic activity, as the screening for inhibitors is normally done with 
(unphysiologically high concentrations of) Co(II) as the cofactor. Other divalent metal ions – 
although able to substitute for the Co(II) in the active site needed for enzymatic activity – 
seem to be unable to act as a binding-mediator. However, the Co(II)-complexes derived from 
these substances should have a higher inhibitory in vivo-potency than the “free substances”. 
The last step after the clarification of the binding mode was therefore the proof of principle. In 
consequence, two of the compounds with the proven binding mode were used as model 
substances and their antibacterial effect against E. coli was tested again, but this time 
additional Co(II) was added to the growth medium of the bacteria. This action increases the 
potency of both thiabendazole and of the compound taken from the literature, thus confirming 
the expected effect and underlying the binding mode clarified by crystallization experiments. 
 
The pharmacokinetic properties of these metal-complexes are probably unfavourable. 
Therefore, it remains questionable if these substances should be used as lead compounds for 
the future drug development and the design of inhibitors using other physiologically more 
common ions such as Ca(II) or Mg(II) will be a challenging task. Even if the aim to get new, 
potent antibacterial drugs was only partly achieved, the in vitro results of the thiabendazole 
analogs together with the crystallization experiments could be used to develop a new scoring 
function for predicting the binding affinities of compounds to a binding site with metal ions. 
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With this scoring function, it is possible to distinguish between the active and the inactive 
substances which was not possible with commonly available functions such as ChemScore or 
with the scoring functions of GOLD. Thus, it will be possible to get reliable docking poses 
and affinity predictions in the future not only for virtual screening procedures with the 
EcMetAP but also with other target (metallo-) proteins where the crystal structure is available. 
 
In conclusion, in vitro screening results should always be considered very carefully to avoid 
unneeded expenditure of human labour, especially when working with metal-dependent 
enzymes. The binding mode of inhibitors should be confirmed by crystal structure 
determination, even if this is often difficult if the crystallization conditions are unknown or 
when working with membrane bound proteins. 
 
During this work, it was possible to combine experimental procedures, molecular modeling 
techniques and crystallization experiments to gain a deeper understanding of the target 
protein. Hopefully, the results presented here will be useful for the future design and 
development of anticancer, antibacterial, antifungal and antiparasitic drugs.  
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6 Zusammenfassung 
 
Nach der erfolgreichen Überexpression und Aufreinigung der E. coli Methionin-
Aminopeptidase ist es gelungen, ein günstiges und einfach durchzuführendes Testverfahren 
zu etablieren. Dieses Testverfahren kann in 96-Well-Platten durchgeführt werden und ist 
daher sowohl zur Charakterisierung des Enzyms geeignet als auch für Screening-Versuche um 
neue, potentielle Hemmstoffe zu identifizieren.  
Der erste Teil der Arbeit befasst sich mit dem Protonierungszustand des aktiven Zentrums, 
der z.B. wichtig ist für die Aufklärung der bei der Umsetzung von Substraten ablaufenden 
Reaktionen. Bei der Methionin-Aminopeptidase handelt es sich um eine Metalloprotease. 
Allerdings ist noch nicht klar, welches Metall als Cofaktor in vivo fungiert. Auf jeden Fall 
aktiviert Co(II) alle bisher bekannten Methionin-Aminopeptidasen, unabhängig von Spezies 
und Subtyp. Daneben gilt aber auch u.a. Mn(II) als möglicher Cofaktor. Das aktive Zentrum 
besteht aus fünf bei allen Methionin-Aminopeptidase-Arten identischen Aminosäuren, die 
zwei Metallionen umgeben; die beiden Metallionen wiederum werden durch ein 
Wassermolekül überbrückt. Der Protonierungszustand dieses Wassermoleküls ist nicht 
bekannt und spielt neben dem Reaktionsmechanismus auch eine Rolle bei der Bindung von 
bestimmten Hemmstoffen. Fumagillin ist solch ein kovalent bindender Hemmstoff der 
Methionin-Aminopeptidase und ist gilt als potentielles Krebstherapeutikum, da Fumagillin die 
Angiogenese verhindert. Um nun den Protonierungszustand des aktiven Zentrums aufzuklären 
wurden zunächst einige Computersimulationen mit diversen theoretisch denkbaren bzw. 
möglichen Protonierungszuständen durchgeführt. Parallel wurde experimentell die pH-
Abhängigkeit der Fumagillin-Bindung untersucht. Die Computersimulationen wurden durch 
die experimentellen Daten bestätigt und beide Lösungsansätze kommen zu folgendem 
Ergebnis: Prinzipiell scheinen zwei Protonierungszustände möglich zu sein: Das 
überbrückende Wassermolekül lässt sich durch einen pKs-Wert von ca. 7 charakterisieren und 
kann unter physiologischen Bedingungen entweder als koordinierendes Wassermolekül oder 
als überbrückendes Hydroxid-Ion vorliegen. Der Zustand bei einem niedrigeren pH-Wert ist 
relevant für die Bindung von Fumagillin. Dieses Epoxid wird leichter gebunden, wenn es vor 
dem nucleophilen Angriff eines sich in der Nähe des aktiven Zentrums befindlichen Histidins 
protoniert wird. Für die Spaltung von Substraten allerdings scheinen basischere Bedingungen 
günstiger zu sein. Aufgrund dieser Ergebnisse konnte ein modifizierter 
Reaktionsmechanismus vorgeschlagen werden. Zusätzlich bieten diese Ergebnisse wichtige 
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Hinweise für das zukünftige Design kovalent bindender Hemmstoffe und für die weitere 
Entwicklung von Krebstherapeutika. 
Der zweite Teil der Arbeit befasst sich mit der Entwicklung neuer Hemmstoffe der E. coli 
Methionin Aminopeptidase. Nach der oben erwähnten ersten Charakterisierung des Enzyms 
sollte ein Screening durchgeführt werden. Zu diesem Zweck wurden kleine Moleküle mit 
einer Epoxid-Gruppe synthetisiert und neben diversen Fumagillin-Analoga, Peptidomimetika, 
bekannten Arzneimitteln, Derivaten von bekannten Hemmstoffen und anderen Substanzen aus 
dem Arbeitskreis getestet. Es wurden ca. 35 Substanzen synthetisiert und mehrere Hundert 
Substanzen wurden insgesamt untersucht. Mit der zsätzlichen Hilfe von virtuellen Screening-
Methoden konnte schließlich eine in vitro sehr aktive Substanz identifiziert werden: 
Thiabendazol, ein bekanntes Fungizid und in der Behandlung von Parasiten eingesetztes 
Arzneimittel. Der IC50-Wert von Thiabendazol liegt bei ca. 500 nM. Eine Reihe von 
Thiabendazol-Analoga wurde synthetisiert und getested. Es wurde klar, dass nur Substanzen 
mit einer potentiellen Metallbindungsstelle die Co(II)-aktivierte E. coli Methionin 
Aminopeptidase hemmen konnten. Es war allerdings schwierig, weitere Struktur-Wirkungs-
Beziehungen zu erkennen. Auch der Einsatz von Molecular-Modeling Methoden brachte 
keine weiteren Erkenntnisse. Zudem waren alle Substanzen unwirksam gegen das Mn(II)-
aktivierte Enzym und konnten das Wachstum von E. coli Bakterien erst in einer 
Konzentration von über 100 µg/ml hemmen, obwohl sie an dem freien Enzym teilweise IC50-
Werte von unter 100 nM aufweisen und aufgrund der Verwendung von Thiabendazol als 
Arzneimittel wahrscheinlich auch akzeptable pharmakokinetische Eigenschaften besitzen. 
Aufgrund dieser Ergebnisse, einer fragwürdigen Docking-Position von Thiabendazol beim 
virtuellen Screening und dem Wunsch, diese Arbeit mit einem rationalen Wirkstoffdesign 
fortzuführen brachten uns dazu, die Kristallstruktur der E. coli Methionin-Aminopeptidase 
mit gebundenem Hemmstoff aufzuklären. Das Ergebnis war ein neuer und überaschender 
Bindungsmodus: Thiabendazol übt keinerlei direkte Wechselwirkungen mit den Metallionen 
des aktiven Zentrums aus, wie aufgrund von Röntgenstrukturen der Methionin-
Aminopeptidase mit anderen kompetitiven Hemmstoffen oder auch aufgrund unserer eigenen 
Docking-Versuche erwartet wurde. Stattdessen bindet Thiabendazol mit Hilfe eines dritten 
Metallions, also als Metallkomplex, an ein im Laufe der Evolution erhalten gebliebenes 
Histidin in der Nähe des aktiven Zentrums und blockiert so dessen Eingang. Weiterführende 
Röntgenstrukturuntersuchungen mit einem Thiabendazol-Analogon und einer in der Literatur 
beschriebenen Verbindung einer anderen Klasse lassen den gleichen Bindungsmodus 
erkennen. Diese Ergebnisse und die Tatsache, dass auch andere Verbindungsklassen ein 
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unterschiedliches in vitro- und in vivo-Verhalten zeigen, legen die Vermutung nahe, dass 
dieser Bindungsmodus noch weiter verbreitet sein könnte. Dieser unerwartete 
Bindungsmodus erklärt die antibakterielle oder auch antiangiogenetische Unwirksamkeit 
vieler Substanzen – schließlich wird das Screening für neue Hemmstoffe normalerweise mit 
(unphysiologisch) hohen Co(II)-Konzentrationen durchgeführt. 
Andere zweiwertige Metallionen können nicht als „Bindungsvermittler“ fungieren, auch wenn 
sie anscheinend die Co(II)-Ionen im aktiven Zentrum ersetzen können. Die Co(II)-Komplexe 
dieser Verbindungen sollten bei vorausgesetzter Stabilität zumindest theoretisch eine höhere 
in vivo-Potenz besitzen als die „freien“ Substanzen. Der letzte Schritt in dieser Arbeit nach 
der Aufklärung des Bindungsmodus war schließlich der Beweis des Bindungsprinzips: Zwei 
der Substanzen, die ihre in vitro-Hemmaktivität als Co(II)-Komplexe ausüben, wurden als 
Modellsubstanzen ein weiteres Mal auf ihre antibaktielle Aktivität untersucht, allerdings 
wurde diesmal Co(II) zum Wachstumsmedium der Bakterien gegeben. Dadurch konnte in 
beiden Fällen eine signifikante Verstärkung der Hemmwirkung beider Substanzen festgestellt 
werden. Da die Metallkomplexe wahrscheinlich ungünstige pharmakokinetische 
Eigenschaften haben, bleibt die Frage offen, ob diese Verbindungen als Leitsubstanzen für die 
weitere Hemmstoffentwicklung dienen sollten. Auch dürfte es sehr schwierig werden, die 
Substanzen so zu modifizieren, dass das Co(II) durch andere physiologische Metallionen wie 
Ca(II) oder Mg(II) ersetzt werden kann.  
Auch wenn das Ziel neue, potente antibakteriell wirksame Stoffe zu finden nur zum Teil 
erreicht wurde, war es möglich, anhand der Kristallisationsexperimente in Kombination mit 
den in vitro-Ergebnissen eine neue Scoring-Funktion namens Turboscore für das virtuelle 
Screening von Substanzen zu entwickeln. Diese Funktion besitzt spezielle Parameter um 
Bindungsaffinitäten zwischen Heteroatomen und Metallionen zu bewerten. Mit Turboscore ist 
es möglich, zwischen aktiven und inaktiven Substanzen zu unterscheiden, was mit 
kommerziell erhältlichen Funktionen und Programmen wie GOLD oder ChemScore nicht 
gelungen war. Mit dieser Scoring-Funktion wird es möglich sein, für virtuelle Screening 
Versuche nicht nur mit der E. coli Methionin Aminopeptidase sondern auch mit anderen 
metallabhängigen Proteinen in der Zukunft zuverlässige Docking-Positionen zu erhalten. 
 
Zusammenfassend lässt sich sagen, dass in vitro Versuche immer vorsichtig bewertet werden 
sollten. Ganz besonders aber dann, wenn es sich um metallabhängige Enzyme handelt. Wenn 
es irgendwie möglich ist, sollte der Bindungsmodus eines Hemmstoffs mittels 
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Röntgenstruktur überprüft werden, auch wenn dies bei unbekannten 
Kristallisationsbedingungen oder bei membrangebundenen Enzymen oft schwierig ist. 
 
Bei dieser Arbeit ist es gelungen, durch eine Kombination von experimentellen Verfahren, 
computerunterstützten Modeling-Versuchen und Röntgenkristallstrukturuntersuchungen ein 
tieferes Verständnis der E. coli Methionin-Aminopeptidase und deren Hemmstoffen zu 
erhalten. Hoffentlich werden die hier präsentierten Ergebnisse nützlich sein für die weitere 
Hemmstoffentwicklung von zukünftigen antibakteriellen, fungiziden, antiparasitären 
Wirkstoffen bzw. Krebstherapeutika. 
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7 Materials and Methods 
 
All chemicals and reagents were of the highest quality available and were obtained from 
Acros (Neuss, Germany), Aldrich (Steinheim, Germany), Bachem (Weil am Rhein, 
Germany), Fluka (Neu-Ulm, Germany), Lancaster (Mülheim am Main, Germany), Merck 
(Darmstadt, Germany), Macherey-Nagel (Düren, Germany), Molecular Probes/Invitrogen 
(Karlsruhe, Germany), Roche (Mannheim, Germany), Roth (Karlsruhe, Germany), Serva 
(Heidelberg, Germany), Sigma-Aldrich (Deisenhofen, Germany). Chemicals and solvents 
were normally used without further purification. The constitution of buffers and media used 
within this work are described in the respective (bio-) chemical sections. The most important 
chemicals and reagents are listed below, laboratory equipment, material and other instruments 
are listed in each section. 
 
Enzymes 
Horseradish Peroxidase    Sigma-Aldrich (Deisenhofen, Germany) 
Amino acid oxidase (from Crotalus  Sigma-Aldrich (Deisenhofen, Germany) 
adamanteus, Type I) 
Ribonuklease A (RNAse A)   Roth (Karlsruhe, Germany) 
Desoxyribonuklease I (DNAse I)  Roche (Mannheim, Germany) 
Restriction enzymes    New England Biolabs (Frankfurt, Germany) or
      Takara (Otsu, Japan) 
 
Chemicals 
Amplex Red Molecular Probes/Invitrogen (Karlsruhe, 
Germany) 
MGMM     Bachem (Weil am Rhein, Germany) 
N-Octanoylsucrose    Calbiochem (San Diego, USA) 
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7.1  Chemistry 
 
7.1.1 General Information 
 
7.1.1.1 1H-NMR-Spectroscopy 
1H-NMR spectra were recorded on a Bruker (Karlsruhe, Germany) DRX-500 spectrometer 
(500 MHZ). Chemical shifts are reported as values (ppm) relative to either internal 
tetramethylsilane (0 ppm) or the solvent peak. The abbreviations of the signals are: s 
(singulet), d (doublet), dd (double doublet), t (triplet), q (quartet), m (multiplet). Coupling 
constants (J) are given in Hz. 
 
7.1.1.2 Elemental Analyses 
Elemental analyses were performed in the group of Prof. Huber, Department of Analytical 
Chemistry, University of the Saarland. 
 
7.1.1.3 IR-Spectroscopy 
IR spectra were measured with a Vector 33, Bruker (Karlsruhe, Germany); with a Zn/Se-
ATR-Unit (ATR Harrick MVP, Software OPUS Version 4.0). 
 
7.1.1.4 Melting Points 
Melting points were measured with a Stuart Melting Point Apparatus SMP3, Bibby Sterlin 
(Essex, United Kingdom). The heating rate was 6 °C / min. 
 
7.1.1.5 Laboratory Equipment/Other Instruments 
Vacuum distillations of solvents during purification of compounds were done with a 
Rotavapor R, Büchi (Uster, Swiss) and a membrane vacuum pump CVC-2, Vacuumbrand 
(Wertheim, Germany). For the temperature regulation of the water bath the thermostat E51 
from Haake (Erlangen, Germany) was used. Fluorescent lamp was a Minuvis from Desaga 
(Heidelberg, Germany). Magnetic stirrers (model RTC basic) were from IKA (Staufen, 
Germany).  
7.1 Chemistry 117 
 
7.1.2 Synthetic Procedures and Characterization of Compounds 
 
Some of the compounds were synthesized for the first time. Although some of the other 
compounds are mentioned in the literature, they are often not characterized or no detailed 
procedure is given. The nomenclature of the compounds is according to the IUPAC. 
 
7.1.2.1 List of Compounds 
 
Cpd. Proc. Cpd. Proc. Cpd. Proc. Cpd. Proc. 
RS 1 A RS 73 F-5 RS 33 H RS 52 O 
RS 2 A RS 74 G RS 34 O RS 53 T 
RS 3 A RS 75 H RS 35 O RS 54 T 
RS 4 A RS 26 I RS 36 O RS 55 U 
RS 5 A RS 27 I RS 37 O RS 56 U 
RS 6 A RS 17 J RS 38 P RS 57 O 
RS 7 B RS 18 J RS 39 Q RS 58 O 
RS 8 B RS 19 K RS 40 O RS 59 O 
RS 9 B RS 20 L RS 41 O RS 60 O 
RS 10 B RS 21 M RS 42 O RS 61 O 
RS 11 C RS 22 N RS 43 R RS 62 R 
RS 12 C RS 23 I RS 44 S RS 63 V 
RS 13 D RS 24 I RS 45 S RS 64 O 
RS 14 E RS 25 N RS 46 S RS 65 O 
RS 15 E RS 28 H RS 47 O RS 66 O 
RS 16 F-1 RS 29 H RS 48 O RS 67 O 
RS 70 F-2 RS 30 H RS 49 O RS 68 R 
RS 71 F-3 RS 31 H RS 50 O RS 69 R 
RS 72 F-4 RS 32 H RS 51 O   
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7.1.2.2 Preparation of Starting Materials 
 
7.1.2.2.1 Starting Materials for the Preparation of Derivatives of RS 17 
 
For the preparation of derivatives of pyridine-2-carboxylic acid, pyridine-2-sulfonylchloride 
and pyridine-2-carbonyl chloride were needed as starting materials and prepared according to 
the following procedures: 
 
Pyridine-2-sulfonyl chloride[178-181]:  
2-Mercaptopyridine (20 g, 0.18 mol) was dissolved in concentrated HCl (250 ml), and 
chlorine gas was bubbled through at 0 °C for 2 h. The mixture was poured into ice-water (500 
ml) and extracted three times with dichloromethane. The combined organic fractions were 
washed with brine and dried with Na2SO4. After filtering, concentration under reduced 
pressure yielded a clear oil that solidified in the freezer. The yield was 88 % (Lit. 55-97 %) 
and the product was used without further purification. 
 
Pyridine-2-carbonyl chloride[182, 183]: 
To a stirred solution of thionyl chloride (15 ml) was added picolinic acid (2.47 g, 20 mmol) 
with heating at 85 °C for 1 h. The reaction mixture was evaporated to afford crude picolinic 
chloride as a dark purple solid. The yield was 100 % and the product was used without further 
purification. 
 
7.1.2.2.2 Starting Materials for the Preparation of Derivatives of Thiabendazole 
 
Pyridine-2-carboxamidine hydrochloride and Pyrazine-2-carboxamidine hydrochloride[184]: 
 
N
N
N NH
NH2
N
NH
O CH3
CH3O- 
CH3OH
NH4Cl
 
Fig. 7-1 Reaction scheme for the preparation of pyridine-2-carboxamidine (or other amidines) 
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A solution of 26.0 g (0.25 mol) of 2-cyanopyridine (or 2-cyanopyrazine) and 1.35 g (0.025 
mol) of sodium methoxide in 25 ml of methanol was allowed to stand overnight at room 
temperature. The amidine salt has then been prepared in situ from the imidate with an amount 
of ammonium chloride equivalent to the total base present. The reaction mixture was merely 
stirred for a few hours until the salt dissolved. The reaction time varied from 1-24 hrs. The 
solvent methanol was evaporated to recover the amidine salt that was used without further 
purification. The yield was 96 % (m. p. 146-148 °C) for Pyridine-2-carboxamidine 
hydrochloride (Lit. 149-151 °C) and 63 % (m.p. 217-220 °C, decomp.) for Pyrazine-2-
carboxamidine hydrochloride (Lit. 215-218 °C). 
 
 
Thiazole-4-carboxylic acid: 
The reaction scheme is depicted in Fig. 4-31. At first, bromopyruvic acid was prepared 
according to Ref.[185]: 
1 mol of pyruvic acid was heated to 50 °C in a 3-neck flask equipped with ground glass joints, 
and 1 mol of bromine, previously dried by shaking with concentrated H2SO4, was added 
dropwise with stirring and exclusion of moisture. The heat of the reaction was usually 
sufficient to keep the temperature at 50 °C; external temperature control was resorted to when 
necessary. The thick fuming syrup was immediately poured into a large crystallizing dish, the 
flask washed with a small amount of hot benzene, and the washing added to the main product. 
Sometimes the material set in the flask to a fuming crystal mass which was dissolved in a 
small amount of hot benzene. The mixture was placed in a vacuum desiccator over moist 
NaOH pellets, and the solvent removed by suction. On the next day the material was ground 
to a fine powder and kept in vacuo over NaOH pellets for 48 to 72 hrs with frequent renewal 
of the alkali, until no more fumes of HBr were given off. The yield was 97 %, m.p. 55-57 °C 
(Lit: 70-98 %, 55-74 °C). 
The thiazole-4-carboxylic acid was then prepared using a modification of the procedure 
described in Ref [186, 187]. 
To a stirred solution of 7.75 g (172 mmol) of formamide in 250 ml of THF (or 200 ml 
dioxan), which was cooled to 0 °C, was added all at once 13.2 g (30 mmol) of solid P4S10. 
After this addition, the ice bath was removed and the reaction was stirred at 30 °C (refluxed) 
for 3 hrs. The resultant mixture was cooled to room temperature, filtered and added to a 
solution of 2.7 g (16.2 mmol) of 3-brompyruvic acid in some THF (or dioxane). The mixture 
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was then heated to 40-50 °C (50-60 °C) for 3 hrs and a precipitate started to appear. After 
cooling, the precipitate was filtered off, dissolved in some water with concentrated H2SO4 and 
the pH adjusted to pH 2-3 with NH4OH, and the product precipitated as a white solid in the 
refrigerator. Yields were normally about 22 % (up to 56 %), m.p. 193-195 °C (Lit: 27 %, m.p. 
195-197°). 1H-NMR (500 Mhz, d6-DMSO, ppm): 8.53 (1H, s), 9.17 (1H, s). 
 
 
Pyrazine-2,3-diamine[188-190]. 
 
N
N NH2
NH2N
N NH2
N3N
+
N NH2
O
N
+
N
O
O
NH2
N
N NH2
O
 
Fig. 7-2 Reaction scheme for the preparation of Pyrazine-2,3-diamine 
 
A solution of pyrazinecarboxamide (24.6 g, 0.20 mol) in 90 % formic acid (100 ml) and 30 % 
hydrogen peroxide (62.5 ml) was stirred and heated. The temperature was kept between  
40-50 °C for 4 hrs and then at 40 °C for 1 hr. A colourless solid started to separate from the 
solution after heating for approximately 10 minutes. The mixture was refrigerated overnight, 
then filtered, washed with water and dried to give 59 %, m.p. 303-306 °C (Lit: 66 %, m.p. 
303-306 °C) of the N-oxide. This material was used directly in successive transformation 
without further purification. 
Sodium hypochlorite solution (4.0 mmol/ml available chlorine) was added dropwise to a 
stirred solution of sodium hydroxide (8.08 g, 0.20 mmoles) in water (125 ml) at room 
temperature. The amide (6.956 g, 0.050 mmol) was added in one portion to the above 
solution, and the resulting mixture was heated at 70 °C with stirring for 1 hour. During this 
period, the amide dissolved. After cooling below 20 °C, the solution was acidified to pH 0 
with concentrated hydrochloric acid and then again basified at pH 9-10 with 2 N NaOH. The 
mixture was evaporated to dryness in vacuo, and the residue was powdered and extracted with 
chloroform by a Soxhlet extractor for 24 hrs to give 70 %, m.p. 175-177 °C (Lit: 78 %, m.p. 
177-178 °C) of 3-aminopyrazine-1-oxide. 
To 1 mmol of the oxide, which was stirred under nitrogen, MeCN (8 cm3), trimethylsilyl 
azide (0.17 cm3, 1.2 mmol) and finally diethylcarbamoylchloride (0.16 cm3, 1.2 mmol) were 
added via syringe. The mixture was stirring under reflux for 18 hrs and then evaporated under 
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reduced pressure. The residue was subjected to chromatography on silica gel eluting with 
hexane-EtOAc (10:1 to 3:1) and gave 92 %, m.p. 228 °C (decomp) (Lit: 99 %, m.p. 225 °C 
(decomp)) of 2-amino-3-azidopyrazine. 
A mixture of the azidopyrazine (1 mmol) and tin(II) chloride dihydrate (1.128 g, 5 mmol) in 
12 N HCl (3.0 ml) and MeOH (3.0 ml) was stirred and heated at 60 °C until the starting 
material was completely consumed. After cooling to room temperature., the solution was 
basified with solid Na2CO3 to pH 8-9 and then evaporated to dryness in vacuo. The residue 
was extracted with EtOAc while hot, or by Soxhlet apparatus, and the extract was dried 
(MgSO4). Evaporation and chromatography on silica gel gave 2,3-diaminopyrazine, 14 %, 
m.p. 191-193 °C (Lit: 87 %, m.p. 207-209 °C). The low yield in the last step can be explained 
by a prolonged allowed reaction time or a higher reaction temperature what can lead to the 
forming of 3-amino-2(1H)-pyrazinone. The diamine was used without further purification. 
 
 
7.1.2.3 General Procedures and Analytical Data 
 
Procedure A: Preparation of chloro- and methyl-substitued phenyloxiranes[191, 192] RS 1, 
RS 2, RS 3, RS 4, RS 5, RS 6: 
3-Chloroperbenzoic acid (3.71 g of 57 % mCPBA, 9.8 mmol) was added portionwise over a 
15-min period to a cold (ice bath) stirring solution of a suitable substituted styrene (1.5 g, 8.2 
mmol) in CH2Cl2 (50 ml). The reaction mixture was gradually warmed to room temperature 
and allowed to stir for 1 h, at which time it was diluted with CCl4 (50 ml), and the precipitated 
3-chlorobenzoic acid was removed by suction filtration. The filtrate was washed with a 1:1 
mixture of 5 % aqueous NaHCO3 and 5 % aqueous NaHSO3 (3x25 ml). the aqueous layer was 
subsequently extracted with CCl4 (2x100 ml), the combined organic extracts were dried over 
anhydrous Na2SO4 and concentrated under reduced pressure to yield the epoxide as a 
colorless liquid. 
 
RS 1: Procedure A 
2-(2-Chloro-phenyl)-oxirane: yield 64 %, 86 °C (13 mbar) (Lit 41 °C (0.2 torr). C8H7ClO (154.60). 1H-NMR (500 Mhz, 
CDCl3, ppm): 2.66 (1H, dd, J=5.4, 2.5 Hz), 3.18 (1H, dd, J=5.7, 4.1 Hz), 4.21 (1H, dd, J=4.1, 2.5 Hz), 7.20-7.26 (3H, m), 
7.33-7.36 (1H, m) 
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RS 2: Procedure A 
2-(3-Chloro-phenyl)-oxirane: yield 60 %, 96 °C (13 mbar). C8H7ClO (154.60). 1H-NMR (500 Mhz, CDCl3, ppm): 2.75 (1H, 
dd, J=5.4, 2.6 Hz), 3.14 (1H, dd, J=5.3, 4.1 Hz), 3.83 (1H, dd, J=4.1, 2.6 Hz), 7.15-7.19 (1H, m), 7.25-7.28 (3H, m) 
 
RS 3: Procedure A 
2-(4-Chloro-phenyl)-oxirane: yield 66 %, 97 °C (13 mbar). C8H7ClO (154.60). 1H-NMR (500 Mhz, CDCl3, ppm): 2.74 (1H, 
dd, J=5.4, 2.5 Hz), 3.13 (1H, dd, J=5.4, 4.1 Hz), 3.82 (1H, dd, J=3.8, 2.8 Hz), 7.19-7.21 (2H, m), 7.29-7.32 (2H, m) 
 
RS 4: Procedure A 
2-o-Tolyl-oxirane: yield 65 %, 80 °C (13 mbar). C9H10O (134.18). 1H-NMR (500 Mhz, CDCl3, ppm): 2.41 (3H, s), 2.68 (1H, 
dd, J=5.7, 2.8 Hz), 3.14 (1H, dd, J=5.7, 4.1 Hz), 3.99 (1H, dd, J=4.1, 2.5 Hz), 7.13-7.21 (4H, m) 
 
RS 5: Procedure A 
2-m-Tolyl-oxirane: yield 68 %, 81 °C (13 mbar). C9H10O (134.18). 1H-NMR (500 Mhz, CDCl3, ppm): 2.34 (3H, s), 2.68 (1H, 
dd, J=5.7, 2.8 Hz), 3.12 (1H, dd, J=5.7, 4.4 Hz), 3.82 (1H, dd, J=4.1, 2.8 Hz), 7.07-7.12 (3H, m), 7.21-7.24 (1H, m) 
 
RS 6: Procedure A 
2-p-Tolyl-oxirane: yield 39 %, 83 °C (13 mbar). C9H10O (134.18). 1H-NMR (500 Mhz, CDCl3, ppm): 2.33 (3H, s), 2.78 (1H, 
dd, J=5.7, 2.8 Hz), 3.11 (1H, dd, J=5.7, 4.1 Hz), 3.81 (1H, dd, J=4.1, 2.8 Hz), 7.07-7.12 (3H, m), 7.08-7.27 (4H, m) 
 
 
Procedure B: Preparation of methoxy- and nitro-substitued phenyloxiranes[193-198], RS 7, 
RS 8, RS 9, RS 10: 
The literature procedures differ in the reaction conditions such as time, temperature and ratio 
of reactants. After trying several different conditions, the following procedure was used: In a 
three-neck flask with reflux condenser and under nitrogen 10 mmol 
Trimethylsulfoniumjodide (TMSJ), 20 mmol KOH, 2.5 mmol water and 10 ml acetonitril 
were heated for 30 min at 60 °C and stirred vigorously. Then 10 mmol aldehyd dissolved in 
10 ml acetonitril were added dropwise and heating was continued for an additional 3 hrs. 
After cooling the solid phase (KI, KOH) was separated and the solution was narrowed in 
vacuo. The residue was diluted with absolute ether and more KI precipitated. This procedure 
was repeated until no more KI precipitated. The filtrate was then dried over sodium sulfate 
and the solvent evaporated. The residue was distilled (or recrystallized). It is crucial that the 
KOH is powdered; the reaction did not work with pastilles as for example described in 
Ref.[198]. 
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RS 7: Procedure B 
2-(2-Methoxy-phenyl)-oxirane: yield 47 %, 102 °C (18 mbar). C9H10O2 (150.18). 1H-NMR (500 Mhz, CDCl3, ppm): 2.70 
(1H, dd, J=5.7, 2.5 Hz), 3.13 (1H, dd, J=5.7, 4.1 Hz), 3.86 (3H, s), 4.20 (1H, dd, J=4.1, 2.8 Hz), 6.86-6.95 (2H, m), 7.13-7.15 
(1H, m), 7.23-7.27 (1H, m) 
 
RS 8: Procedure B 
2-(3-Methoxy-phenyl)-oxirane: yield 36 %, 112 °C (13 mbar). C9H10O2 (150.18). 1H-NMR (500 Mhz, CDCl3, ppm): 2.76 
(1H, dd, J=5.4, 2.5 Hz), 3.11 (1H, dd, J=5.4, 4.1 Hz), 3.79 (3H, s), 3.83 (1H, dd, J=4.1, 2.5 Hz), 6.80-6.89 (3H, m), 7.25 (1H, 
t, J=7.9 Hz) 
 
RS 9: Procedure B 
2-(4-Methoxy-phenyl)-oxirane: yield 29 %, 112 °C (13 mbar). C9H10O2 (150.18). 1H-NMR (500 Mhz, CDCl3, ppm): 2.80 
(1H, dd, J=5.4, 2.5 Hz), 3.11 (1H, dd, J=5.4, 4.1 Hz), 3.80 (3H, s), 3.81 (1H, dd, J=4.1, 2.5 Hz), 6.86-6.89 (2H, m), 7.18-7.21 
(2H, m) 
 
RS 10: Procedure B 
2-(2-Nitro-phenyl)-oxirane: yield 77 %, m.p. 65 °C. C8H7NO3 (165.15). 1H-NMR (500 Mhz, CDCl3, ppm): 2.67 (1H, dd, 
J=5.7, 2.5 Hz), 3.30 (1H, dd, J=5.4, 4.4 Hz), 4.48 (1H, dd, J=4.4, 2.8 Hz), 7.46-7.50 (1H, m), 7.60-7.68 (2H, m), 8.14-8.16 
(1H, dd, J=8.2, 0.9 Hz) 
 
 
Procedure C: Preparation[199-202] of RS 11 and RS 12: 
To a solution of 50 mmol aldehyde in 250 ml CH2Cl2 were added 0.4 mmol TBAJ, 80 mmol 
TMSJ and 50 ml of 50 % NaOH. The mixture was heated under reflux for 24 hrs and after 
cooling added to 1 l of ice-water. The organic phase was separated, the water phase extracted 
with CH2Cl2 and the combined organic extracts were dried over sodium sulfate and the 
solvent evaporated. The product was then purified over silica gel (Ether-petrolether 1:1 for 2-
(3-Nitro-phenyl)-oxirane) or recrystallized from MeOH (for 2-(4-Nitro-phenyl)-oxirane). 
 
RS 11: Procedure C 
2-(3-Nitro-phenyl)-oxirane: yield 74 %, oil. C8H7NO3 (165.15). 1H-NMR (500 Mhz, CDCl3, ppm): 2.81 (1H, dd, J=5.4, 2.5 
Hz), 3.23 (1H, dd, J=5.4, 4.1 Hz), 3.98 (1H, dd, J=4.1, 2.5 Hz), 7.52-7.54 (2H, m), 8.13-8.17 (2H, m) 
 
RS 12: Procedure C 
2-(4-Nitro-phenyl)-oxirane: yield 57 %, m.p. 84 °C (Lit. 67 %, 84-85 °C). C8H7NO3 (165.15). 1H-NMR (500 Mhz, CDCl3, 
ppm): 2.78 (1H, dd, J=5.7, 2.5 Hz), 3.23 (1H, dd, J=5.7, 4.1 Hz), 3.97 (1H, dd, J=4.1, 2.5 Hz), 7.44-7.47 (2H, m), 8.19-8.22 
(2H, m) 
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Procedure D: Preparation[203] of RS 13: 
In a three-neck flask with reflux condenser, CaCl2-tube, dropping funnel and stirrer, 300 ml of 
absolute ethanol and 6.99 g of natrium were given. After complete solution of the natrium, a 
mixture of each 0.3 mol of dry starting materials was added dropwise while cooling with ice. 
For the synthesis of glycid esters, a mixture of 0.2 mol benzaldehyde and 0.3 mol of chloro 
acetic acid ethyl ester was used at -10 °C. The mixture was left overnight at room temperature 
and then neutralized with acetic acid and added to 1 l of ice water. The mixture was extracted 
with ether several times and the combined organic extracts were washed well with water and 
dried over sodium sulfate. After evaporation of the solvent, the residue was purified by 
distillation. 
 
RS 13: Procedure D 
3-Phenyloxirane-2-carboxylic acid-methyl ester: yield 85 %, 130 °C (7 mbar) (Lit. 90 %, 130 °C (7 mbar)). C10H10O3 
(178.19). 1H-NMR (500 Mhz, d6-DMSO, ppm): 3.51 (1H, d, J=1.9 Hz), 3.82 (3H, s), 4.1 (1H, d, J=1.6 Hz), 7.26-7.41 (5H, 
m) 
 
 
Procedure E: Preparation of the oxirane-carbonitriles[204, 205], RS 14 and RS 15: 
15.1 g of  chloro acetonitrile (0.2 mol) were added slowly to a vigorously stirred mixture of an 
aldehyde or a ketone (23.3 g benzaldehyde, 0.22 mol), 40 ml of a 50 % NaOH, 50 ml 
dichloromethane and 1 g of  triethylbenzylammoniumchloride at 15-20 °C. Stirring was 
continued for another 40 min at this temperature. Then, the mixture was diluted with 30 ml of 
water and the organic phase was separated. It was washed two times with water, dried over 
sodium sulfate and distilled. When using ketones it is better to leave out the dichloromethane 
and add 80 ml of ether instead after the reaction. 
 
RS 14: Procedure E 
3-Phenyl-oxirane-2-carbonitrile: yield 51 %, 100-104 °C (13 mbar) (Lit. 50 %, 104-108 °C (19 mbar) and 79 %, 87 ° (5 
mm)). C9H7NO (145.16).  1H-NMR (500 Mhz, CDCl3, ppm): 3.95 (1H, d, J=1.89 Hz), 3.76 (1H, d, J=3.47 Hz), 4.23 (1H, d, 
J=3.78 Hz), 4.27 (1H, d, J=1.89 Hz), 7.24-7.27 (1H, m), 7.37-7.44 (4H, m) 
 
RS 15: Procedure E 
1-Oxa-spiro-[2.5]octane-2-carbonitrile: yield 59 %, 128-134 °C (13 mbar) (Lit. 45 %, 130-135 °C (19 mbar) and 75 %, 120 
°C (6 mm)). C8H11NO (137.18). 1H-NMR (500 Mhz, CDCl3, ppm): 1.48-1.85 (10 H, m), 3.22 (1H, s) 
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Procedure F: Preparation of RS 16 
The epoxide RS 16 was synthesized according to the following sequence starting with 
cyclohexanone via the intermediates RS 70 to RS 73. 
O
CH3
O
Cl
CH3
O
O
O
CH3
O
O
CH3
CH3
CH3
O
CH3
CH3
O
 
                               RS 70                              RS 71                              RS 72                          RS 73                         RS 16 
Fig. 7-3 Reaction scheme for the preparation of RS 16 
 
Procedure F-1: 1-(2-Chloro-cyclohex-2-enyl)-ethanone[206], RS 70:  
Into a three-neck flask provided with a stirrer, a reflux codenser protected from atmospheric 
moisture, and a dropping funnel, 120 g of aluminium chloride and 150 ml of dry 
dichloroethane were put. A mixture of 36.5 g of cyclohexanone and 86 g of acetyl chloride 
was added with vigorous stirring and cooling by water at room temperature; the mixture was 
stirred for 18 hours and then decomposed with ice to which 15 ml of concentrated HCl had 
been added. The organic layer was separated, and the water layer was extracted three times 
with dichloroethane. The combined extracts were washed with water and dried over calcium 
chloride. The solvent was driven off in a slight vacuum and the residue distilled, the fraction 
with b.p. 105-120 °C (20 mm) being collected. After redistillation there was obtained 49.5 g 
(82 %) of a substance with b.p. 124-129 (30 mm). A third distillation yielded the product. 
 
Procedure F-2: 1-(1,4-Dioxa-spiro[4.5]dec-6-yl)-ethanone[206], RS 71:  
Into a three-neck flask provided with a stirrer, a dropping funnel, and a reflux condenser with 
a tube containing soda-lime, a solution of 7.2 g potassium hydroxide in 50 ml of glycole was 
put. 60 ml of dioxane was added and the mixture heated to boiling. Then 19.7 g of acetyl-2-
chloro-cyclohexene-2 was added dropwise with vigorous stirring, and the mixture was boiled 
and stirred for 5 hrs. The cooled reaction mixture was poured into water and extracted four 
times with ether, the extracts dried with magnesium sulfate, and the solvent distilled off. 
Fractionation of the residue in vacuo and redistillation yielded the product. 
 
Procedure F-3: 6-((E)-1-Methyl-propenyl)-1,4-dioxa-spiro[4.5]decane[207], RS 72  
Ethyltriphenylphosphoniumbromid (74.2) g in dry DMSO (150 ml) was added to a solution of 
methylsulfinylmethanide [from NaH (4.8 g) and anhydrous DMSO (40 ml)] and to the 
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resulting red solution the ketone (6-acetyl-1,4-dioxaspiro[4,5]decane (18.4 g; 100 mmol)) in 
dry DMSO/THF (1:1, 25 ml) was added over 0.5 hr. The mixture was stirred at 50 °C 
overnight, diluted with water (500 ml) and extracted with hexane (3x300 ml). The combined 
extracts were washed with water, dried and evaporated o give a residue which on distillation 
yielded the alkene as a colourless liquid. 
 
Procedure F-4: 2-((E)-1-Methyl-propenyl)-cyclohexanone[207], RS 73: 
The cyclic acetal RS 72 (14.5 g) in acetone (60 ml) was stirred with toluene-4-sulfonic acid 
(0.5 g) and water (2ml) for 5 hrs, after which time the product was isolated. Distillation gave 
the ketone as a colourless liquid. 
 
Procedure F-5: 4-((E)-1-Methyl-propenyl)-1-oxa-spiro[2.5]octane[207], RS 16: 
A solution of the ketone RS 73 (10.0 g) in dry DMSO/THF (1:1, 40 ml) was added to 
dimethylsulfoxonium methanide [from NaH (1.68 g), TMSI (15.4 g) and anhydrous DMSO 
(40 ml] during 10 min. After stirring at 50 °C for an additional 1.5 hrs the product was 
isolated. Fractionation of the crude extract on a 25-cm spinning-band column gave starting 
material and the spiro epoxide as a colourless liquid. 
 
RS 16: Procedure F-1 
4-((E)-1-Methyl-propenyl)-1-oxa-spiro[2.5]octane: yield 61%, b.p. 80 °C (12 mbar), nD20 1.4790 (Lit. 85 %, nD20 1.4801). 
C11H18O (166.27). 1H-NMR (500 Mhz, CDCl3, ppm): 1.60 (3H, d, J=6.0 Hz), 1.67 (3H, s), 2.34, 2.43, 2.6 and 2.9 (2H, q, 
J=5.5 Hz), 5.45 (3H, q, J=6.0 Hz) 
 
RS 70: Procedure F-2 
1-(2-Chloro-cyclohex-2-enyl)-ethanone: yield 78 % resp. 69%, b.p. 105 °C (27 mbar), nD20 1.4960 resp. 1.4969 (Lit. 82 %, 
b.p. 108-109° (15 mm), nD20 1.4985; other Lit. data (Patent): b.p. 93-98° (9 mm), nD20=1.4952). C8H11ClO (158.63). 
 
RS 71: Procedure F-3 
1-(1,4-Dioxa-spiro[4.5]dec-6-yl)-ethanone: yield 68 %, b.p. 121-123 °C (13 mbar), nD20 1.4788 (Lit. 61 %, b.p. 121-122 °C 
(10 mm), nD20 1.4781). C10H16O3 (158.63). 
 
RS 72: Procedure F-4 
6-((E)-1-Methyl-propenyl)-1,4-dioxa-spiro[4.5]decane: yield 54 %, b.p. 101 °C (12 mbar), nD20 1.4827 (Lit. 77 %,  
b.p. 96-98 °C (7.5 mm), nD20 1.4805). C12H10O2 (196.29). 1H-NMR (500 Mhz, CDCl3, ppm): 1.59 (3H, d, J=5.5 Hz), 1.69 
(3H, s), 2.66 (1H, dd, J=12.5, 4.0 Hz), 3.81 (4H, s), 5.25 (1H, q, J=5.5 Hz) 
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RS 73: Procedure F-5 
2-((E)-1-Methyl-propenyl)-cyclohexanone: yield 87 %, b.p. 90 °C (11 mbar), nD20 1.4840 (Lit. 89 %, b.p. 59-60 °C (1.25 
mm), nD20 1.4805). C10H16O (152.24). 1H-NMR (500 Mhz, CDCl3, ppm): 1.62 (3H, d, J=6.0 Hz), 1.68 (3H, s), 3.34 (1H, m), 
5.38 (1H, q, J=6.0 Hz) 
 
 
Procedure G: Procedure[208] for the synthesis of RS 74: 
To a solution of benzoyl chloride (7.73 g, 55 mmol) in ether (50 ml) were added successively 
an appropriate allylic alcohol (50 mmol) and triethylamine (55 mmol) at 0 °C under N2. After 
stirring at 0 °C for 2 hrs and then at room temperature overnight, the mixture was diluted with 
EtOAc and washed successively with 2 HCl (2x10 ml), saturated NaHCO3 and brine. The 
organic layer was dried (MgSO4) and concentrated, and the residue was distilled under 
reduced pressure.  
 
RS 74: Procedure G 
Benzoic acid 3-methyl-but-2-enylester: yield 81 %, b.p. 123-126 °C (13 mbar) (Lit: 84 %, 82 °C (0.01 mm Hg)). C12H14O2 
(190.24). 1H-NMR (500 Mhz, CDCl3, ppm): 1.78 (6H, d, J=7.9 Hz), 4.82 (2H, d, J=7.3 Hz), 5.45-5.49 (1H, m), 7.42 (2H, t, 
J=7.9 Hz), 7.53 (1H, t, J=7.6 Hz), 8.04 (2H, dd, J=8.5, 1.3 Hz) 
 
 
Procedure H: General procedure for the preparation of -ester and –amide-derivatives[209] of 
quinoline, RS 28 - RS 33 and compound RS 75: 
25 mmol of an appropriate amine or alcohol, pyridine (44 mmol) and an appropriate 
carboxylic acid chloride or sulfonic acid chloride (26 mmol) were heated on a steam-bath for 
2 hrs, then poured into water and the product was collected and recrystallized or purified by 
chromatography over silica gel. 
 
RS 75: Procedure H 
4-Methyl-N-pyridin-3-yl-benzenesulfonamide: yield 82 %, m.p. 190 °C, recrystallized from EtOH (Lit. 191-192 °C). 
C12H12N2O2S (248.31). 1H-NMR (500 Mhz, d6-DMSO, ppm): 2.33 (3H, s), 7.27 (1H, ddd, J=8.2, 4.7, 2.6 Hz), 7.35 (2H, d, 
J=7.9 Hz), 7.49 (1H, ddd, J=8.5, 2.8, 1.6 Hz), 7.65 (2H, d, J=8.2 Hz), 8.24 (1H, d, J=4.7, 1.6 Hz), 8.27 (1H, d, J=2.8 Hz), 
10.48 (1H, br. s) 
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RS 28: Procedure H 
Benzoic acid-quinolin-8-yl-ester: yield 89 %, m.p. 121-123 °C, recrystallized from EtOH (Lit. 118-126 °C). C16H11NO2 
(249.27). 1H-NMR (500 Mhz, CDCl3, ppm): 7.46 (1H, dd, J=8.5, 4.4 Hz), 7.55 (2H, t, J=7.9 Hz), 7.59-7.62 (2H, m), 7.66 
(1H, tt, J=7.6, 1.3 Hz), 7.76-7.80 (1H, m), 8.25 (1H, dd, J=8.2, 1.6 Hz), 8.37 (2H, dd, J=8.5, 1.3 Hz), 8.93 (1H, dd, J=4.4, 1.6 
Hz) 
 
RS 29: Procedure H 
N-Quinolin-8-yl-benzamide: yield 71 %, m.p. 91-92 °C, purified over silica gel (EtOAc-Hexan 1+2) (Lit. 90-93 °C). 
C16H11N2O (248.29). 1H-NMR (500 Mhz, CDCl3, ppm): 7.48 (1H, dd, J=8.2, 4.1 Hz), 7.53-7.62 (5H, m), 8.10 (2H, dd, J=7.9, 
1.3 Hz), 8.20 (1H, d, J=8.2 Hz), 8.85 (1H, dd, J=4.1, 1.3 Hz), 8.95 (1H, dd, J=7.6, 1.3 Hz), 10.75 (1H, br. s) 
 
RS 30: Procedure H 
N-Quinolin-8-yl-benzenesulfonamide: yield 77 %, m.p. 128-132 °C (Lit 133-135 °C), recrystallized from ethanol. 
C15H12N2O2S (284.34).1H-NMR (500 Mhz, CDCl3, ppm): 7.36 (2H, t, J=7.9 Hz), 7.41-7.49 (4H, m), 7.86 (1H, dd, J=6.6, 1.9 
Hz), 7.90-7.93 (2H, m), 8.13 (1H, dd, J=8.2, 1.6 Hz), 8.76 (1H, dd, J=4.1, 1.6 Hz), 9.33 (1H, br. s) 
 
RS 31: Procedure H 
Benzenesulfonic acid quinolin-8-yl ester: yield 94 %, m.p. 111-112 °C, recrystallized from EtOH (Lit. 111 °C). C15H11NO3S 
(285.32).1H-NMR (500 Mhz, CDCl3, ppm): 7.43-7.49 (3H, m), 7.55 (1H, t, J=7.9 Hz), 7.60 (1H, td, J=7.5, 1.3 Hz), 7.68 (1H, 
d, J=7.6 Hz), 7.78 (1H, d, J=8.2 Hz), 8.03 (2H, d, J=8.2 Hz), 8.21 (1H, d, J=8.5 Hz),8.86 (1H, t, J=1.9 Hz) 
 
RS 32: Procedure H 
Toluene-4-sulfonic acid quinolin-8-yl ester: yield 80 %, m.p. 117-118 °C (Lit 115-117 °C), recrystallized from EtOH. 
C16H13NO3S (299.35). 1H-NMR (500 Mhz, d6-DMSO, ppm): 2.38 (3H, s), 7.40 (2H, d, J=8.2 Hz), 7.49 (1H, dd, J=7.6, 1.3 
Hz), 7.55-7.63 (2H, m), 7.81 (2H, d, J=8.5 Hz), 7.95 (1H, dd, J=8.5, 1.3 Hz), 8.40 (1H, dd, J=8.2, 1.6 Hz), 8.83 (1H, dd, 
J=4.1, 1.9 Hz) 
 
 
RS 33: Procedure H 
Pyridine-2-sulfonic acid quinolin-8-yl ester: yield 26 %, m.p. 112-115 °C, purified over silica gel (EtOAc-Hexan 1+1,5). 
C14H10N2O3S (286.31). 1H-NMR (500 Mhz, d6-DMSO, ppm): 7.55-7.57 (2H, m), 7.62 (1H, t, J=7.9 Hz), 7.79-7.81 (1H, m), 
7.98 (1H, dd, J=8.2, 0.9 Hz), 8.09 (1H, dt, J=7.6, 1.3 Hz), 8.14 (1H, td, J=7.9, 1.9 Hz), 8.42 (1H, dd, J=8.2, 1.6 Hz), 8.71 (1H, 
dd, J=4.1, 1.9 Hz), 8.75 (1H, ddd, J=4.7, 1.6, 0.9 Hz) 
 
 
Procedure I: Procedure[210] for the preparation of RS 26 and RS 27: 
A solution of a suitably protected amino acid (1 mmol) in methylene chloride/DMF (10 ml) 
was stirred with cyanoethanol (2 mmol) in the presence of a catalytic amount of DMAP. A 
solution of DCC (1.1 mmol) in methylene chloride was added dropwise. The reaction was 
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stirred at room temperature overnight. At the end of the reaction, after filtering DCU, the 
solvent was removed under reduced pressure. The residual mass was dissolved in EtOAc and 
succesively washed with 5 % aq. NaHCO3, water, 5 % citric acid and brine. The organic layer 
was dried over Na2SO4 and concentrated. The crude product was purified by flash 
chromatography (EtOAc-Hexan 1+3.5 to EtOAc-Hexan 2+1 to EtOAc to MeOH). 
To 1.0 g (3.3 mmol) of a Boc-protected amino acid (derivative), for example RS 26, 25 ml  
1 M HCl in ether (25 mmol) were added. After 1 h, another 25 ml of absolute ether were 
added and the mixture put in the freezer over night. Then, the solvent was evaporated and the 
residue was recrystallized from THF-ether.  
 
RS 26: Procedure I 
2-Amino-4-methylsulfanyl-butyric acid 2-cyano-ethyl ester hydrochloride: yield 12 %, m.p. 125-127 °C. C8H14N2O2SHCl 
(202.2836.46). 1H-NMR (500 Mhz, d6-DMSO, ppm): 2.06 (3H, s), 2.07-2.13 (2H, m), 2.56-2.70 (2H, s), 2.97 (2H, t, J=6.0 
Hz), 4.16 (1H, t, J=6.3 Hz), 4.30-4.34 (1H, m), 4.39-4.43 (1H, m), 8.66 (3H, br. s). MS: 202.96 m/z (M+H)+. IR (ZnSe-
ATR-FTIR): ν = 3211, 2817 (br), 2593, 2263, 1745, 1492, 1231, 1193, 1076, 1029, 992 cm-1.  
 
RS 27: Procedure I 
2-tert-Butoxycarbonylamino-4-methylsulfanyl-butyric acid 2-cyano-ethyl ester: yield 49 %, m.p. 56-58 °C (Lit 92 %, m.p. 
57-59 °C). C13H22N2O4S (302.40). 1H-NMR (500 Mhz, CDCl3, ppm): 1.49 (9H, s), 1.93-2.01 (1H, m), 2.11 (3H, s), 2.17 (1H, 
s), 2.55-2.62 (2H, m), 2.75 (2H, t, J=6.3 Hz), 4.32-4.41 (2H, m), 4.46 (1H, br. s), 5.13 (1H, br. s) 
 
 
Procedure J: General procedure for the preparation of carboxylic acid amides[146]: 
To a mixture of a suitable carboxylic acid (for example pyridine-2-carboxylic acid (1.23 g, 10 
mmol)), thiazol-2-ylamine (1.01 g, 10 mmol) or another suitable amine and HOBT (1.45 g, 
10.75 mmol) in dry DMF (10 ml) was added DCC (2.16 g, 10.05 mmol). The reaction 
mixture was stirred at room temperature for 24 hrs. The reaction mixture was then diluted 
with 50 ml of EtOAc and 20 ml of H2O. The aqueous phase was extracted with EtOAc and 
the combined organic phases were then washed with 10 % HCl (and/or NaHCO3 if needed), 
water and brine. The organic phases were dried over sodium sulfate, filtered and the solvent 
evaporated in vacuo. The residue was then chromatographed (3:1 petrolether-EtOAc) to yield 
the product. 
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RS 17: Procedure J 
Pyridine-2-carboxylic acid thiazol-2-ylamide[146]: yield 47 %, m.p. 146-148 °C. C9H7N3OS (205.24). 1H-NMR (500 Mhz,  
d6-DMSO, ppm): 7.36 (1H, d, J=3.5 Hz), 7.58 (1H, d, J=3.5 Hz), 7.72-7.75 (1H, m), 8.11 (1H, td, J=7.9, 1.9 Hz), 8.19 (1H, 
dt, J=7.9, 1.2 Hz), 8.76-8.78 (1H, m), 11.98 (1H, br. s). MS: 205.91 m/z (M+H)+  
 
RS 18: Procedure J 
Pyridine-2-carboxylic acid (5-methyl-isoxazol-3-yl)-amide: yield 69 %, m.p. 125-128 °C. C10H9N3O2 (203.20). 1H-NMR 
(500 Mhz, d6-DMSO, ppm): 2.42  (3H, s), 6.75 (1H, s), 7.70 (1H, ddd, J=7.5, 4.7, 1.3 Hz), 8.07 (1H, td, J=7.7, 1.9 Hz), 8.14 
(1H, dt, J=7.9, 0.9 Hz), 8.73 (1H, ddd, J=4.7, 1.5, 0.9 Hz), 11.0 (1H, s); MS: 204.6 m/z (M+H)+. IR (ZnSe-ATR-FTIR): 
ν = 3206, 2927, 1730, 1688, 1606, 1523, 1466, 1441, 1416, 1266, 1016, 891, 797, 738, 698, 683, 618 cm-1.  
 
RS 23: Procedure J 
Pyridine-2-carboxylic acid 2-cyano-ethyl ester: yield 4 %, oil, purified twice over silica gel (gradient from hexane-
ethylacetate 2:1 to ethylacetate to methanol). C9H8N2O2 (176.18). 1H-NMR (500 Mhz, d6-DMSO, ppm): 2.92 (2H, q, J=6.6 
Hz), 4.64 (2H, t, J=6.6 Hz), 7.54-7.56 (1H, m), 7.91 (1H, td, J=7.6, 1.9 Hz), 8.17 (1H, dt, J=7.9, 1.2 Hz), 8.79-8.81 (1H, m). 
MS: 177.6 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2968, 2254, 1725, 1585, 1438, 1305, 1244, 1127, 1089, 
1046, 993, 822, 747, 705, 620 cm-1.  
 
RS 25: Procedure J 
4-Nitro-N-thiazol-2-yl-benzamide: yield 11 %, m.p. 287-290 °C, recrystallized from methanol (Lit. 278-297 °C). 
C10H7N3O3S (249.25). 1H-NMR (500 Mhz, d6-DMSO, ppm): 7.32 (1H, d, J=3.5), 7.59 (1H, d, J=3.8 Hz), 8.29-8.38 (4H, m), 
13.02 (1H, br. s). MS: 249.94 m/z (M+H)+ 
 
 
Procedure K: Preparation[211] of RS 19: 
A solution of 4 mmol amine and 4.8 mmol of pyridine-2-sulfonyl chloride (0.853 g) in a 1:1 
mixture of ether (8ml) and 4 M K2CO3 (8ml) was stirred vigorously for 1-6 hrs at 0 °C. The 
aqueous phase was extracted with dichloromethane (2x20 ml), dried (Na2SO4), and 
evaporated to dryness. The residue was then dissolved in aqueous NaOH and precipitated 
again with HCl.  
 
RS 19 : Procedure K 
Pyridine-2-sulfonic acid thiazol-2-ylamide yield 22 %, m.p. 183-185 °C (decomp.). C8H7N3O2S2 (241.29). 1H-NMR (500 
Mhz, d6-DMSO, ppm): 6.87 (1H, d, J=4.7 Hz), 7.27 (1H, d, J=4.9 Hz), 7.60 (1H, ddd, J=7.6, 4.7, 1.3 Hz), 7.93 (1H, dt, J=7.9, 
0.9 Hz), 8.03 (1H, td, J=7.9, 1.9 Hz), 8.64 (1H, ddd, J=4.7, 1.9, 0.9 Hz), 12.87 (1H, br. s). MS: 242.5 m/z (M+H)+. IR 
(ZnSe-ATR-FTIR): ν = 2792 (br), 1572, 1523, 1426, 1300, 1163, 1113, 1083, 1003, 935, 856, 772, 738, 650, 
612, 592, 554 cm-1.  
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Procedure L: Preparation[212] of RS 20: 
In a 10 ml-flask, isoxazol-2-ylamine (1.0 g, 10.2 mmol) was dissolved in 4 g of anhydrous 
pyridine and 2-Pyridine-sulfonic acid chloride (3.0 g, 16.8 mmol) was added with stirring. 
Solution takes place with evolution of heat and the reaction was completed by warming at  
60 °C for one-half to one hour. The crude derivative obtained by pouring the dark solution 
into ice-water was dissolved in one equivalent of aqueous sodium hydroxide, decolorized, and 
reprecipitated by addition of hydrochloric acid. The product can be recrystallized from 
hexane/EtOAc. 
 
RS 20: Procedure L 
Pyridine-2-sulfonic acid (5-methyl-isoxazol-3-yl)-amide: yield 91 %, m.p. 155-158 °C. C9H9N3O3S (239.25). 1H-NMR (500 
Mhz, d6-DMSO, ppm): 2.29 (3H, d, J=0.9 Hz), 6.12 (1H, s), 7.69 (1H, ddd, J=7.6, 4.4, 0.9 Hz), 8.04 (1H, dt, J=7.9, 0.9 Hz), 
8.12 (1H, td, J=7.9, 1.6 Hz), 8.72 (1H, ddd, J=4.7, 1.6, 0.9 Hz), 11.67 (1H, br. s). MS: 240.5 m/z (M+H)+. IR (ZnSe-
ATR-FTIR): ν = 2789 (br), 1620, 1586, 1499, 1431, 1339, 1254, 1179, 1122, 1088, 1034, 1005, 927, 892, 781, 
737, 692, 590, 558 cm-1.  
 
 
Procedure M: Preparation[213] of RS 21: 
Amino alcohol (1 mmol) and triethylamine (2 mmol) were stirred in CH2Cl2 (25 ml) and 
cooled to 0 °C. The appropriate acid chloride (1 mmol) was added dropwise to the solution, 
and the mixture was stirred for 18 hrs at room temperature. Water was added, and the layers 
were separated. The organic layer was washed with saturated NaHCO3 solution, dried, 
filtered, and evaporated to give the crude amide, which were purified by recrystallization from 
hexane/EtOAc. 
 
RS 21: Procedure M 
Pyridine-2-carboxylic acid cyanomethyl-amide: yield 50 %, m.p. 165-168 °C, purified twice over silica gel (EtOAc-Hexan 
1:2 and 1:3) and recrystallized from EtOAc-Hexan 1:1. C8H7N3O (161.16). 1H-NMR (500 Mhz, d6-DMSO, ppm): 4.31 (2H, 
d, J=6.0 Hz), 7.65 (1H, ddd, J=7.6, 5.0, 1.6 Hz), 8.03 (1H, td, J=7.6, 1.6 Hz), 8.07 (1H, dt, J=7.9, 1.3 Hz), 8.68 (1H, d, J=4.7 
Hz), 9.46 (1H, t, J=5.4 Hz). MS: 162.08 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 3329, 2362 (w), 1666, 1507, 
1467, 1431, 1291, 1160, 1002, 899, 818, 752, 661, 622, 596 cm-1.  
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Procedure N: Preparation of pyridine-2-carboxylic acid cyano alkyl esters[214], RS 22,  
RS 24: 
To a stirred suspension of picolinic acid (12.4 g, 100 mmol) in dry triethylamine (20 ml, 200 
mmol), chloro acetonitril (15 g, 200 mmol) was slowly added with stirring. The mixture 
warmed up to 60 °C and solidified after some time because of separation of triethylamine-
hydrochloride. Heating was continued for 1 h. Then, the solvent was evaporated and the dark 
solid was taken up with CHCl3/water (1:1), treated with charcoal and filtered. After that, the 
phases could easily be separated. The water phase was saturated with K2CO3 and extracted 
with CHCl3 (3x50 ml). The combined organic fractions were dried over K2CO3 with addition 
of charcoal and distillation of the brown oily residue after evaporation of the solvent yielded 
the product. The product was further purified by chromatography on silica gel (EtOAc). 
 
RS 22: Procedure N 
Pyridin-2-carboxylic acid-cyanomethyl ester: yield 57 %, light yellow oil, purified over silica gel (EtOAc) after distillation, 
120 °C (0.3 mbar) (Lit 133-137 °C (0.1 torr), m. p. 42-43 °C). C8H6N2O2 (162.15). 1H-NMR (500 Mhz, d6-DMSO, ppm): 
5.27 (2H, s), 7.70 (1H, dd, J=7.6, 4.7 Hz), 8.04 (1H, t, J=7.9 Hz), 8.11 (1H, dd, J=7.9, 0.9 Hz), 8.76 (1H, td, 4.7, 0.9 Hz). 
MS: 162.96 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 3211, 2817, 2593, 1745, 1604, 1492, 1231, 1193, 1076, 
1029, 992 cm-1.  
 
RS 24: Procedure N 
Pyridin-2-carbonsäure-cyanopropyl ester: yield 76 %, oil, purified over silica gel (EtOAc) after removal of residual 
chlorobutyronitrile by distillation. C10H10N2O2 (190.20). 1H-NMR (500 Mhz, d6-DMSO, ppm): 2.05 (2H, q, J=6.6 Hz), 2.67 
(2H, q, J=7.2 Hz), 4.35 (2H, t, J=6.2 Hz), 7.63-7.66 (1H, m), 8.00 (1H, td, J=7.6, 1.9 Hz), 8.11 (1H, dt, J=7.9, 1.2 Hz), 8.72-
8.74 (1H, m). MS: 191.6 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2959, 2247, 1737, 1720, 1584, 1438, 1305, 
1281, 1244, 1131, 1088, 1045, 955, 821, 747, 706, 620 cm-1.  
 
 
Procedure O: General Procedure for the preparation of substituted heteroaryl-
benzimidazoles[215] for the compounds RS 34, RS 35, RS 36, RS 37, RS 40, 
RS 41, RS 42, RS 47, RS 48, RS 49, RS 50, RS 51, RS 52, RS 57, RS 58, RS 59, RS 60, 
RS 61, RS 64, RS 65, RS 66 and RS 67: 
A mixture of an appropriate derivative of o-phenylendiamine, the corresponding carboxylic 
acid and 5-20 equivalents of polyphoshoric acid was stirred in an oil bath at 180 °C for 2 hrs. 
The solution was cooled and poured in a thin stream into rapidly stirred water. The pH was 
adjusted to 9 with 26 % ammonium hydroxide. The solid was collected by filtration, dissolved 
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in hot ethanol and treated with charcoal. The ethanol was evaporated again and the residue 
was recrystallized unless stated otherwise. 
 
RS 34: Procedure O 
2-Pyridin-3-yl-1H-benzoimidazole: light purple solid, yield: 93 %, m.p. 245 °C, recrystallized twice from ethanol. C12H9N3 
(195.23). 1H-NMR (500 Mhz, d6-DMSO, ppm): 7.23-7.25 (2H, m), 7.59 (1H, dd, J=8.2, 4.7 Hz), 7.64 (2H, br. s), 8.50 (1H, 
dt, J=7.9, 1.9 Hz), 8.7 (1H, dd, J=5.0, 1.6 Hz), 9.36 (1H, d, J=2.2 Hz), 12.94 (1H, br. s). MS: 196.15 m/z (M+H)+. IR (ZnSe-
ATR-FTIR): ν = 3042-2795 (br), 2359, 1488, 1447, 1429, 1316, 1108, 961, 882, 769, 753, 742, 711, 699, 634, 534 cm-1. 
 
RS 35 : Procedure O 
2-Thiophen-2-yl-1H-benzoimidazole: light brown solid, yield: 80 %, m.p. 344 °C, recrystallized from ethanol. C11H8N2S 
(200.26).  1H-NMR (500 Mhz, d6-DMSO, ppm): 7.17-7.21 (2H, m), 7.23 (1H, dd, J=5.0, 3.5 Hz), 7.56 (2H, s), 7.72 (1H, dd, 
J=5.0, 1.1 Hz), 7.84 (1H, dd, J=3.8, 1.3 Hz), 12.94 (1H, s). MS: 201.11 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2642 (br), 
1571, 1451, 1423, 1314, 1276, 1235, 1095, 1074, 945, 852, 742, 704 cm-1. 
 
RS 36: Procedure O 
2-Furan-2-yl-1H-benzoimidazole: light yellow needles, yield: 40 %, m.p. 286 °C, purified by column chromatography 
(EtOAc-Hexan 1+1,5) and recrystallized from ethanol. C11H8N2O (184.20). 1H-NMR (500 Mhz, d6-DMSO, ppm): 6.73 (1H, 
m), 7.18 (2H, d, J= 0.95 Hz), 7.19 (1H, d, J=0.63 Hz), 7.49 (1H, br. s), 7.61 (1H, br. s), 7.94 (1H, dd, J=1.9, 0.6 Hz), 12.90 
(1H, s). MS: 185.23 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2661 (br), 1631, 1525, 1443, 1416, 1364, 1319, 1279, 1235, 
1011, 979, 906, 884, 732, 589 cm-1. 
 
RS 37: Procedure O 
2-(1H-Benzoimidazol-2-yl)-phenol: light grey-green solid, yield: 40 %, m.p. 242 °C, recrystallized from ethanol. C13H10N2O 
(210.24). 1H-NMR (500 Mhz, d6-DMSO, ppm): 3.57 (1H, br. s), 7.02-7.07 (2H, m), 7.28-7.32 (2H, m), 7.37-7.41 (1H, m), 
7.69 (2H, dd, J=5.7, 3.5 Hz), 8.08 (1H, dd, J=7.9, 1.6 Hz), 13.21 (1H, br. s). MS: 211.15 m/z (M+H)+. IR (ZnSe-ATR-FTIR): 
ν = 3324, 1632, 1590, 1491, 1453, 1420, 1396, 1321, 1282, 1262, 1238, 1134, 839, 799, 724, 560 cm-1. 
 
RS 40: Procedure O 
2-Pyridin-2-yl-1H-benzoimidazole: white solid, yield: 93 %, m.p. 224 °C, recrystallized from ethanol and washed with 
hexane. C12H9N3 (195.23). 1H-NMR (500 Mhz, d6-DMSO, ppm): 7.19-7.26 (2H, m), 7.50-7.52 (1H, m), 7.53-7.55 (1H, m), 
7.70 (1H, d, J=7.9 Hz), 8.00 (1H, td, J=7.9, 1.9 Hz), 8.33 (1H, d, J=7.9 Hz), 8.72-8.74 (1H, m), 13.09 (1H, s). MS: 196.15 
m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2923 (br), 1442, 1400, 1315, 1280, 1122, 742, 702, 543 cm-1. 
 
RS 41: Procedure O 
6-(1H-Benzoimidazol-2-yl)-pyridin-2-ol: white solid, yield 46 %, m.p. 284-285 °C washed with some hot ethanol. C12H9N3O 
(211.23). 1H-NMR (500 Mhz, d6-DMSO, ppm): 3.0-4.0 (1H, br. s (weak)), 6.66 (1H, d, J=8.5 Hz,), 7.24 (2H, m), 7.45 (1H, d, 
J=5.8 Hz), 7.63 (2H, s), 7.72 (1H, t, J=7.9 Hz), 12.8 (1H, br. s (weak)). MS: 212.15 m/z (M+H)+. IR (ZnSe-ATR-FTIR):  
ν = 3241, 2922 (br), 1658, 1617, 1547, 1523, 1463, 1156, 1019, 907, 805, 740, 721, 657, 582, 545 cm-1. 
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RS 42: Procedure O 
2-(1H-Benzoimidazol-2-yl)-pyridin-3-ol: light-grey solid, yield 98 %, m.p. 189 °C, purification not necessary. C12H9N3O 
(211.23). 1H-NMR (500 Mhz, d6-DMSO, ppm): 3.0-4.0 (1H, br. s (weak)), 7.31 (2H, d, J=3.5 Hz), 7.45 (1H, dd, J=8.5, 4.4 
Hz), 7.51 (1H, dd, J=8.5, 1.5 Hz), 7.61 (1H, br. s,), 7.76 (1H, br. s, ), 8.28 (1H, dd, J=4.4, 1.3 Hz), 13.15 (1H, br. s). MS: 
212.15 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2979 (br), 1464, 1382, 1279, 1249, 797, 741, 535 cm-1. 
 
RS 47 : Procedure O 
5-Methyl-2-thiazol-4-yl-1H-benzoimidazole: brown solid, yield 52 %, m.p. 240-241 °C, recrystallized from aqueous EtOH. 
C11H9N3S (215.28). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.40 (1H, ddd, J=8.5, 1.6, 0.6 Hz), 7.6 –7.61 (1H, m), 
8.2 (1H, d, J=8.2 Hz), 8.88 (1H, d, J=1.9 Hz), 9.49 (1H, d, J=1.9 Hz). MS: 216.24 m/z (M+H)+. IR (ZnSe-ATR-FTIR):  
ν = 3094 (br), 2361, 1627, 1579, 1473, 1444, 1395, 1339, 1309, 1281, 1229, 1195, 1092, 984, 902, 873, 837, 804, 724, 660, 
599, 532 cm-1. 
 
RS 48 : Procedure O 
5-Methyl-2-pyridin-2-yl-1H-benzoimidazole: brown solid, yield 77 %, m.p. 164 °C, purification not necessary. C13H11N3 
(209.25). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 2.51 (3H, s), 7.42 (1H, d, J=8.2 Hz), 7.63 (1H, s), 7.72-7.77 (2H, 
m), 8.22 (1H, td, J=7.9, 1.6 Hz), 8.41 (1H, d, J=7.9 Hz), 8.91 (1H, d, 4.1 Hz). MS: 210.17 m/z (M+H)+. IR (ZnSe-ATR-
FTIR): ν = 2941 (br), 1590, 1445, 1403, 1311, 1120, 995, 794, 742, 701, 536 cm-1. 
 
RS 49 : Procedure O 
5,6-Dimethyl-2-thiazol-4-yl-1H-benzoimidazole: brown solid, yield 74 %, m.p. 247-249 °C, recrystallized from aqueous 
EtOH. C12H11N3S (229.31). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 2.39 (6H, s), 7.58 (2H, s), 8.86 (1H, d, J=1.6 
Hz), 9.48 (1H, d, J=1.9 Hz). MS: 230.33 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2963 (br), 2360, 1580, 1441, 1408, 1316, 
1234, 1202, 1164, 1110, 1096, 999, 908, 850, 724 cm-1. 
 
RS 50 : Procedure O 
5,6-Dimethyl-2-pyridin-2-yl-1H-benzoimidazole: light brown solid, yield 86 %, m.p. 193 °C, purification not necessary. 
C14H13N3 (223.28). 1H-NMR (500 Mhz, d6-DMSO, ppm): 2.32 (6H, s, -CH3), 7.31 (1H, s), 7.46-7.48 (2H, m), 7.96 (1H, dt, 
J=7.6, 1.6 Hz), 8.29 (1H, d, J=7.9 Hz), 8.69 (1H, d, J=4.4 Hz), 12.85 (1H, s, -NH). MS: 224.19 m/z (M+H)+. IR (ZnSe-ATR-
FTIR): ν = 2920 (br), 2333, 1594, 1450, 1399, 1261, 995, 795, 679 (br) cm-1. 
 
RS 51 : Procedure O 
5-tert-butyl-2-thiazol-4-yl-1H-benzimidazole: grey-brown solid, yield 50 %, m.p. 165-168 °C, recrystallized from aqueous 
EtOH. C14H15N3S (257.36). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 1.37 (9H, s), 7.67-7.76 (3H, m), 8.91 (1H, d, 
J=1.9 Hz), 9.49 (1H, d, J=1.9 Hz). MS: 258.46 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2952 (br), 2361, 1477, 1389, 1306, 
1091, 902, 814, 721, 655 cm-1. 
 
RS 52 : Procedure O 
5-tert-Butyl-2-pyridin-2-yl-1H-Benzoimidazole: grey solid, yield 59 %, m.p. 151 °C, recrystallized from aqueous EtOH. 
C16H17N3 (252.33). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 1.38 (9H, s), 7.60-7.88 (4H, m), 8.23 (1H, td, J=7.9, 1.6 
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Hz), 8.41 (1H, d, J=7.9 Hz), 8.91-8.93 (1H, m). MS: 253.65 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2950 (br), 2359, 1593, 
1445, 1391, 1314, 1280, 1149, 995, 865, 798, 743, 696, 656, 510 cm-1. 
 
RS 57 : Procedure O 
5-Fluoro2-thiazol-4-yl-1H-benzimidazole: brown-red solid, yield 76 %, m.p. 260-261 °C, recrystallized from aqueous EtOH. 
C10H6FN3S (219,24). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7,43 (1H, td, J=9.1, 2.2 Hz), 7,67 (1H, dd, J=8.5, 2.2 
Hz), 7,84 (1H, dd, J=8.8, 4.4 Hz), 8,90 (1H, d, J=1.9 Hz), 9,49 (1H, d, J=1.9 Hz). MS: 220,19 m/z (M+H)+. IR (ZnSe-ATR-
FTIR): ν = 3092 (br), 2362, 1629, 1477, 1448, 1396, 1351, 1310, 1247, 1221, 1143, 1094, 987, 963, 904, 838, 800, 729, 653, 
613, 535 cm-1. 
 
RS 58 : Procedure O 
5-Fluoro-2-pyridin-2-yl-1H-benzoimidazole: dark purple solid, yield 96 %, m.p. 181 °C, purification not necessary. 
C12H8FN3 (213.22). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.44 (1H, td, J=9.3, 2.5 Hz), 7.67 (1H, dd, J=8.5, 2.5 
Hz), 7.74-7.77 (1H, m), 7.87 (1H, dd, J=9.1, 4.4 Hz), 8.22 (1H, td, J=7.9, 1.6 Hz), 8.41 (1H, dt, J=7.9, 0.9 Hz), 8.90-8.91 
(1H, ddd, J=4.7, 1.6, 0.9 Hz). MS: 214.15 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 3142 (br), 1598, 1478, 1447, 1406, 1309, 
1252, 1138, 1107, 999, 964, 836, 793, 745, 693, 610 cm-1. 
 
RS 59 : Procedure O 
5-Chloro-2-thiazol-4-yl-1H-benzimidazole: grey solid, yield 56 %, m.p. 238-240 °C, recrystallized from aqueous EtOH. 
C10H6ClN3S (235.70). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.57 (1H, dd, J=8.5, 1.9 Hz), 7.82 (1H, d, J=8.5 Hz), 
7.88 (1H, d, J=1.9 Hz), 8.90 (1H, d, J=1.9 Hz), 9.48 (1H, d, J=1.9 Hz). MS: 236.24 m/z (M+H)+. IR (ZnSe-ATR-FTIR):  
ν = 3093 (br), 2361, 1620, 1578, 1441, 1389, 1335, 1308, 1278, 1222, 1193, 1093, 1061, 984, 928, 903, 876, 838, 807, 730, 
702, 656, 598, 534 cm-1. 
 
RS 60 : Procedure O 
5-Chloro-2-pyridin-2-yl-1H-benzoimidazole: white solid, yield 49 %, m.p. 141 °C, extracted with hot benzene and treated 
with charcoal, then purified over silica gel (EtOAc) and recrystallized from benzene. C12H8ClN3 (229.67). 1H-NMR (500 
Mhz, d6-DMSO-5 % TFA, ppm): 7.55 (1H, d, J=8.8, 1.9 Hz), 7.73-7.76 (1H, m), 7.83 (1H, d, J=8.5 Hz), 7.88 (1H, d, J=1.9 
Hz), 8.20 (1H, td, J=7.9, 1.6 Hz), 8.41 (1H, d, J=7.9 Hz), 8.88-8.90 (1H, m). MS: 230,13 m/z (M+H)+. IR (ZnSe-ATR-FTIR): 
ν = 3054 (br), 2364, 1595, 1445, 1401, 1305, 1218, 1059, 996, 924, 791, 739, 698 cm-1. 
 
RS 61 : Procedure O 
Phenyl-(2-thiazol-4-yl-1H-benzoimidazol-5-yl)-methanone: light yellow solid, yield 35 %, m.p. 95-98 °C, purified over silica 
gel (EtOAc-Hexan 1+2.5) and recrystallized from aqueous ethanol. C17H11N3OS (305.36). 1H-NMR (500 Mhz, d6-DMSO- 
5 % TFA, ppm): 7.6 (2H, t, J=7.9 Hz), 7.71 (1H, t, J=7.6 Hz), 7.79 (2H, d, J=7.9 Hz), 7.90-7.96 (2H, m), 8.10 (1H, s), 8.95 
(1H, d, J=1.5 Hz), 9.50 (1H, d, J=1.6 Hz). MS: m/z 305.6 (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2930 (br), 1729, 1644, 1618, 
1446, 1405, 1352, 1272, 1179, 1121, 1075, 977, 898, 875, 827, 708, 625, 529 cm-1. 
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RS 64: Procedure O 
2-Thiazol-4-yl-1H-imidazo[4,5-b]pyridine: purple solid, yield 97 %, m.p. 306 °C, purification not necessary. C9H6N4S 
(202.24). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.69 (1H, dd, J=8.2, 5.7 Hz), 8.49 (1H, d, J=7.9 Hz), 8.68 (1H, d, 
H=5.8 Hz), 8.88 (1H, d, J=1.8 Hz), 9.46 (1H, d, J=1.8 Hz). MS: 203.11 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 3064 (br), 
1595, 1417, 1398, 1269, 1097, 906, 884, 837, 800, 771, 734, 643, 565 cm-1. 
 
RS 65: Procedure O 
2-Pyridin-2-yl-1H-imidazo[4,5-b]pyridine: brown solid, yield 46 %, m.p. 242-243 °C, recrystallized from EtOH. C11H8N4 
(196.21). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.69-7.73 (2H, m), 8.15 (1H, td, J=7.6, 1.5 Hz), 8.44 (1H, d, J=7.9 
Hz), 8.52 (1H, dd, J=7.9, 0.9 Hz), 8.71 (1H, d, J=5.5 Hz), 8.87 (1H, d, J=4.3 Hz). MS: 197.15 m/z (M+H)+. IR (ZnSe-ATR-
FTIR): ν = 2971 (br), 1592, 1444, 1412, 1376, 1267, 797, 766, 742, 702, 564 cm-1. 
 
RS 66: Procedure O 
2-Thiazol-4-yl-1H-imidazo[4,5-c]pyridine: white solid, yield 98 %, m.p. 273 °C, purification not necessary. C9H6N4S 
(202.24). 1H-NMR (500 Mhz, d6-DMSO, ppm): 7.55 (1H, s), 8.31 (1H, d, J=5.7 Hz), 8.58 (1H, d, 1.9 Hz), 8.93 (1H, s), 9.36 
(1H, d, J=1.9 Hz), 13.10 (1H, br. s). MS: 203.11 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2627 (br), 1620, 1586, 1462, 1405, 
1301, 1226, 1082, 1027, 964, 901, 886, 844, 804, 730, 633, 605, 536 cm-1. 
 
RS 67: Procedure O 
2-Pyridin-2-yl-1H-imidazo[4,5-c]pyridine: white solid, yield 78 %, m.p. 232 °C, recrystallized from EtOH. C11H8N4 
(196.21). 1H-NMR (500 Mhz, d6-DMSO, ppm): 7.57-7.60 (2H, m), 8.04 (1H, td, J=7.9, 1.6 Hz), 8.34 (1H, d, J=5.7 Hz), 8.38 
(1H, d, J=7.9 Hz), 8.77 (1H, d, J=4.8 Hz), 9.00 (1H, s), 13.52 (1H, br. s). MS: 197.15 m/z (M+H)+. IR (ZnSe-ATR-FTIR):  
ν = 2626 (br), 1621, 1463, 1445, 1407, 1283, 1224, 1171, 1116, 1022, 995, 948, 909, 889, 794, 740, 703, 639, 606, 591, 542 
cm-1. 
 
 
Procedure P: Procedure[216] for the preparation of RS 38: 
O-phenylenediamine (1.94 g, 0.018 mol) and 5-amino-3H-1,2,4-dithiazole-3-thione (3.3g, 
0.022 mol, known as isoperthiocyanic acid) in absolute ethanol (30 ml) was refluxed for  
22 hrs. The solvent was distilled from the reaction mixture and the residue treated with 
aqueous sodium hydroxide (1 N, 3x25 ml) and then filtered. The filtrate was carefully 
neutralized to pH 7 and kept in a refrigerator for 8 hrs. The white precipitate (3.22 g, 96 %) 
that had formed was collected, washed with water, and dried. 
 
RS 38: Procedure P 
1H-Benzimidazol-2-yl-thiourea: white solid, yield 92 %, m.p. 196-198 °C, purification not necessary. C8H8N4S (192.24).  
1H-NMR (500 Mhz, d6-DMSO, ppm): 7.09-7.13 (2H, m), 7.43-7.47 (2H, m), 9.08 (1H, br. s.), 10.24 (1H, br. s.), 11.11 (2H, 
br. s.). MS: 193.25 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 3081 (br), 1578, 1543, 1439, 1264, 1084, 1024, 833, 741 cm-1. 
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Procedure Q: Procedure[217] for the preparation of RS 39: 
To a stirred and refluxing suspension of (1H-benzimidazol-2-yl)-thiourea (3.64 mmol) in 
water (3 ml) was added dropwise 1,2-dichloroethyl ethylether (3.86 mmol). After 2 hrs, the 
cooled mixture was basified (NaOH). The product was filtered and recrystallized from 
aqueous EtOH. 
 
RS 39: Procedure Q 
(1H-Benzimidazol-2-yl)-thiazol-2-yl-amine: white solid, yield 85 %, m.p. 252-254 °C, recrystallized from aqueous EtOH. 
C10H8N4S (216.27). 1H-NMR (500 Mhz, d6-DMSO, ppm): 6.90 (1H, d, J=3.8 Hz), 7.03-7.07 (2H, m), 7.30-7.34 (3H, m), 
11.65 (2H, br. s.). MS: 217.28 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2765 (br), 1632, 1601, 1476, 1435, 1370, 1224, 1133, 
1061, 1024, 864, 834, 740, 664, 603, 524 cm-1. 
 
 
Procedure R: General Procedure for the preparation of substituted benzimidazoles[218] for the 
compounds RS 43, RS 62, RS 68, RS 69: 
The appropriate diamine, usually as free base, was thoroughly mixed in a mortar with two 
equivalents each of anhydrous sodium acetate and the amidine salt. The temperature of the 
mixture was slowly raised until evolution of ammonia set in, and heating was continued until 
the melt resolidified. The cake was then treated with 1 N-NaOH and the mixture decolorized 
with charcoal and filtered. The hot filtrate was neutralized with glacial acetic acid or by 
addition of solid ammonium chloride. The product was filtered and recrystallized from water. 
 
RS 43: Procedure R 
2-Pyrazin-2-yl-1H-benzoimidazole: yellow solid, yield 85 %, m.p. 242-244 °C, recrystallized from aqueous EtOH. C11H8N4 
(196.21). 1H-NMR (500 Mhz, d6-DMSO, ppm): 7.23-7.31 (2H, m), 7.57 (1H, dt, J=7.9, 0.9 Hz), 7.76 (1H, d, J=7.9 Hz), 8.76 
(1H, d, J=2.5 Hz), 8.80 (1H, dd, 2.5, 1.6 Hz), 9.50 (1H, d, 1.6 Hz), 13.32 (1H, br. s). MS: 196.21 m/z (M+H)+. IR (ZnSe-
ATR-FTIR): ν = 3086 (br), 1433, 1313, 1261, 1106, 1046, 1021, 855, 801, 735, 666, 534 cm-1. 
 
RS 62: Procedure R 
Phenyl-(2-pyridin-2-yl-3H-benzoimidazol-5-yl)-methanone: light yellow solid, yield 20 %, m.p. 73-76 °C, not soluble in 
1 N-NaOH, therefore the cake was dissolved in EtOH and the product was precipitated with water and then recrystallized 
from aqueous EtOH. C19H13N3O (299.33). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.9 (2H, t, J=7.9 Hz), 7.69-7.80 
(4H, m), 7.88-7.96 (2H, m), 8.11 (1H, s), 8.21 (1H, td, J=7.9, 1.5 Hz), 8.44 (1H, d, J=7.9 Hz), 8.91 (1H, d, J=4.9 Hz).  
MS: m/z 300.6 (M+H)+. IR (ZnSe-ATR-FTIR): ν = 3243 (br), 1644, 1614, 1595, 1572, 1440, 1353, 1317, 1290, 1233, 1110, 
955, 901, 824, 796, 724, 704, 646 cm-1. 
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RS 68: Procedure R 
8-Pyridin-2-yl-7(9)H-purine: white solid, yield 62 %, m.p. 289-291 °C, recrystallized from H2O. C10H7N5 (197.20). 1H-NMR 
(500 Mhz, d6-DMSO, ppm): 7.63-7.66 (1H, m), 8.09 (1H, td, J=7.9, 1.6 Hz), 8.43 (1H, d, J=7.6 Hz), 8.81-8.22 (1H, m), 8.98 
(1H, s), 9.17 (1H, s). MS: 198.15 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2966 (br), 1573, 1536, 1469, 1439, 1412, 1387, 
1343, 1226, 954, 921, 867, 833, 798, 743, 703, 614, 589, 570, 556 cm-1. 
 
RS 69: Procedure R 
2-Pyridin-2-yl-1H-imidazo[4,5-b]pyrazine: light brown solid, yield 69 %, m.p. 306-309 °C, recrystallized from aqueous 
ethanol. C10H7N5 (197.20). 1H-NMR (500 Mhz, d6-DMSO, ppm): 7.62-7.65 (1H, m), 8.06-8.10 (1H, m), 7.72-7.75 (1H, m), 
8.40 (1H, br. s), 8.44 (1H, dd, J=7.9, 0.9 Hz), 8.50 (1H, br. s), 14.18 (1H, s). MS: 198.33 m/z (M+H)+. IR (ZnSe-ATR-FTIR): 
ν = 2972 (br), 1468, 1441, 1394, 1357, 1201, 1095, 993, 947, 837, 811, 752, 706, 594, 580 cm-1. 
 
 
Procedure S: General Procedure for the preparation of N-alkylated benzimidazoles[219] for 
the compounds RS 44, RS 45 and RS 46: 
To a suspension of a suitable benzimidazole (thiabendazole or compound RS 17) in dry 
dimethylformamide and benzene was added a suspension of sodium hydride in benzene. The 
solution was warmed under nitrogen for 30 min and then a solution of methyl iodide (or 
benzyl chloride) in benzene was added dropwise and the mixture was refluxed under nitrogen 
for 1 h. The cooled mixture was washed with water, dried over sodium sulphate, and 
evaporated to dryness to yield crude product.  
 
RS 44: Procedure S 
1-Methyl-2-thiazol-4-yl-1H-benzoimidazol: white solid, yield 79 %, m.p. 150 °C, purified over silica gel (EtOAc) and 
recrystallized from EtOH. C11H9N3S (215,28). 1H-NMR (500 Mhz, d6-DMSO, ppm): 4,17 (3H, s, N-CH3), 7,24-7,32 (2H, 
m), 7,62 (1H, dd, J=7.9, 1.3 Hz), 7,66-7,68 (1H, m), 8,49 (1H, d, J=1.9 Hz), 9,35 (1H, d, J=2.2 Hz). MS: 216,13 m/z (M+H)+. 
IR (ZnSe-ATR-FTIR): ν = 3095, 3032, 2924, 2854, 1459, 1430, 1404, 1367, 1315, 1258, 1097-1018 (br), 917, 876, 799, 731 
cm-1. 
 
RS 45: Procedure S 
1-Benzyl-2-thiazol-4-yl-1H-benzoimidazole: white solid, yield 35 %, m.p. 146 °C, purified over silica gel (EtOAc-Hexan 
1+2). C17H13N3S (291,38). 1H-NMR (500 Mhz, CDCl3, ppm): 6,15 (2H, s, N-CH2), 7,15-7,17 (2H, m), 7,22-7,31 (4H, m), 
7,34-7,37 (2H, m), 7,89-7,91 (1H, m), 8,74 (1H, s), 8,90 (1H, d, J=1.9 Hz). MS: 292,19 m/z (M+H)+. IR (ZnSe-ATR-FTIR): 
ν = 3073, 2929 (br), 1730, 1494, 1473, 1459, 1404, 1360, 1332, 1310, 1259, 1159-999 (br), 924, 835, 799, 738, 723, 
 692 cm-1. 
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RS 46: Procedure S 
1-Benzyl-2-pyridin-2-yl-1H-benzoimidazole: white solid, yield 47 %, m.p. 116-118 °C, purified over silica gel with EtOAc-
Hexan 1+3. C19H15N3 (285.35). 1H-MR (500 Mhz, d6-DMSO, ppm): 6.23 (2H, s), 7.12-7.28 (7H, m), 7.49-7.52 (1H, m), 
7.55-7.59 (1H, m), 7.74-7.78 (1H, m), 8.00 (1H, td, J=7.9, 1.9 Hz), 8.37 (1H, dt, J=8.2, 0.9 Hz), 8.69-8.70 (1H, m).  
MS: 286.23 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 2928, 2364, 1733, 1586, 1465, 1441, 1394, 1369, 1330, 1278, 730, 695 
cm-1. 
 
 
Procedure T: General Procedure for the preparation of nitrated benzimidazoles[220] for the 
compounds RS 53 and RS 54: 
To a solution of a suitable benzimidazole (thiabendazole or compound RS 17, 164 mmol) in 
concentrated H2SO4 (75 ml) was added concentrated HNO3 (12.5 ml) dropwise between 0 °C 
and 10 °C. The mixture was stirred at room temperature for 2 hrs and then poured into ice-
water. Cautious neutralization with 50 % NaOH provided a solid, which was filtered off and 
crystallized from MeOH to yield the desired product. 
 
RS 53: Procedure T 
5-Nitro-2-thiazol-4-yl-1H-benzoimidazole: light yellow solid, yield 55 %, m.p. 242 °C, recrystallized from EtOH. 
C10H6N4O2S (246.25). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.84 (1H, d, J=8.8 Hz), 8.23 (1H, dd, J=8.8, 2.2 Hz), 
8.51 (1H, d, J=2.2 Hz), 8.76 (1H, d, J=1.9 Hz), 9.43 (1H, d, J=1.9 Hz). MS: 247.13 m/z (M+H)+. IR (ZnSe-ATR-FTIR):  
ν = 1439, 1374, 1331, 1274, 1195, 1130, 1069, 910, 881, 810, 737, 618cm-1. 
 
RS 54: Procedure T 
5-Nitro-2-pyridin-2-yl-1H-benzoimidazole: light yellow solid, yield 43 %, m.p. 213-214 °C, recrystallized from MeOH. 
C12H8N4O2 (240.22). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.62-7.65 (1H, m), 7.82 (1H, dd, J=8.8, 0.6 Hz), 8.09 
(1H, td, J=7.9, 1.6 Hz), 8.19 (1H, dd, J=9.1, 2.2 Hz), 8.40 (1H, dt, J=7.9, 0.9 Hz), 8.53 (1H, d, J=2.2 Hz), 8.80-8.82 (1H, m), 
13.08 (1H, br. s (weak)). MS: 241.17 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 3106 (br), 2332, 1519, 1446, 1437, 1404, 
1339, 1316, 1064, 823, 737, 700 cm-1. 
 
 
Procedure U: Reduction on Pd/charcoal[221] for the compounds RS 55 and RS 56:  
1.0 g of a nitro-derivative was dissolved in 100 ml absolute ethanol, and the solution was 
reduced catalytically over 0.5 g of 10 % palladium-on-charcoal at normal pressure and room 
temperature. After the uptake of hydrogen was complete, the catalyst was removed by 
filtration and the solvent was evaporated in vacuo. Upon recrystallization the pure compounds 
were obtained.  
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RS 55: Procedure U 
5-Amino-2-thiazol-4-yl-1H-benzimidazole: light yellow solid, yield 62 %, m.p. 233-235 °C, recrystallized from aqueous 
ethanol. C10H8N4S (216.27). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.32 (1H, dd, J=8.8, 1.9 Hz), 7.58 (1H, d, J=1.9 
Hz), 7.79 (1H, d, J=8.5 Hz), 8.85 (1H, d, J=1.9 Hz), 9.47 (1H, d, J=1.9 Hz). MS: 217.29 m/z (M+H)+. IR (ZnSe-ATR-FTIR): 
ν = 3109 (br), 1631, 1408, 1359, 1309, 904, 804, 715, 645, 620 cm-1. 
 
RS 56: Procedure U 
2-Pyridin-2-yl-1-benzoimidazol-5-ylamine: light yellow solid, yield 80 %, m.p. 217 °C, recrystallized from EtOH. C12H10N4 
(210.24). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.31 (1H, d, J=8.5 Hz), 7.6 (1H, s), 7.68-7.71 (1H, m), 7.80 (1H, d, 
J=8.8 Hz), 8.16 (1H, td, J=7.9, 1.6 Hz), 8.38 (1H, d, J=7.9 Hz), 8.85-8.87 (1H, m). MS: 211.17 m/z (M+H)+. IR (ZnSe-ATR-
FTIR): ν = 2984 (br), 1591, 1494, 1438, 1324, 1167, 880, 794, 742, 692, 617 cm-1. 
 
 
Procedure V: Procedure[222, 223] for the preparation of RS 63: 
A stirred solution of pyridine-2-carbaldehyde (85.7 mg, 0.8 mmol) and 3,4-diamino-
benzonitrile (100 mg, 0.75 mmol) in 8 ml of nitrobenzene was heated at 145 °C under N2 
overnight. The cooled reaction mixture was treated with 3 % HCl (3x25 ml) and the pH 
adjusted to 8 with NH4OH. The voluminous precipitate was filtrated and then purified by 
column chromatography (EtOAc:hexane 1:1) to give RS 63. 
 
RS 63: Procedure V 
2-Pyridin-2-yl-1H-benzoimidazole-5-carbonitrile: white solid, yield 36 %, m.p. 216-218 °C, purified over silica gel (EtOAc-
Hexan 1+1). C13H8N4 (220.24). 1H-NMR (500 Mhz, d6-DMSO-5 % TFA, ppm): 7.66 (1H, t, J=6.3 Hz), 7.73 (1H, d, J=8.5 
Hz), 7.85 (1H, d, J=8.5 Hz), 8.12 (1H, t, J=7.8 Hz), 8.25 (1H, s), 8.41 (1H, d, J=7.9 Hz), 8.83 (1H, d, J=5.6 Hz).  
MS: 221.15 m/z (M+H)+. IR (ZnSe-ATR-FTIR): ν = 3143 (br), 2222, 1727, 1602, 1470, 1448, 1414, 1312, 1001, 793, 740, 
696, 624, 533 cm-1. 
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7.1.2.4 Elemental Analyses of Thiabendazole Analogs 
 
Cpd. Molecular 
formula 
Calculated % Found % 
RS 17 C9H7N3OS C 52.67 H 3.44 N 20.47 O 7.80 S 15.62 C 53.86 H 3.38 N 19.34 
RS 34 C12H9N3 C 73.83 H 4.65 N 21.52 C 71.22 H 5.62 N 23.17  
RS 35 C11H8N2S C 65.97 H 4.03 N 13.99 S 16.01 C 65.98 H 4.54 N 13.47  
RS 36 C11H8N2O C 71.73 H 4.38 N 15.21 O 8.69 C 71.72 H 4.60 N 14.99 
RS 37 C13H10N2O C 74.27 H 4.79 N 13.32 O 7.61 C 74.05 H 5.03 N 13.30 
RS 38 C8H8N4S C 49.98 H 4.19 N 29.14 S 16.68 C 50.50 H 4.47 N 28.39 
RS 39 C10H8N4S C 55.54 H 3.73 N 25.91 S 14.83 C 56.09 H 3.82 N 25.27 
RS 40 C12H9N3 C 73.83 H 4.65 N 21.52 C 74.13 H 4.56 N 21.28 
RS 41 C12H9N3O C 68.24 H 4.29 N 19.89 O 7.57 C 68.58 H 4.16 N 19.68 
RS 42 C12H9N3O C 68.24 H 4.29 N 19.89 O 7.57 C 67.39 H 4.72 N 20.31 
RS 43 C11H8N4 C 67.34 H 4.11 N 28.55 C 67.71 H 3.76 N 28.52  
RS 44 C11H9N3S C 61.37 H 4.21 N 19.52 S 14.89 C 61.32 H 4.23 N 18.93  
RS 45 C17H13N3S C 70.08 H 4.50 N 14.42 S 11.00 C 70.40 H 5.14 N 13.46 
RS 46 C19H15N3 C 79.98 H 5.30 N 14.73 C 80.30 H 5.22 N 14.49 
RS 47 C11H9N3S C 61.37 H 4.21 N 19.52 S 14.89 C 61.70 H 4.23 N 19.17 
RS 48 C13H11N3 C 74.62 H 5.30 N 20.08 C 74.13 H 5.74 N 20.13 
RS 49 C12H11N3S C 62.86 H 4.84 N 18.32 S 13.98 C 62.76 H 5.08 N 18.18  
RS 50 C14H13N3 C 75.31 H 5.87 N 18.82 C 75.06 H 6.20 N 18.74 
RS 51 C14H15N3S C 65.34 H 5.87 N 16.33 S 12.46 C 65.31 H 6.12 N 16.11 
RS 52 C16H17N3 C 76.46 H 6.82 N 16.72 C 76.29 H 7.00 N 16.72 
RS 53 C10H6N4O2S C 48.78 H 2.46 N 22.75 O 12.99 S 13.02 C 49.17 H 2.40 N 22.42 
RS 54 C12H8N4O2 C 60.00 H 3.36 N 23.32 O 13.32 C 60.46 H 3.30 N 22.92 
RS 55 C10H8N4S C 55.54 H 3.73 N 25.91 S 14.83 C 55.77 H 3.79 N 25.27 
RS 56 C12H10N4 C 68.56 H 4.79 N 26.65 C 69.05 H 4.90 N 26.05 
RS 57 C10H6FN3S C 54.78 H 2.76 F 8.67 N 19.17 S 14.62 C 55.05 H 2.76 N 18.90 
RS 58 C12H8FN3 C 67.60 H 3.78 F 8.91 N 19.71 C 67.11 H 3.76 N 20.21 
RS 59 C10H6ClN3S C 50.96 H 2.57 Cl 15.04 N 17.83 S 13.60 C 51.31 H 2.51 N 17.55 
RS 60 C12H8ClN3 C 62.76 H 3.51 Cl 15.44 N 18.30 C 62.59 H 4.07 N 17.91 
RS 61 C17H11N3OS C 66.87 H 3.63 N 13.76 O 5.24 S 10.50 C 67.17 H 3.92 N 13.18 
RS 62 C19H13N3O C 76.24 H 4.38 N 14.04 O 5.34 C 75.72 H 4.52 N 14.42 
RS 63 C13H8N4 C 70.90 H 3.66 N 25.44 C 72.54 H 4.00 N 23.46 
RS 64 C9H6N4S C 53.45 H 2.99 N 27.70 S 15.85 C 53.76 H 2.94 N 27.44 
RS 65 C11H8N4 C 67.34 H 4.11 N 28.55 C 66.79 H 4.15 N 29.05 
RS 66 C9H6N4S C 53.45 H 2.99 N 27.70 S 15.85 C 53.70 H 2.87 N 27.57 
RS 67 C11H8N4 C 67.34 H 4.11 N 28.55 C 67.82 H 4.02 N 28.16 
RS 68 C10H7N5 C 60.91 H 3.58 N 35.51 C 61.63 H 3.64 N 34.72 
RS 69 C10H7N5 C 60.91 H 3.58 N 35.51 C 61.96 H 2.96 N 35.08 
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7.2 Biochemistry 
 
7.2.1 Laboratory Equipment, Materials and Instruments 
 
All assays were done with black Polypropylene 96 well plates (V-bottom) from Greiner 
(Frickenhausen, Germany, Cat.-Nr. 651209) with pipettes (Model Research) from Eppendorf 
(Hamburg, Germany) or Gilson (Middleton, USA) and measured with a Wallac Victor2 1420 
Multilabel Counter (PerkinElmer, Boston, USA). For the determination of the MIC-values, 
transparent 96 well plates (flat bottom, Cat.-Nr. 391H8046) from Merck (Darmstadt, 
Germany) were used. 
 
Table-top centrifuges  
Universal 32 R, Micro 24-48 R  Hettich, Tuttlingen , Germany 
Minifuge     Heraeus, Hanau, Germany. 
Centrifuge RC 5B Plus    Sorvall, Newtown, USA 
Rotors SS-34, SLA-1500    Sorvall, Newtown, USA 
Gel electrophoresis chamber EC120   EC-Apparatus Corp., St.Petersburg, USA 
Gel electrophoresis chamber flatbed   LTF, Wasserburg, Germany 
Gel electrophoresis chamber 45-1010  PeqLab, Erlangen, Germany 
Power-Supply Power Packs P25   Biometra, Göttingen, Germany 
Power-Supply Power Packs P300   Bio Rad, Munich, Germany 
Incubator Shakers     Infors HT, Bottmingen, Switzerland 
Incubators      Heraeus, Hanau, Germany 
Cell disruption equipm., One shot model, Unit 3 Constant Systems Ltd, Warwick, UK 
Microcooler II     Boeckel, Emersacker, Germany 
Ultrasonic bath Sonsorex RK 106 Transistor Bandelin, Berlin, Germany 
Water Bath WBU45     Memmert, Schwalbach, Germany 
Photometer Heλios β     Unicam, Cambridge, UK  
Thermoblock HB 120 Thermoleader   Uni Equip, Martinsried, Germany 
Magnetic Stirrer RCT-Basic    IKA-Labortechnik, Staufen, Germany 
pH-Meter 766      Knick, Berlin, Germany  
Electroporator EC 100    EC-Apparatus Corp., St. Petersburg, USA 
Balance 440-45     Kern, Balingen, Germany 
Balance SBC 21     SCALTEC, Heiligenstadt, Germany 
RP-Osmosis-plant Milli-Q Plus PF    Millipore, Eschborn, Germany 
Vortex-Genie 2      Scientific Industries, Bohemia, N.Y., USA 
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7.2.2 Expression and Purification of EcMetAP 
 
A C-terminal poly-His-tagged form of E. coli MetAP was obtained by overexpression in E. 
coli using an Arg-175-Gln mutant kindly provided by Prof. B. W. Matthews and W. T. 
Lowther. The expression vector used was constructed with the Novagen pet28b expression 
vector as described in the literature[70]. In short, it encodes for the E. coli MetAP Arg-175-Gln 
mutation with a C-terminal poly-His-tag flanked by a thrombin-cleavage site. The Arg-175-
Gln mutation eliminates a secondary thrombin cleavage site on a surface loop and does not 
affect activity. 
The expression and purification of the EcMetAP was done according to a literature 
procedure[70]: 
Four liter fermentation cultures of BL21(DE3) E. coli cells containing the expression plasmid 
were grown in Luria-Bertani broth with kanamycin (100 mg/liter) at 37 °C and 250 rpm. 
Expression was induced after cooling to 25 °C by the addition of isopropyl ß-D-
thiogalactoside to 1 mM at 0.5-0.6 OD600 and the cells allowed to grow for another 3 hrs at  
25 °C. The cells were centrifuged at 8500 rpm and 4 °C for 15 min, resuspended in medium 
and centrifuged again at 4500 rpm and 4 °C for 15 min. The cells were frozen at -80 °C and 
crashed in a mortar under cooling with nitrogen. The resulting powder wass suspended in 100 
ml of an altered +T/G buffer at 4 °C [50 mM Hepes, pH 7.9 / 10 % glycerol / 0.1 % Triton X-
100 / 0.5 M KCl / 5 mM imidazole and additionally 40 µg/ml DNase / 1 mM MgCl2 / 15 mM 
methionine / 1 mM PMSF] and the cells lysed in a french press at 1.0 kbar. The resulting 
solution was then centrifuged at 40,000 g at 4 °C for 30 min. The supernatant was loaded onto 
a 10-ml nitrilotriacetic acid-agarose column (Qiagen, Hilden, Germany) equilibrated with 
+T/G buffer. After washing with +T/G buffer and –T/G buffer (-T/G buffer without glycerol, 
Triton X-100 and inhibitor cocktail), MetAP was eluted at 4 °C with about 160 ml of –T/G 
buffer containing 60 mM imidazole directly into 1 ml of 500 mM EDTA, pH 8.0. Additional 
EDTA was added, if necessary, to give a final concentration of 5 mM. The yield/protein 
concentrations were determined by absorption at 280 nm with the extinction coefficient of 
16350 M-1·cm-1 with a conversion factor of 1.89. Typical yields were 100-150 mg/liter of 
culture. Freshly transformed BL21(DE3) gave significantly higher yields. For stored 
BL21(DE3) cells, typical yields were about 40-75 mg/L. 
After dialysis at 4 °C against 25 mM Hepes buffer, pH 7.9, 150 mM KCl, 15 mM Methionine, 
MetAP was concentrated to a volume of about 30 ml and stored at -80 °C at about 20 mg/ml. 
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For dialysis and buffer exchange, ultrafiltration can be used (cfr. 7.2.4.1.3 Buffer Exchange 
and Concentration of Protein Solutions). The poly-His-tail was removed by incubation of 100 
mg of MetAP with 0.1-1 U/mg of thrombin (Novagen/Merck, Darmstadt, Germany) / 2,5 mM 
CaCl2 at 15 °C in a Microcooler for 18-20 hrs. Passage of the protein through another 
nitrilotriacetic acid-agarose column equilibrated with –T/G buffer resulted in His-tag free 
protein. For this step, only a small volume of agarose should be used (0.5 ml-1 ml for a digest 
of about 100 mg). The resulting protein solution was narrowed to 2-3 ml and the MetAP was 
subsequently loaded onto a Superdex 75 Hi-load, prep-grade 16/60 gel filtration column 
(Pharmacia/Pfizer, New York, USA) equilibrated with 25 mM Hepes, pH 7.1, 25 mM K2SO4, 
100 mM NaCl und further purified. Column cleaning and storage of the NTA-column: The 
column is washed with 100 ml of 100 mM EDTA, then with 150 ml of water and finally with 
150 ml of 20 % ethanol. For storage, the enzyme is concentrated to 20-80 mg/ml and shock 
frozen on dry ice/ethanol or liquid nitrogen and stored at -80 °C. 
 
 
7.2.3 Assays 
 
All assays were performed in black 96-well microtiter plates with a V-bottom (Greiner, 
Frickenhausen, Germany, Cat.-Nr. 651209). Reagents and buffers were prepared in deionized 
milliQ-filtered water. The Wallac Victor multiplate reader settings were as follows: 
 
Height of the plate   14.1 mm 
Offset of the wells   11.2 mm, 14.3 mm 
Distance between wells  9.0 mm, 9.0 mm 
Measurement height   8.00 mm 
Scanning horizontal positions 1 
Scanning vertical positions  1 
Scanning point displacement  1.00 mm 
Scanning mode   Rectangular 
Label technology   Prompt fluorometry 
CW-lamp filter name   544 
Emission filter name   590 
Measurement time   1.0 s 
Emission aperture   Normal 
CW-lamp energy   2001 
Emission side    Above 
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The measurement has to be done at room temperature (20-28 °C) as higher temperatures lead 
to the formation of small gas bubbles that interfere with the fluorescence measurement. 
Another important aspect for getting reproducible measurements is the mixing of the assay 
solutions. Especially after adding the detection enzymes in a relative small volume of 20 µl 
compared to an overall volume of 250 µl, it is important to mix the solution by extensive 
pipetting with the 8-way pipette. This step should be done very carefully in order to avoid the 
formation of air bubbles.  
 
 
7.2.3.1 pH-Dependency of Fumagillin-Binding 
In a typical assay, MetAP (49.33 nM) was incubated with CoCl2 (1.33 mM) and buffer (25 
mM tris/maleate, 0.1 % DMSO, pH 5-8.5) with and without fumagillin (66.6 µM) for 15 
minutes at 37 °C (total volume 30 µl). For the ensuing Met-Gly-Met-Met hydrolysis and 
detection, the pH was adjusted to 7.5 by adding a mixture of substrate (MGMM), NaCl, buffer 
(100 mM tris/maleat pH 7.5) and BSA to a total volume of 200 µl resulting in the following 
concentrations in the assay: MetAP 7-8 nM, CoCl2 200 µM, NaCl 100 mM, fumagillin 10 
µM, BSA 0.1 % and MGMM 200 µM. The reaction was stopped after 15 minutes at 37 °C 
with a mixture of EDTA/Amplex Red reagent in buffer (100 mM tris/maleate, pH 7.5). 
Detection was started with the addition of a mixture of horseradish peroxidase/L-amino acid 
oxidase resulting in a total volume of 250 µl and the following concentrations: 9 mM EDTA, 
10 µM Amplex, 1.05 U HRP and 0.0075 U AAO. The resulting fluorescence was measured 
using a Wallac Victor2 multiplate reader (Greiner, filters: λex=544 nm, λem= 590 nm) and 
corrected by the corresponding blanks. All experiments were performed in triplicate with 
three independent measurements. 
 
 
7.2.3.2 pH-Profile of MetAP Activity 
In a typical assay, MetAP was preincubated with CoCl2, buffer (100 mM tris/maleate, pH 5-
8.5), MGMM, NaCl and BSA resulting in the following concentrations: MetAP 12 nM, CoCl2 
200 µM, NaCl 100 mM, BSA 0.1 % (15 minutes, 37 °C, total volume 80 µl). The reaction 
was started by the addition of 20 µl substrate resulting in 200 µM MGMM and was stopped 
after 15 minutes at 37 °C and the pH adjusted to 7.4 by adding a mixture of EDTA/Amplex 
Red Reagent in buffer (1 M tris/maleate pH 7.4). Detection was started with the addition of a 
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mixture of horseradish peroxidase/L-amino acid oxidase resulting in a total volume of 250 µl 
and the following concentrations: 9 mM EDTA, 10 µM Amplex, 1.05 U HRP and 0.0075 U 
AAO. The resulting fluorescence was measured using a Wallac Victor2 Multiplate Reader 
(Greiner, filters: λex=544 nm, λem= 590 nm) and corrected by the corresponding zero values. 
All experiments were performed in quadruplicate.  
 
 
7.2.3.3 IC50-Values 
The IC50 value is defined as the concentration of inhibitor that leads to 50 % inhibition of the 
enzyme. Normally, it is the result of the procentual inhibition of at least three different 
concentrations that have to lie in the linear range of the sigmoid IC50-value curve (log 
(concentration of inhibitor) / % inhibition). 
In a typical assay, MetAP (20 µl, 75-150 nM in buffer with 0.1 % BSA) was preincubated 
with CoCl2 (20 µl, 2 mM), buffer (62 µl, 50 mM tris/maleate, pH 7.5), NaCl (20 µl, 1 M) and 
BSA (18 µl, 1 %) and with inhibitor (20 µl, different concentrations in 50 mM tris/maleate 
buffer pH 7.5 containing 1 % DMSO) or without inhibitor (20 µl, 50 mM tris/maleate buffer 
pH 7.5 containing 1 % DMSO) for 30 minutes at 37 °C. Then, the reaction was started by the 
addition of MGMM (40 µl, 1 mM) resulting in a total volume of 200 µl with the following 
concentrations: MetAP 7.5-15 nM, CoCl2 200 µM, NaCl 100 mM, BSA 0.1 % and MGMM 
200 µM. The reaction was stopped after 15 minutes at 37 °C by adding a mixture of 
EDTA/Amplex Red Reagent (29.5 µl, 76.3 mM EDTA and 0.5 µl Amplex 5 mM). Detection 
was started with the addition of a mixture of horseradish peroxidase/L-amino acid oxidase (16 
µl 0.065625 U/µl HRP and 4 µl, 0.001875 U/µl AAO) resulting in a total volume of 250 µl 
and the following concentrations: 9 mM EDTA, 10 µM Amplex, 1.05 U/well HRP and 0.0075 
U/well AAO. The resulting fluorescence was measured using a Wallac Victor2TM Multiplate 
Reader (Greiner, filters: λex=544 nm, λem= 590 nm) for 100 min and corrected by the 
corresponding zero values. The IC50 values were obtained by calculating the mean value of 
three independent measurements with all experiments performed once within one assay-
procedure (value with a certain inhibitor concentration and corresponding zero value). For 
IC50-values larger than 10 µM, the procedure was the same but the IC50 values were obtained 
by calculating the mean value of three values corrected against the corresponding zero value 
within one measurement. Reagents and buffers were prepared in deionized milliQ-filtered 
water. 
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7.2.3.4  KM-Values 
 
First, a bundle of calibration curves was determined for different MGMM concentrations as 
described above. Instead of MetAP, buffer was used and methionine was added to give final 
concentrations of 0-8.75 µM in a volume of 200 µl. The final concentrations of MGMM were 
100 µM. 150 µM, 200 µM, 400 µM, 800 µM, 1200 µM, 2000 µM and 3000 µM respectively 
and detection was started after 15 min preincubation at 37 °C. Each methionine concentration 
was measured in triplicate and corrected against a blank. The correlation for each curve was 
0.98 or better. 
After the determination of calibration curves, the Km/KM’-value(s) was/were determined as 
follows: 
In a typical assay, MetAP (15-60 µl, 7.5 nM) was preincubated with CoCl2 (20 µl, 2 mM), 
buffer (26-66.5 µl, 50 mM tris/maleate, pH 7.5), NaCl (20 µl, 1 M) and BSA (14-18,5 µl,  
1 %) and with thiabendazole (20 µl, 5 µM in 50 mM tris/maleate buffer pH 7.5 containing  
1 % DMSO) or without inhibitor (20 µl, 50 mM tris/maleate buffer pH 7.5 containing 1 % 
DMSO) for 30 minutes at 37 °C. Then, the reaction was started by the addition of the 
appropriate MGMM solution (40µl) resulting in a total volume of 200 µl with the following 
concentrations: MetAP 0.5-2 nM, CoCl2 200 µM, NaCl 100 mM, BSA 0.1 %, thiabendazole 
500 nM and MGMM (100 µM-3 mM). The reaction was stopped after 15 minutes at 37 °C by 
adding a mixture of EDTA/Amplex Red reagent (29.5 µl, 76,3 mM EDTA and 0.5 µl Amplex 
5 mM) and the released methionine was quantified as follows: Detection was started with the 
addition of a mixture of horseradish peroxidase/L-amino acid oxidase (16 µl 0.065625 U/µl 
HRP and 4 µl, 0.001875 U/µl AAO) resulting in a total volume of 250 µl and the following 
concentrations: 9 mM EDTA, 10 µM Amplex, 1.05 U HRP and 0.0075 U AAO. The resulting 
fluorescence was measured using a Wallac Victor2 Multiplate Reader (Greiner, filters: 
λex=544 nm, λem= 590 nm) for 100 min and corrected by the corresponding zero values. The 
KM value was obtained by calculating the conversion rate of MGMM v* and the mean 
substrate concentration s* (mean value of the substrate concentration at the beginning of the 
reaction minus substrate concentration at the end of the reaction) and by plotting 1/s* against 
1/v*. The KM-value was calculated according to the Lee and Wilson modified Lineweaver-
Burk equation as the reciprocal value of the negative X-axis intercept. Normally, eight 
different substrate concentrations were used and the correlation was 0.98 or better. KM values 
are given as the mean value of three independent measurements.  
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7.2.3.5 MIC-Values 
 
The determination of MIC-values was done in 96-well-plates (Greiner, Frickenhausen, 
Germany). A starting culture of E. coli BL21(DE3) was grown overnight and used for the 
inoculation of the wells. First, solutions of inhibitors in DMSO (12.5 mg/ml) were diluted 
1:47.5 with LB-medium (with and without added CoCl2) to give 263 µg/ml with 2 % DMSO 
(and possibly CoCl2). The following 1:1 dilutions were done with LB-medium containing 2 % 
DMSO (and possibly CoCl2). Ciprofloxacin was dissolved in 10 % HOAc to 10 mg/ml and a 
solution of 3.125 µg/ml was done that was further diluted 1:47.5 with LB-medium containing 
2 % DMSO. 190 µl of each solution (containing the desired concentration of inhibitor, 2 % 
DMSO and possibly CoCl2) was placed in a well and 10 µl of the bacterial culture was added. 
Thus, the final dilution of inhibitors was 1:50 (250 µg/ml). The starting culture was diluted 
with LB before in such a way that the resulting increase in OD590 in each inoculated well was 
about 0.02. Starting ODs were in the range of 0.1. The plate was incubated at 37 °C and 
bacteria growth was followed with the Victor Wallac Multiplate reader. The OD590 after 
different times (16 hrs, 45 hrs) of incubation were measured and used for the determination of 
the MIC-value by comparison against a control (LB, 2 % DMSO and possibly CoCl2 without 
an inhibitor). 
 
 
7.2.4 Other Biochemical Methods 
7.2.4.1 Working with Proteins 
7.2.4.1.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Proteins can be separated in an electrical field according to their molecular weights with use 
of the SDS-PAGE[224]. The addition of sodium-dodecylsulfat (as an anionic detergent) to a 
sample of proteins has several effects: SDS masks the individual charge of a protein. The 
binding of SDS is proportional to the mass of a protein (1.4 g SDS / g protein). Thus, all 
proteins are negatively charged and migrate to the anode. Additionaly, SDS breakes H-bonds 
and hydrophobic interactions. Secondary structures get lost and the proteins are denaturated. 
The addition of the reducing agent Dithiothreitol (DTT) cleaves disulfide-bonds and abolishes 
tertiary- and quartenary structures. 
7.2 Biochemistry 149 
 
The pore size and the separating characteristics depend on the acrylamide-/bisacrylamide 
concentration of the gel. Normally, 10 or 12.5 % are used according to the size of the proteins 
and a constant voltage of 120 – 150 V is applied to vertical flatbed gels (8.0 cm x 5,5 cm x 
0.075 cm). 
 
For sample preparation the mixture is incubated with reducing sample buffer at 95 °C for  
5 min. A small stacking gel is used for concentration of the sample. The molecular weight can 
be determined with the help of a reference (marker) that contains proteins with a defined MW. 
Prestained SDS-PAGE Standards Low Range (Prestained Marker BioRad, Kalifornien, USA) 
was used. 
 
 
Acrylamid-Gel-Solution:  Acrylamide 30 % (w/v), Bisacrylamide 0.8 % (w/v) 
Stacking buffer (4x) pH 6.8: Tris-HCl (pH 6.8) 0,5 M, SDS 0.4 % (w/v), TEMED 0.4 % (v/v) 
Seperating buffer (4x) pH 8.8: Tris-HCl (pH 8.8) 1,5 M, SDS 0.4 % (w/v), TEMED 0.4 % (v/v) 
Ammoniumperoxodisulfat (APS): 10 % (w/v) in MilliQ-water 
Reducing sample buffer (2x): Tris-HCl (pH 6.8) 0,125 M, SDS 4 % (w/v), Glycerole 20 % 
(v/v), EDTA 2 mM, Bromphenol blue 0.02 % (w/v), DTT 194 
mM 
SDS-Running-Buffer (10x): Tris 0.25 M, Glycine 1.92 M, SDS 1 % 
 
Separating-Gel (10 %) example 
 3.3 ml Acrylamide-solution 
 2.5 ml Separating Buffer (4x) 
 4.1 ml MilliQ 
 0.1 ml 10 % Ammoniumperoxodisulfat solution 
 
Stacking-Gel example 
 0.44 ml Acrylamide--solution 
 0.83 ml Stacking-Gel-Buffer (4x) 
 2.06 ml MilliQ 
 0.02 ml 10 % Ammoiumperoxodisulfat solution 
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Table 7-1 Constitution of stacking gels and of separating gels 
 Stacking gel Separating gel 
(10 %) 
Separating gel 
(12,5 %) 
Acrylamide-Solution 4 % (w/v) 10 % (w/v) 12.5 % (w/v) 
Tris-HCl pH 8.8 - 0.375 M 0.375 M 
Tris-HCl pH 6.8 0.125 M - - 
TEMED 0.1 % (v/v) 0.1 % (v/v) 0.1 % (v/v) 
SDS 0.1 % (w/v) 0.1 % (w/v) 0.1 % (w/v) 
APS 0.6 % (w/v) 0.1 % (w/v) 0.1 % (w/v) 
 
 
Table 7-2 Constitution of prestained marker BioRad 
Protein Molecular weight (Dalton) 
Phosphorylase B 113,000 
Bovine serum albumin 92,000 
Ovalbumin 52,300 
Carbonic anhydrase 35,300 
Soybean trypsin inhibitor 28,700 
Lysozyme 21,300 
 
 
7.2.4.1.2 Staining of Protein Gels 
 
Gels were stained with the colloidal-coomassie-method according to Neuhoff. Coomassie 
Brilliant Blue G-250 is an acidic dye that unspecifically binds to cationic and hydrophobic 
protein side chains. 10 % acetic acid was used for decolorizing. For documentation the gels 
were incubated for 30 min in a solution 10 % glycerole in water and then dried between two 
layers of plastic film (Bringmann, Wendelstein, Germany). 
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7.2.4.1.3 Buffer Exchange and Concentration of Protein Solutions 
 
For the concentration of the protein solution, ultrafiltration was used. Ultrafiltration is a 
convective process that uses anisotropic semi-permeable membranes to separate 
macromolecular species and solvents primarily on the basis of size. It is particularly 
appropriate for the concentration of macromolecules and can also be used to purify molecular 
species or for solvent exchange. Ultrafiltration is a gentle, non denaturing method that is more 
efficient and flexible than alternative processes. In this case, Vivaspin 20 (Cat-Nr. VS2001) 
and Vivaspin 4 (Cat-Nr. VS0403) were used with a cutoff of 10 kDa and a PES-mebrane. 
 
 
7.2.4.1.4 MALDI-TOF-MS and ESI-MS-MS-Measurements 
 
For the determination of the molecular weight of EcMetAP before and after the cleavage of 
the His-tag, a protein solution of about 3 mg/ml in buffer was measured in the positive, linear 
mode with sinapinic acid as matrix for the MALDI-TOF-MS-measurement. The same 
solution was measured with the ESI-MS-MS with the addition of 1% HOAc with 100 scans (1 
scan defined as the average of 10 scans) between 400 and 1500 Da. 
 
7.2.4.2 Working with Escherichia coli 
 
7.2.4.2.1 Handling of Strains 
 
Newly transformed strains were stored at -70 °C to protect them from contamination and from 
losing their original or newly gained function(s). When needed, they can be freshly cultured. 
For the storage of a strain, the bacteria of a complete grown plate are gathered with a sterile 
cotton tip and are then resuspended in 1.8 ml PPM-medium (15 g Proteose Pepton, 5 g NaCl, 
1 g starch, 1 g KH2PO4, 0.8 g K2HPO4, 232.5 ml glycerine 86 %, aqua dest. ad 1000 ml) that 
is distributed on two vials with glass beads for cryoconservation with ethanol/dry ice. 
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7.2.4.2.2 Preparation of Competent Cells 
 
Several transformation methods such as electroporation or heat shock can be used to transport 
foreign DNA material into E. coli. Only cells that have been prepared for DNA uptake by pre-
treatment can be used, so called competent cells. Different protocols exist depending on the 
method used for transformation. For the generation of chemical competent cells the cells were 
treated as described by Inoue et al.[225], for the generation of electrocompetent cells, the 
protocol of Neumann was applied[226]. 
 
7.2.4.2.3 Transformation of Competent Cells 
 
Transformation of competent made cells was done either by the SEM method or by 
electroporation. The protocols are listed below: 
 
SEM method: 
 competent cells are carefully thawed and kept on ice 
 DNA is added (max. 10 µl per 100 µl cells) and incubated for 30 min 
 a heat shock is applied: 30 sec 42° C, then the cells are directly kept on ice again 
 0.8 ml SOC medium are added and mixed carefully 
 incubation at 37° C at 200 U/min for 1h 
 plating 
 
Electroporation: 
 competent cells are carefully thawed and kept on ice 
 DNA is added (max. 10 µl per 100 µl cells) 
 the mixture is filled in a special 1mm cuvette for electraporation and an impulse of 1800 V is 
applied 
 1.0 ml SOC medium are added and mixed carefully 
 incubation at 37° C at 50 U/min for 2h 
 plating 
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7.2.4.2.4 Media  
 
Luria-Bertani-Medium (LB-Medium)[227] was used to breed bacteria. The pH was adjusted to 
7.3 before autoclaving. The addition of kanamycin allowed the selection of plasmid 
containing cells. For this reason, 50 or 100 mg kanamycin were added per liter of medium. 
SOC-Medium is used for the regeneration and for the growth of freshly transformed cells. 
 
 
Luria-Bertani-Medium (LB-Medium) 
 Trypton 10.0 g 
 Yeast extract 5.0 g 
 NaCl 5.0 g 
 MilliQ-Waterr ad 1000.0 ml 
 
 SOC Medium 
 Trypton 20.0 g 
 Yeast extrakt 5.0 g 
 NaCl 0.5 g 
 KCl (250 mM Sol.) 10.0 ml 
 MilliQ-Water 975 ml 
 
The pH-value is adjusted to 7.0 with NaOH. After autoclaving the following solutions were 
made sterile by filtration and added: 
 Glucose (1 M Lsg.) 20.0 ml 
 MgCl2 (2 M Lsg.)  5.0 ml 
 
 
7.2.4.2.5 LB Agar-Plates 
 
For the production of agar plates, 16.0 g Agar were used per liter LB-Medium. The pH was 
adjusted to before autoclaving. Kanamycin was added afterwards at about 60 °C. 
7 Materials and Methods 154 
 
7.2.4.3 Working with DNA 
 
7.2.4.3.1 Plasmid Isolation 
 
Kits from diverse companies (GFX Micro Plasmid Prep Kit (Amersham Biosciences), 
E.Z.N.A.® Plasmid Miniprep Kit I and II, peqlab, Erlangen, Deutschland) were used for the 
isolation of plasmids. They all share a common principle: The cells are lysed open by an 
alcalic hydrolisis. The purification of plasmid-DNA is done by anion-exchange 
chromatography. The backbone of nucleic acids contains phophate groups that are negatively 
charged at pH-values larger than 2 and thus bind to the anion-exchange column and can be 
eluted with water or buffer. Instructions are provided with every kit and were used according 
to the manufacturers’ instructions. 
 
7.2.4.3.2 Digestion with Restriction Enzymes 
 
Restriction enzymes recognize specific DNA sequences and cut the DNA in a way that 
fragments with defined ends and sizes are generated. The applied incubation conditions and 
concentrations of the used reagents correspond to the manufacturers’ instructions. 
 
 
7.2.4.3.3 Gel Electrophoresis 
 
Agarose gel electrophoresis is used for the separation of DNA fragments and for the 
determination of their size. Negatively charged nucleic acids move to the anode in an 
electrical field with small fragments moving faster. Separation is performed with 0.8 % or  
1.5 % agarose gels. Agar is dissolved in TA-buffer (40 mM Tris, 10 mM Na-acetate, 1mM 
EDTA, pH 7.8) with heating. DNA samples are diluted 1:10 with sample buffer (10x, 1 % 
SDS, 50 % glycerole, 0.05 % Bromphenolblue, Takara, Otsu, Japan). Thus, the density is 
increased and the samples can be pipetted in the pockets of the gel and sink down. A voltage 
of about 100 V is applied. 
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The gel is incubated for at least 30 min in ethidiumbromide (1 µg/ml) for detection. Then it is 
washed with water and the ethidiumbromid that intercalates in the double-stranded DNA can 
be detected at 312 nm due to its fluorescing properties and can be documented via a camera-
system. 
 
The size of the DNA fragments can be determined with the help of a reference (marker). A 
100 Bp Ladder (Promega; Madison, USA) and a 1 kBp Ladder (Promega; Madison, USA) or 
alternatively the Lambda DNA-HindIII Marker (New England Biolabs; Frankfurt, Germany) 
were used as an internal standard within a gel. 
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7.3 Structural Biology 
 
7.3.1 Material 
 
All crystallization experiments were done with Cryschem Plates (Sitting Drop Plates, HR3-
160), Hampton Research, USA) in cooperation with AG Klebe (Department of 
Pharmaceutical and Medicinal Chemistry, Marburg University). 
 
 
7.3.2 Crystallization of apo-EcMetAP 
 
Ten different crystal screens (with 48 conditions each) varying in pH, precipitant(s), buffers 
and additives were tested with different protein concentrations (9 mg/ml, 13 mg/ml, 18 
mg/ml, 24 mg/ml and 32 mg/ml), different protein charges, apo-MetAP and His-tagged 
MetAP and with and without the addition of N-octanoylsucrose but without success. Only 
salt-crystals were obtained, possibly because of the presence of K2SO4 in the protein buffer. 
Thus, K2SO4 was substituted by KCl. 
 
Crystals were grown using a slight modification of the conditions described before[52]. In 
brief, freshly prepared enzyme was kept in buffer containing 25 mM Hepes, pH 6.8, 25 mM 
KCl, 100 mM NaCl, 1 mM CoCl2, and 15 mM methionine. Crystals of the Co(II)-substituted 
enzyme were obtained over night at 22 °C by vapor diffusion in 20 µl sitting drops after 
mixing the protein solution in buffer (13.5 mg/ml) to which N-octanoylsucrose (Calbiochem- 
Novabiochem Corp., La Jolla, CA) was added to a concentration of 48.8 mM, 1:1 with well 
solutions (500 µl) containing 24-33 % PEG 4000, 0.1 M Hepes, pH 7.1 and fresh 2 mM 
CoCl2. 
 
A typical plate for a screening from 10-45% PEG is depicted in Fig. 7-4 
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Fig. 7-4 Scheme for the pipetting of mother liquor of a PEG-screening in a  typical sitting-drop 
crystallization plate 
 
 
7.3.3 Co-Crystallization of Inhibitors with EcMetAP 
 
Crystals of the thiabendazole complex were obtained by incubating the enzyme (13.5 mg/ml, 
0.43 mM, 49.8 mM N-octanoylsucrose) at room temperature for 5 min with a solution of 
thiabendazole dissolved in DMSO at 21.8 mg/ml (109 mM) (122.5 µl protein-solution + 2.5 
µl inhibitor solution). The final inhibitor:enzyme ratio was 5:1 (1 % DMSO, 24.4 mM N-
octanoylsucrose) after mixing the preformed complex 1:1 with well solution (0.1 M Hepes, 
pH 7.1, 2 mM CoCl2 and 24-33 % PEG 4000). 
For compound RS 17, the inhibitor-enzyme ratio was 2.5 : 1 and the well solution contained 4 
mM CoCl2. Only a single crystal was obtained with these conditions. 
 
 
7.3.4 Data Collection and Refinement 
 
The data set was collected on a Rigaku/MSC rotating anode generator (RU 300) operated at 
50 kV, 90 mA equipped with a Raxis 4++ imaging plate detector. 360 frames with δ(ϕ) = 0.5° 
at a crystal-to-detector distance of 100 mm were collected at -170 °C with 18 % glycerole in 
mother liquid as cryoprotectant. For compound RS 17, the data set was collected with a Raxis 
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4 imaging plate according to the conditions and parameters mentioned and consisted of 240 
frames. 
Data were processed and scaled with HKL 2000[228]. The MetAP-structure published by 
Lowther and coworkers[52](PDB code 2MAT) was used without the cobalt atoms or water 
molecules as a starting model for molecular replacement in PHASER[229] followed by a rigid 
body refinement in CNS[230]. Initial refinement was continued in CNS using positional and 
slow-cooling protocols followed by restrained B-value refinement. Refinement was then 
continued with SHELXL-97[231]. At least 20 cycles of conjugate gradient minimization with 
restraints on bond distances, angles, and B-values were performed for each refinement step. In 
the final stages, hydrogen atoms were placed in calculated positions without use of additional 
parameters. Intermittent cycles of model building were done with the program O[232].  
The coordinates have been deposited in the PDB (http://www.rcsb.org/pdb/) with access code 
1YVM. All images were created with PYMOL[233]. 
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8 Appendix 
Listed below are the results of inhibition tests of various substances against Co(II)-loaded 
EcMetAP:
 
 
Table 8-1 Inhibition tests of aldehydes against Co(II)-loaded EcMetAP 
Compound H
O
R
 
IC50 
[µM] % inhibition (at a certain concentration) 
Benzaldehyde R = H > 300 34 % inhibition at 300 µM 
2-Hydroxy-benzaldehyde 2-OH 5.9  
3-Hydroxy-benzaldehyde 3-OH 105.7  
4-Hydroxy-benzaldehyde 4-OH > 300 
6 % inhibition at 100 µM 
8 % inhibition at 300 µM 
2-Methoxy-benzaldehyde 2-OMe > 300 36 % inhibition at 300 µM 
3-Methoxy-benzaldehyde 3-OMe 100-300 
32 % inhibition at 100 µM 
61 % inhibition at 300 µM 
4-Methoxy-benzaldehyde 4-OMe > 300 29 % inhibition at 300 µM 
2-Nitro-benzaldehyde 2-NO2 > 300 
0 % inhibition at 100 µM 
23 % inhibition at 300 µM 
3-Nitro-benzaldehyde 3- NO2 35.0  
4-Nitro-benzaldehyde 4- NO2 45.2  
Vanilline 4-OH, 3-OMe > 300 32 % inhibition at 300 µM 
2,4-Dichloro-benzaldehyde 2-Cl, 4-Cl >> 100 0 % inhibition at 100 µM 
 
 
Table 8-2 Inhibition tests of styrenes against Co(II)-loaded EcMetAP 
Compound R
 
IC50 
[µM] % inhibition (at a certain concentration) 
Vinyl-benzene R = H > 300 4 % inhibition at 300 µM 
2-Vinyl-phenole 2-OH > 300 2 % inhibition at 300 µM 
3-Vinyl-phenol 3-OH > 300 2 % inhibition at 300 µM 
4-Vinyl-phenol 4-OH > 300 4 % inhibition at 300 µM 
1-Methyl-2-vinyl-benzene 2-Me > 300 30 % inhibition at 300 µM 
1-Methyl-3-vinyl-benzene 3-Me > 300 9 % inhibition at 300 µM 
1-Methyl-4-vinyl-benzene 4-Me > 300 2 % inhibition at 300 µM 
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Table 8-3 Inhibition tests of carboxylic acids against Co(II)-loaded EcMetAP 
Compound OH
O
R
 
IC50 
[µM] % inhibition (at a certain concentration) 
2-Hydroxy-benzoic acid 2-OH > 100 0 % inhibition at 100 µM 
3-Amino-benzoic acid 3-NH2 > 100 0 % inhibition at 100 µM 
4-Amino-benzoic acid 4-NH2 > 100 0 % inhibition at 100 µM 
2-Nitro-benzoic acide 2-NO2 > 100 0 % inhibition at 100 µM 
3-Nitro-benzoic acid 3- NO2 > 100 0 % inhibition at 100 µM 
4-Nitro-benzoic acid 4- NO2 > 100 0 % inhibition at 100 µM 
Nicotinic acid N
OH
O
 
> 300 0 % inhibition at 300 µM 
Pyridine-2-carboxylic acid N
OH
O
 
20.3  
 
 
Table 8-4 Inhibition tests of sulfonamides against Co(II)-loaded EcMetAP 
Compound IC50 [µM] % inhibition (at a certain concentration) 
Sulfamethoxazol 68,0  
Sulfaphenazol > 300 0 % inhibition at 300 µM 
Sulfathiazol > 300 36 % inhibition at 300 µM 
Sulfatdiazin > 300 17 % inhibition at 300 µM 
Sulfaguanidin > 300 0 % inhibition at 300 µM 
Sulfisoxazol > 300 0 % inhibition at 300 µM 
Sulfanilamid > 300 0 % inhibition at 300 µM 
Sulfadimidin > 300 24 % inhibition at 300 µM 
Sulfamoxol > 300 37 % inhibition at 300 µM 
Sulfadimethoxin > 300 20 % inhibition at 300 µM 
Sulfisomidin > 300 0 % inhibition at 300 µM 
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Table 8-5 Inhibition tests of drugs and drug-like substances against Co(II)-loaded EcMetAP 
Compound  IC50 [µM] 
% inhibition (at a certain 
concentration) 
Cyclohexanone 
O
 
> 300 9 % inhibition at 100 µM
a
 
9 % inhibition at 300 µM 
SU6A 
N
O
HCl.
 
> 100 7 % inhibition at 100 µM 
SU21A 
O
S
N
HCl.
 
> 100 24 % inhibition at 100 µM 
Thiamine dichloride N
N
N+
SOH
NH2Cl
ClH.
 
> 300 17 % inhibition at 300 µM 
Isoniazid 
N
O N
H
NH2
 
10-100 26 % inhibition at 10 µM 56 % inhibition at 100 µM 
Desipramine-HCl N NH
 
> 100 29 % inhibition at 100 µM 
Nalidixic acid 
N N
O O
O
 
> 10 10 % inhibition at 10 µM 
Niclosamid 
OH
N
H
OCl
Cl
NO2
 
> 25 31 % inhibition at 10 µM 
Salicylanilide NH
O
OH
 
> 100 21 % inhibition at 100 µM 
GK01664 
N
N S
S
N
 
>> 1 0 % inhibition at 1 µM 
SPB06965 N S
NN
S
 
>> 1 10 % inhibition at 1 µM 
Phenoxymethylpenicilline 
O
N
O N
S
OO
O
K
+
 
>> 10 0 % inhibition at 10 µM 
a) 15 min preincubation 
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Table 8-6 Inhibition tests of synthetic intermediates and other small molecules against Co(II)-loaded 
EcMetAP 
Compound  IC50 [µM] % inhibition (at a certain concentration) 
RS 70 
1-(2-Chloro-
cyclohex-2-
enyl)-ethanone 
O
Cl
 
> 100 
9 % inhibition at 100 µMa 
19 % inhibition at 300 µM 
RS 71 
1-(1,4-Dioxa-
spiro[4.5]dec-6-
yl)-ethanone 
O
O
O
 
> 100 
3 % inhibition at 100 µMa 
10 % inhibition at 300 µM 
RS 72 
6-((E)-1-
Methyl-
propenyl)-1,4-
dioxa-
spiro[4.5]decane O
O
 
> 100 
3 % inhibition at 100 µMa 
13 % inhibition at 300 µM 
RS 73 
2-((E)-1-
Methyl-
propenyl)-
cyclohexanone O
 
> 100 
22 % inhibition at 100 µMa 
47 % inhibition at 300 µM 
RS 74 
Benzoic acid 3-
methyl-but-2-
enyl ester 
O
O
 
> 300 0 % inhibition at 100 µM 
RS 75 
4-Methyl-N-
pyridin-3-yl-
benzenesulfona
mide 
SO O
NH
N
 
>> 10 0 % inhibition at 10 µM 
a) 15 min preincubation 
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10 Abbreviations 
 
σ  Mean deviation, measurement for the level of density 
(br)  Broad 
AAO  L-Amino acid oxidase  
b.p.  Boiling Point 
BSA  Bovine Serum Albumine 
CCl4  Tetrachlormethane 
CH2Cl2  Dichloromethane 
Da  Dalton 
DMF  Dimethylformamid 
DMSO  Dimetylsulfoxid 
DTNB  5,5’-dithiobis(2-nitrobenzoic acid) 
DTT  Dithiothreitol 
EDTA  ethylene diamine tetra acetic acid 
EtOH  Ethanol 
Fig.  Figure 
g  Gram 
h  Hour 
hrs  Hours 
HPLC  High Pressure Liquid Chromatography   
  (Hochdruckflüssigkeitschromatographie) 
HRP  Horseradish Peroxidase 
IC50  Inhibitor concentration to inhibit 50 % of the enzyme activity 
IPTG  Isopropyl-ß-D-thiogalactopyranosid 
IR  Infra red spectroscopy 
J  Coupling constant 
kDa  Kilodalton 
l  Liter 
LB  Luria Bertani Medium 
m  Meta (substituted); multiplet 
M  Molar 
m-CPBA  meta-Chlorperbenzoic acid (MCPBA) 
MeOH  Methanol 
mg  Milligramm 
MGMM  NH2-Met-Gly-Met-Met-COOH 
min  Minute(s) 
mM  Millimolar 
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m.p.  Melting point 
MW  Molecular Weight 
nm  Nanometer 
NMR  Nuclear Magnetic Resonance Spectroscopy 
OD  Optical Density 
OD280  Optical Density at 280 nm 
OS  Octanoylsucrose 
p  Page 
PAGE  Polyacrylamide Gel Electrophoresis 
pH  negative dekadic logarithm of the protein concentration 
pKa  negative dekadic logarithm of the dissociation constants of acids 
PMSF  Phenylmethylsulfonylfluoride 
ppm  Parts per million 
r  Korrelation coefficient 
RNA  Ribonucleic Acid 
SDS  Sodiumdodecylsulfat 
sec  second 
t-BuOOH  tert.-Butylperoxide 
TFA  Trifluoro acetic acid 
THF  Tetrahydrofuran 
TLC  Thin Layer Chromatography 
Temed  N,N,N',N'-tetramethylethylenediamine 
TMS  Tetramethylsilane 
Tris  2-Amino-2-Hydroxymethyl-1,3-Propandiol 
U  Unit(s) 
V  Volt 
v/v  volume per volume 
w/v  weight per volume 
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